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ABSTRACT 
 Toll-like Receptors (TLRs) are important constituents of the immune response, 
capable of both protecting the host from danger and inciting harm from within. In this 
Thesis, I present evidence that the last human orphan toll-like receptor, TLR10, has a 
unique function that differs from its other family members in that TLR10 is capable of 
suppressing inflammatory responses. I will describe the relationship between pattern-
recognition receptors (PRRs) and the maintenance and induction of chronic 
inflammation to underscore the importance of TLR10’s novel suppressive function. I will 
then present multiple different lines of evidence that TLR10 is a suppressor of 
inflammatory responses.  Our experimental approaches included transfected cell lines, 
antibody-mediated engagement on primary human leukocytes and the development of 
two different transgenic mouse lines. Taken together, our data show that TLR10 is 
capable of suppressing both TLR-dependent and –independent stimulatory signals 
within both monocytes and B cells as evidenced by inhibitory effects on phosphorylation 
of signaling proteins, the transcriptome, secretion of cytokines, proliferation, 
differentiation, cellular co-stimulation and antibody generation. The research findings 
suggests that TLR10 could be a useful therapeutic target in the resolution of chronic 
inflammatory conditions, especially autoimmune diseases that are driven by overactive B 
cells. In summary, this Thesis outlines the novel understanding that as a previously 
uncharacterized TLR, TLR10 can function as a broad immune suppressor on primary 
human leukocytes. 
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CHAPTER I: TOLL-LIKE RECEPTORS IN THE IMMUNE RESPONSE 
 
1.1 Immunological Sentries: Pattern-Recognition Receptors in Innate Immunity 
The mammalian immune system has evolved over millions of years to first detect 
and then respond to foreign “non-self” components most often represented by invasive 
microorganisms. While the skin and mucous membranes act as a very efficient primary 
barrier for many microorganisms, once bypassed, a complex symphony of immune 
responses are brought to bear on the invading organism to prevent systemic 
dissemination across the host (Janeway, 1989; Medzhitov, 2009).  
  The immune system of all eukaryote organisms is divided into innate and 
adaptive immune systems based upon their inherent ability to recognize and adapt to 
different foreign antigens. The innate immune system is evolutionarily quite old with 
varying components found in plants, fungi, invertebrates and vertebrates. In plants and 
fungi, they rely solely on intrinsic cellular mechanisms to both recognize and responds to 
pathogens. In invertebrates, the evolution of a body cavity, called a coelom, coincides 
with the evolution of specialized cells known as coelomocytes, the first example of an 
innate immune cell. With the evolution of a functional circulatory system in vertebrates 
also came the opportunity for innate immune cells to circulate throughout the body 
scanning for non-self components. This has allowed for the expansion of different innate 
immune cells within vertebrate innate immune systems broadly grouped into two 
subsets, granulocytes and myeloid cells. Furthermore, all vertebrates from bony fish to 
birds and mammals have an adaptive immune system comprised of cells called 
lymphocytes whose unique function is conserved across the different vertebrate 
phylogenetic Classes and discussed later in this Chapter (Janeway, 1989; Medzhitov, 
2009).  
 First postulated by Charles Janeway in 1989, the innate immune system is 
composed of several different classes of germ-line encoded pattern-recognition 
receptors (PRRs) that have evolved to recognize different conserved motifs present on 
viral, bacterial and fungal species denoted as pathogen-associated molecular patterns 
(PAMPs). These PRRs include several different families such as the Toll-like receptors 
(TLRs), Nod-like receptors (NLRs), C-type lectin receptors (CLRs) and RIG-1-like 
receptors (RLRs); subsets of which are expressed on all leukocytes as well as epithelial 
cells. Their purpose is to detect non-self components on microorganisms and induce an 
inflammatory response which, at its core, is defined as the recruitment of additional 
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leukocytes to the site of infection. In this Chapter, I will focus on the TLR family of PRRs 
and how their activation on different leukocytes contributes to almost every aspect of the 
inflammatory response (Creagh & O’Neill, 2006).  
The mammalian complement of leukocytes are divided into cells of the myeloid 
and lymphocyte lineages which are generally divided into cells of the innate and 
adaptive immune systems respectively as well. Both of these progenitor cells arise from 
a hematopoietic stem cell that is retained in the bone marrow. The myeloid progenitor 
gives rise to monocytes, macrophages and dendritic cells along with the granulocytic 
neutrophils, basophils and mast cells. The lymphoid progenitor is the precursor to B 
cells, T cells and natural killer (NK) cells. Neutrophils make up approximately 60% of the 
total human leukocyte population in the blood with lymphocytes (75% T cells) and 
monocytes making up 30% and 5% respectively with the remaining consisting of 
basophils, mast cells and NK cells. While the majority of leukocytes are bone-marrow 
derived and are constantly replenished, there is also a subset of macrophages, B cells 
and dendritic cells that are yolk sac derived, permanently reside in the tissues and have 
the capability of self-renewing throughout the lifetime of the host.  
Cytokines are secondary messenger molecules that act to recruit and activate 
additional leukocytes. They can be divided into several different families based on their 
varying activity and signaling responses. Some of the most common pro-inflammatory 
cytokines are; IL-1β, IL-6, TNFα, IL-12 and the interferons alpha, beta and gamma. 
These cytokines have many pleotropic effects upon both immune cells and the 
physiology of the host. For example, IL-6 is a well-known pyretic (fever inducer) that is 
thought to broadly increase leukocyte motility, phagocytosis and proliferation in the host. 
Additionally, some pathogens have very strict growth temperatures that may be effected 
by increasing the internal body temperature of the host. Interleukin-6 mediates this effect 
by binding its cognate receptor on the surface of the hypothalamus. This in turn activates 
the arachidonic acid pathway to produce a class of pro-inflammatory lipid mediators 
known as prostaglandins via the cyclooxygenase (COX) enzymes COX-1 and COX-2. 
More specifically, the paracrine factor prostaglandin E2 binds to its receptor in the 
dorsomedial hypothalamus and induces the sympathetic nervous system to increase the 
internal body temperature (Geissmann et al, 2003; Lauvau et al, 2015; Naugler & Karin, 
2008; Xiong et al, 2015). 
Another common sign of inflammation, mediated by a subset of cytokines called 
chemokines, is the redness and swelling in the tissues. These proteins such as IL-8, 
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MIP-1α and MIP-1β, can cause chemokine-induced smooth muscle relaxation of the 
vasculature which results in lower blood pressure. This assists in allowing neutrophils 
and monocytes to enter the infected tissue from the bloodstream. The myeloid cells 
express an integrin protein L-selectin (CD62L) that has low affinity for its receptor CD34 
expressed on endothelial cells. Chemokines released by the infected tissue causes 
myeloid cells to chemotax to the infected tissues and for endothelial cells to upregulate 
CD34, making it easier for the myeloid cells to “stick” to those endothelial cells. Then 
through an LFA-1:ICAM-1 interaction, both of which are up-regulated by chemokines on 
the surface of myeloid cells and endothelial cells respectively, allow for the 
transmigration of myeloid cells into the infected tissues. Chemokines also downregulate 
the proteins involved in forming the tight junctions in-between endothelial cells, making 
them “leaky” and allowing for easier transmigration. Once present in the tissues, myeloid 
cells follow the chemokine gradient to reach the site of infection (Kawai & Akira, 2010; 
Lauvau et al, 2015; Naugler & Karin, 2008). 
Once present at the site of infection, neutrophils, macrophages and dendritic 
cells have the ability to recognize the pathogens and kill them via phagocytosis. This 
process is enhanced by another innate immune factor called opsonins such complement 
factor C3b and antibodies of the adaptive immune system that coat the surface of 
pathogens. The pathogen-containing phagocytic vesicle then fuses with a lysosome to 
form a phagolysosome which is responsible for the destruction of the pathogen. The 
phagolysosome contains proteolytic enzymes such as lysozyme, elastase, chymotrypsin 
family members and other defensins to break down the pathogen. Additionally, the 
phagolysosome can produce radical oxygen species (ROS), radical nitrogen species 
(RNS) and hypohalous acids (such as hypochlorite) that can cause widespread damage 
to the pathogen and aid in its killing (Kolaczkowska & Kubes, 2013; O’Neill & Bhardwaj, 
2005; Xiong & Pamer, 2015).  
Granulocytes specifically have other alternative approaches to eliminate 
pathogens. Neutrophils possess a large quantity of granules within their cytosol that are 
pre-loaded with bactericidal proteins such as myeloperoxidase (MPO), elastase, 
lactoferrin and matrix metallopeptidase-9 (MMP-9). Upon stimulation by a TLR, 
neutrophils will release their granules into the extracellular matrix to combat the 
pathogens. Additionally, after exhausting their granules, neutrophils can undergo a 
special form of apoptosis that results in neutrophil extracellular trap (NET) formation. 
This net is formed from the neutrophils own DNA and prevents the dissemination of the 
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pathogen to other tissues of the body. The sheer influx of neutrophils to the site of 
infection coupled with the massive kamikaze nature of neutrophils can often be seen by 
the naked eye in the form of a white “pus” which is primarily composed of dead 
neutrophils and either killed or trapped pathogen (Kolaczkowska & Kubes, 2013). 
Monocytes serve two important functions within the host. While they are relatively 
few in number, they are the primary producer of cytokines upon TLR activation. The 
second function served by monocytes is their ability to differentiate into either 
macrophages or dendritic cells upon migration into the tissues. This allows for the 
replenishment and support of additional antigen-presenting cells at the site of infection. 
Unlike neutrophils whose sole purpose is to eliminate pathogens, macrophages and 
dendritic cells serve auxiliary functions. Macrophages are especially useful at clearing 
debris in the form of apoptotic or necrotic host cells from the site of infection that if left 
unchecked can cause permanent damage and limit the healing process. Dendritic cells 
meanwhile act as a bridge linking the innate and adaptive immune systems. They are 
constantly sampling their environment and presenting antigen to lymphocytes via their 
MHC class II receptor. Once activated by TLRs, they will also migrate from the tissues 
into the lymphatic system where they engage lymphocytes within secondary lymphoid 
tissue (Lauvau et al, 2015; O’Neill & Bhardwaj, 2005).    
 
1.2 Passing the Baton: Connecting Innate and Adaptive Immunity 
The adaptive immune system is a natural extension of innate immunity and 
carries with it many of the same tools such as TLRs. The power of adaptive immunity is 
in its ability to recognize millions of different non-self antigens, compared to PRR family 
members which can usually only recognize a single non-self antigen. The process of 
recognizing a unique antigen though is begun by TLR activation on a subset of myeloid 
cells called professional antigen presenting cells (APCs) and eventually results in an 
antigen-specific antibody created by B lymphocytes. These antibodies can either directly 
neutralize pathogen-derived toxins and viral particles or enhance the natural killing 
efficiency of phagocytic innate immune cells (Browne, 2012; Pasare & Medzhitov, 2005).  
 Professional APCs (commonly macrophages and dendritic cells) are constantly 
sampling their environment for non-self antigens, processing that antigen, and 
presenting it on either a class I or II major histocompatibility complex (MHC) (dependent 
on the antigen being intracellular or extracellular respectively). The antigens presented 
on MHC are non-discriminatory and represent both self and non-self antigens, with the 
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distinction between the two, and the induction of autoimmune diseases, reliant on T and 
B lymphocyte receptors (Arnold-Schrauf et al, 2015; Iwasaki & Medzhitov, 2015). 
 Lymphocytes are divided into T cells and B cells which each possess a unique 
receptor that is vital in distinguishing between self and non-self antigens. T cell receptors 
(TCR) and B cell receptors (BCR) each undergo gene rearrangement during 
development in the bone marrow such that each receptor is slightly different from its 
sister cell allowing for the potential detection of millions of different protein antigens. 
During this maturation process, TCRs and BCRs are screened for reactivity against a 
suite of self-antigens with self-reactive cells eliminated by apoptosis. This process, 
known as central tolerance, ultimately protects the host from generating adaptive 
immune responses against self-antigens and the induction of autoimmune diseases 
(Arnold-Schrauf et al, 2015; Iwasaki & Medzhitov, 2015).  
 One hallmark of the adaptive immune system is that lymphocytes require at least 
two independent stimulatory signals for proper activation, a theory that is called the two-
signal hypothesis. In T cells, signal one is provided by the presentation of antigen on a 
MHC protein that is recognized by the TCR. Two possible accessory proteins assist in 
this signaling by binding to MHC-II and MHC-I respectively, CD4 and CD8. These 
accessory proteins also split T cells into their two respective families as each T cell can 
only express one of the accessory proteins, a commitment that they make early during 
development in the thymus. The second signal received by T cells is through the co-
stimulatory proteins CD28 on T cells and the B7 complex (composed of CD80 and 
CD86) on APC. TLR activation will cause APC to upregulate both their MHC and 
costimulatory proteins while also inducing the third signal, cytokines. The cytokines IL-12 
and IL-4 help to regulate further cellular differentiation of CD4+ helper T cells to promote 
either a TH1 cell-mediated response or a TH2 humoral response respectively. Regardless 
of the type of response, T cells will undergo clonal expansion, secrete cytokines such as 
IL-2, IL-4 and IFNγ as well as migrate to the lymph nodes (Arnold-Schrauf et al, 2015; 
Iwasaki & Medzhitov, 2015). 
 Similarly, B cells have their own set of signals needed to become fully activated. 
Signal one is antigen recognition by their BCR. Importantly, this epitope recognized by 
the BCR does not have to be the same as recognized by the TCR but this epitope does 
determine epitope of the antibodies later produced. B cells are also APC and uptake 
antigen via their BCR and present it via their MHC-II complex. Activated T cells 
recognizing the same antigen presented to them initially by other APC will interact with 
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the B cell MHC and allow other costimulatory proteins to interact, in this case, CD40 on 
the B cell and CD40L (CD154) on the T cell. While T cells generally lack any appreciable 
expression of TLRs and rely on other myeloid derived APC for their third signal, B cells 
strongly express several TLRs that mediate a third activation signal (DeFranco et al, 
2012; Rawling et al, 2012).  
The production of antigen-specific antibodies by B cells is classically thought as a 
T cell dependent (TD) response. While T cell co-stimulation is often required for the 
generation of high affinity antibodies via somatic hypermutation (also known as affinity 
maturation) and class-switch recombination where B cells switch from an IgM isotype to 
an IgG, IgA, IgD or IgE isotype; B cells are now known to produce low affinity IgM 
antibodies in the absence of T cell help. This T cell independent (TI) response is 
possible because the B cell expresses several different TLRs. Co-stimulation of the TLR 
with antigen recognition by the BCR is sufficient to drive differentiation of naïve B cells 
into terminally differentiated antibody-producing plasma cells. Overall, this highlights the 
importance of TLRS within the immune system and underlines the necessity to study 
and fully understand their function within the host to eventually combat the growing 
number of medical diseases attributed to TLR dysfunction (Avalos et al, 2010; 
Bekeredjian-Ding & Jego, 2009; Bernasconi et al, 2003; Browne, 2012; Pasare & 
Medzhitov, 2005).   
 
1.3 Pattern Recognition Receptors in Chronic Inflammation and Autoimmunity 
 The immune system has evolved over generations to balance the need of a 
strong robust inflammatory response and the ability to tolerate potentially damaging 
inflammatory responses. A strong immune response is necessary to control and 
eliminate non-self pathogens from the host but that response can also have deleterious 
effects. Prolonged activation of the immune response can cause damage to vital tissues 
and organs. Sustained cytokine levels can induce a process coined pyroptosis, a form of 
necrosis, which causes cells to burst and die. Not only can this directly damage the host, 
pyroptosis releases a plethora of cellular components that can act to stimulate PRRs. 
These components are called damage-associated molecular patterns (DAMPs) and are 
the hallmarks of chronic inflammatory diseases. Additionally, this chronic inflammatory 
state has been proposed as a natural precursor to the host developing an autoimmune 
disease. One such example is systemic lupus erythematosus (SLE) that is characterized 
by antibodies generated against nuclear-protein/DNA complexes. These antibodies are 
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generated due moderately auto-reactive B cells bypassing central tolerance and for the 
release nuclear-protein/DNA complexes most likely by pyroptosis or necrosis. If left 
untreated, this disease will lead to systemic organ failure and death. Importantly, TLRs 
drive both the release of intracellular components but also the TI activation of B cells 
which makes studying mechanisms of negatively regulating TLR activity an important 
research goal (Browne, 2012; Marshak-Rothstein & Rifkin, 2007; Pasare & Medzhitov, 
2003; Pelka et al, 2016).  
 The assumption that infectious organisms are the leading cause of tissue 
damage is a major misconception. Sustained or chronic inflammation, usually the result 
of the inability of the host to clear an infection efficiently, is the leading cause of tissue 
damage during an infection. As such, many scientific studies (including this thesis) have 
examined how the immune system is regulated, controlled and resolved, each of which 
are important factors that can contribute to chronic inflammatory states. An additional 
factor that is important during chronic inflammation is the immune tolerance within the 
host. Different individuals have variable responses to how much or how long of an 
immune response their tissues can handle before inducing pyroptosis. Research into 
how the host can endure increased inflammatory pressure can perhaps help prevent the 
induction of autoimmunity in the future (Pasare & Medzhitov, 2003; Wang et al, 2014).  
 Overall, the host is well adapted to controlling its immune response although 
several factors can increase the likelihood of autoimmunity. Genetic mutations within 
some immune genes results in the most direct connection to some autoimmune 
diseases while in other cases, small incremental damage over time eventually leads to 
autoimmunity. Because of this and the loss of tissue tolerance, age is a major risk factor 
for autoimmunity.  
 Another major factor in controlling autoimmune diseases is the sex of the host. 
Woman are at a three times greater risk of developing an autoimmune disease 
sometime in their life. There are several factors that may contribute to this though most 
hypotheses revolve around the sex hormones. The female estrogen hormone is a strong 
inducer of TH2 responses which can promote the development of auto-reactive 
antibodies, a hallmark of autoimmune diseases. Conversely, the male androgen 
hormones (such as testosterone) skew the immune response to a TH1 response that may 
help protect males from the same outcome. Estrogen also assists in promoting the 
survival of autoreactive T and B cells. The effects of estrogen are best presented by 
several examples. There are drastic increases in developing SLE in females after 
8 
 
puberty which equally unlikely chances after menopause. There is also exacerbated 
disease symptoms during pregnancy, when estrogen levels are elevated. In direct 
contrast, elevated estrogen levels in multiple sclerosis (MS) and rheumatoid arthritis 
(RA) is protective with symptoms worsening when estrogen levels are low. This shows 
that sex hormones, specifically estrogen, can have drastic effects on autoimmune 
diseases and help, in part, to control the immune response. The observation that women 
have more robust immune response apparently predispose them to a higher risk of 
developing an autoimmune disease; a tradeoff that evolution has conserved to protect 
the female during reproductive years (Pennell et al, 2012).  
 All of the above examples highlight an ongoing evolutionary battle between the 
immune response and immune tolerance or the ability of the host to tolerate an immune 
response. Skewing toward a stronger immune response, above with the host can 
tolerant may better protect against pathogens though also increases the risk of 
developing autoimmune diseases over the long-term. In this thesis, I dissect one aspect 
of this evolutionary battle by highlighting the importance of TLR receptors in controlling 
both innate and adaptive immunity. Additionally, I present evidence that one member of 
this family has a unique functional role that may be advantageous in controlling the 
immune response, resolving chronic inflammation and the treatment/prevention of 
autoimmune diseases.  
 
1.4 The Toll-like Receptor Complex in Ligand Recognition 
 One type of PRR are the toll-like receptors. Toll-like receptors are type-I 
transmembrane receptors that have a conserved leucine-rich repeat (LRR) N-terminal 
extracellular domain with a LxxLxLxxN motif  and a C-terminal Toll/Interluekin-1 
Receptor (TIR) domain responsible for signaling. Over time, the original TLR gene has 
duplicated into several different mammalian TLRs. Each TLR has evolved to recognize 
different ligands which in turn has driven their localization within the cell. Furthermore, 
TLRs can recruit a different adaptor protein for signaling that allows the receptor to tailor 
the resulting immune response to their respective ligand/pathogen (Hashimoto et al, 
1988; Lemaitre et al, 1996; Mikami et al, 2012). 
 The mammalian TLRs are either expressed on the plasma membrane or 
intracellularly within endosomes. Endosomal TLRs recognize nucleic acid moieties of 
viruses and bacteria while plasma membrane TLRs recognize different protein and 
lipoprotein components present on bacterial and fungal species. Each TLR with their 
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respective ligand is listed hereafter: TLR1, 2 and 6 (triacylated and diacylated 
lipoproteins); TLR3 (dsRNA); TLR4 (LPS); TLR5 (flagellin); TLR7, 8 (ssRNA); TLR9 
(dsDNA); TLR10 (unknown); TLR11, 12 (profilin); TLR13 (rRNA) (Figure 1.1) (Hidmark 
et al, 2012; O’Neill et al, 2008).  
All TLRs require dimerization of the receptor complex for proper signaling events 
to occur, though each TLR has slightly different dimerization mechanisms. The TLR TIR 
domains all have a natural affinity to form dimers with each other. This means that the 
LRR domain possesses the selective pressure to either prevent or promote dimerization 
and/or the proper alignment of the TIR domain with and w/o ligand. All TLRs form 
homodimers except for the TLR2 sub-family (TLR1, 2, 6 and 10) and TLR11 sub-family 
(TLR11 and 12) which are unique by forming heterodimers in response to recognize 
their respective ligands. By forming heterodimers, the TLR2 sub-family is able to 
recognize a broad range of ligands. For example, The TLR2/6 dimer can bind many 
different diacylated lipoproteins while the TLR2/1 dimer preferentially binds to triacylated 
lipoproteins. This interaction is achieved because TLR2 contains two pockets in its LRR 
domain for acyl chain binding, while TLR1 contains 1 pocket. This allows both TLRs to 
dimerize and form a functional receptor complex. In the case of TLR6, the third acyl 
chain pocket is blocked by two phenylalanine mutations (F343, F365) preventing it from 
recognizing triacylated lipoproteins though it can still dimerize with TLR2 via alternative 
interactions between their LRR domains. TLR10 is also capable of binding triacylated 
lipoproteins in a TLR2/10 heterodimer though the resulting heterodimer is non-functional. 
One possible explanation, discussed in more detail later, is that the TLR2:10 
heterodimer is non-functional because of the observed differences in the TIR domain of 
TLR10 compared to its closest homologue, TLR1 (Jin et al, 2007; Kang et al, 2009; 
Mikacenic et al, 2013).  
The intracellular TLRs 3, 7, 8, 9 and 13 have a slightly different dimerization 
mechanism. These intracellular TLRs all exist as natural homodimers instead of 
monomers and as a result require an additional level of regulation. These TLRs often 
encounter their ligand when endosomes fuse with lysosomes to form endolysosomes. 
Upon acidification of the endolysosome, the protease cathepsin K cleaves a small 
fragment from the N-terminus that allows the TLR homodimer complex to recognize its 
ligand. Additionally, only upon ligand recognition does a conformation shift occur within 
the TIR domains that allow for the signaling adaptor proteins to bind in the correct 
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conformation to perpetuate the signaling response (Barton & Kagan, 2009; Blasius & 
Beutler, 2010; Park et al, 2008; Qi et al, 2012).  
The localization of each TLR to its respective compartment is also necessary for 
the proper recognition of its ligand. The process of localization is dependent on several 
ER-associated chaperone proteins that interact with the transmembrane domain and its 
proximal residues. One example is the TLR1 (I/S) allelic variant that impairs trafficking of 
TLR1 to the surface. This mutation is thought to impair TLR1’s interaction with the 
chaperone PRAT4A as the TLR1S variant is solely expressed in endosomal 
compartments. Interestingly, overexpression or induction of PRAT4A by IFNγ is 
sufficient to rescue the localization deficiency to the plasma membrane (Hart & Tapping, 
2012; Hart & Tapping, 2012). A second example is the chaperone UNC93B1. This 
protein has been shown to interact with the intracellular TLRs 3, 7, 8 and 9 as well as the 
plasma membrane localized TLR5 via the proximal acidic residues just N-terminal of 
their transmembrane domains (Figure 1.2). The importance of this accessory protein is 
highlighted by a single missense mutation in murine UNC93B1 (H412R) that abolishes 
TLRs 3, 5, 7, 8 and 9 expression throughout the cell (Huh et al, 2014; Kim et al, 2013). 
One last example is the ER chaperone protein GP96. Loss of this chaperone protein 
causes ER retention of all tested TLRs except for TLR3. Additionally, GP96 uses a co-
chaperone protein CNPY3 to correct fold the ectodomains of the TLRs allowing for 
proper transit from the ER. These allelic variants and mutations of chaperone proteins 
highlights the tight regulation that TLRs are under to maintain their proper localization 
and function (Anas et al, 2016; Liu et al, 2010; Randow & Seed, 2001).  
 
1.5 TIR Domain Adaptor Proteins Involved in Toll-like Receptor Signaling 
Three major groups of TIR domain-containing proteins exist. Subgroup 1 have 
extracellular immunoglobulin (Ig) domains such as the IL-1 receptor. Subgroup 2 are the 
TLR family members and subgroup 3 are all of the TIR-domain containing adaptor 
proteins that are purely cytosolic and act as mediators of signaling for both subgroup 1 
and 2 receptors. The TIR domain itself is a conserved tertiary fold of five β-sheets (βA-
βE), 5 α-helixes (αA-αE) and five loops that connect each β-sheet to the next α-helix 
(Mikami et al, 2012). 
Among the TLR TIR domains, the BB loop (connecting the βB and αB) and the 
DD loop are both highly conserved and have been shown to be important in signaling. 
Their importance is highlighted by several allelic variants and mutational studies that 
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have abrogated signaling. The R753Q allelic variant in TLR2 lies within the DD loop and 
results in almost complete loss signaling through MyD88 (Xiong et al, 2012). Within the 
TLR2 subgroup, only TLR2 is capable of recruiting MyD88 independent of dimerization 
although it remains non-functional at that time. A single mutation in the BB loop of TLR1 
(N672D) is sufficient to allow TLR1 to recruit MyD88 independent of dimerization. The 
aspartic residue is only present in TLR2 and not within the other TLR2 sub-family 
members underlining why TLR2 is required for signaling (Brown et al, 2006; Vyncke et 
al, 2016). Lastly, a proline residue within the BB loop is thought to be critical in 
maintaining the orientation of the BB loop. A single missense mutation (P>H) in any TLR 
results in the loss of signaling. This mutation was initially found by Bruce Beutler in 
C3H/HeJ which were defective in LPS signaling. This led to the initial discovery of the 
TLR4 gene as the major LPS sensor within the host (Poltorak et al, 1998) 
All TLRs require adaptor proteins for signal transduction. To date seven known 
TIR-domain containing adaptor proteins are known (MyD88, TRIF, TRAM, TIRAP, 
SARM, BANK1 and BCAP) with most but not all having been shown to associate with 
TLRs. These adaptor proteins are recruited to the dimerized TIR domains of activated 
TLRs. All TLRs utilize MyD88 as their main signaling adaptor except for TLR3 which 
utilizes TRIF. The other TIR-domain containing adaptor proteins seem to only have 
minor functions. TIRAP, also known as MAL, is recruited to phosphatidylinositol 4,5 
bisphosphate (PIP2) via its pleckstrin homology (PH) domain where it may serve to help 
recruit the TLR:MyD88 complex to PIP2 allowing for the induction of the 
phosphoinositide-3-kinase (PI3k) pathway. Similarly, TRAM is thought to serve the same 
purpose for TRIF as TIRAP does for MyD88. Collectively, the adaptors TIRAP, TRAM, 
SARM, BANK1 and BCAP are known as sorting adaptors and serve to modulate MyD88 
and TRIF signaling (Carlsson et al, 2016; Gay et al, 2014; Jenkins & Mansell, 2010; 
Rosadini & Kagan, 2017; Troutman et al, 2012; Wu et al, 2016).  
The resulting signaling complex that results from TLR activation is coined the 
Myddosome or Triffosome. The Myddosome is a complex of 6 MyD88 proteins that form 
a left-handed helical complex nucleated around the TLR TIR domains. The N-terminal 
death domain (DD) of MyD88 recruits 4 IRAK4 proteins and 4 IRAK2/1 proteins. This 
assembly is hierarchical and causes the autophosphorylation of IRAK4 and then the 
phosphorylation of IRAK2/1. Activated IRAK2/1 associates with TRAF6 (TNF receptor-
associated factor) that is an E3 ubiquitin ligase that activates itself via K63-linked 
polyubiquination. TRAF6 can then activate the kinase TAK1 (tumor growth factor β-
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activated kinase) which is stably composed of two subunits, TAB1 and TAB2, by causing 
TAK1 to auto-phosphorylate. Activated TAK1 continues the signaling cascade by 
activating IKK (IκB Kinase) leading to the phosphorylation of IκBα and the release of NF-
κB to the nucleus. Additionally, TAK1 can activate the other MAPK (P38, ERK and JNK) 
leading to phosphorylation and activation of the AP-1 transcription factor. For as yet 
unknown reasons, the TLR7 sub-family of endosomal TLRs are able to recruit TRAF3 in 
addition to TRAF6 to the Myddosome. This allows for TRAF3 to K63 ubiquinate IRF7 
(interferon regulatory factor) and the subsequent phosphorylation of IRF7 by IKK. The 
then phosphorylated IRF7 forms dimers and induces type-1 interferon genes. (Gay et al, 
2014; Häcker et al, 2006; Kawasaki & Kawai, 2014; Lin et al, 2010). 
While the main output of MyD88 is NF-kB and AP-1 activation, TRIF signaling 
leads to the activation of IRF3 and a type-I IFN response. The only TLR known to have 
differential affinity for MyD88 and TRIF is TLR4. TLR4 initially signals through MyD88 at 
the plasma membrane but shortly after stimulation, the receptor complex is 
endocytosed. Endocytosis of plasma membrane TLRs is a mechanism the cell uses to 
modulate signaling, in most cases by degrading the signaling complex but in the case of 
TLR4, a secondary signaling response occurs first. After internalization, TLR4 is now 
able to recruit and activate the adaptor TRIF. Currently, this is the only TLR known to 
have duel specificity for both MyD88 and TRIF (Häcker et al, 2006; Kagan et al, 2008; 
Kawasaki & Kawai, 2014; Rosadini & Kagan, 2017).  
Recently, research has begun to show that TLRs are also capable activating the 
PI3k/Akt signaling pathway. While it is still unknown how TLRs are directly linked to the 
PI3k/Akt pathway, the TIR adaptors TIRAP, TRAM, BCAP and BANK1 have all been 
implicated in linking TLR stimulation to this pathway. While TIRAP may be responsible 
for recruiting the TLR:MyD88 complex to PIP2 domains, BCAP specifically is thought to 
mediate this crosstalk. BCAP’s TIR domain can associate with the TIR domain of 
MAL/TIRAPs and directly with other TLRs. BCAP also possesses a YxxM motif allowing 
for tyrosine phosphorylation and subsequent recruitment of both PI3k through its p85 
regulatory subunit and phosholipaseC (PLC) which both possess Src-homology (SH2) 
domains that recognize phosphorylated tyrosines (Halabi et al, 2016; Troutman et al, 
2012; Wu et al, 2016). These interactions allow the p110 catalytic subunit of the PI3k to 
convert PIP2 into phosphatidylinositol 3,4,5 triphosphate (PIP3). The PH domains of Akt 
(also known as Protein Kinase B) and PDK1 bind to PIP3 allowing for PDK1 to 
phosphorylate Akt at the threonine at aa308. Activated Akt can then go on to 
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phosphorylate a variety of different signaling proteins involved in apoptosis, proliferation, 
migration and specifically mTOR and GSK3 that are involved in glucose metabolism 
(Fruman and Rommel, 2014). Lastly, as hinted at earlier, BCAP can associate with PLC 
which suggests it may also be involved in connecting TLR signaling with Protein Kinase 
C (PKC) activation though more research is needed to confirm this hypothesis (Halabi et 
al, 2016). 
 
1.6 An Overview of Toll-like Receptor 10  
Despite the thousands of research articles on TLR expression, signaling and 
function within the immune system, TLR10 remains an orphan receptor with no 
confirmed ligand, signaling or function. The gene for TLR10 was first cloned in 2000 
though few research articles have been published on TLR10 since. The main reason 
why there has been minimal research done on TLR10 is because in mice, TLR10 exists 
as a non-functional pseudogene. Two retroviruses have inserted within the coding region 
of the TLR10 gene causing many to hypothesize that TLR10 is either not conserved in 
mammals or serves a redundant function. To address this first concern, intact TLR10 
genes have been found in every other mammalian species sequenced to date. Included 
within these species are all primates as well as mammals in the Rodentia Order 
including the Norwegian Rat (Rattus norvegicus), the Chinese Hamster (cricetulus 
griseus) and the Thirteen-Lined Ground Squirrel (ictidomys tridecemlineatus). The 
retroviral insertion into mice occurred evolutionarily long ago as all lab and wild-type 
mice contain this insertion. Additionally, analysis of ancestral DNA provided by JAX 
Laboratories that precedes Mus musculus also contains the retroviral insertion. This 
suggests that the TLR10 gene was disrupted sometime after mice split from rats but 
what evolutionary advantage/disadvantage that this incurred is difficult to interpret for 
several reasons that are expanded upon below (Chuang & Ulevitch, 2001). 
The loss of a functional TLR10 gene in mice is a major deterrent for many 
immunologists to study TLR10 because it prevents the creation of a knock-out mouse to 
assess the functional role for TLR10. Without knowing the functional role of TLR10 
within mice, it is difficult to determine what evolutionary advantages/disadvantages 
disrupting the TLR10 may have brought. While the loss of the TLR10 gene in mice is 
difficult to explain, it is important to highlight that the immune systems of mice and 
humans (or other mammals) vary is some very important ways. For example; the 
different antibody isotypes of mice serve different effector functions compared to 
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humans, mice tend to have a weaker response to LPS even though murine B cells 
express TLR4 while human B cells do not, and lastly the neutrophil is the predominant 
leukocyte in human blood though in mice, they are much less abundant and are in equal 
ratio with lymphocytes and monocytes (Mestas & Hughes, 2004).  
Additionally, there is a discrepancy in the number of TLRs expressed between 
mice and humans. While humans possess 10 functional TLRs (1-10) they also possess 
the TLR11 gene though as a pseudogene in much the same manner as TLR10 in mice. 
Mice have a functional TLR11 and two other novel mammalian TLRs 12 and 13. While 
TLR12 most likely evolved from a duplication event of TLR11, TLR13’s evolutionary 
origin is currently unknown. TLR11/12 form a heterodimer to recognize profilin, a major 
constituent of the cell wall of the intracellular bacteria Toxoplasma gondii. T. gondii 
represents a significant threat to the mice as its main host is within domestic cats. 
Infection of T. gondii in the mouse alters their behavior making it easier for them to be 
preyed upon by cats. This environmental factor has driven murine evolution, conserving 
and expanding the TLR11 gene only within rodents and not the other mammalian 
species. This example highlights that while TLR10 may not be important for murine 
biology, it does not mean that it is not important for other mammalian immune systems 
(Gazzinelli et al, 2014).  
 
1.7 The Divergence of TLR10 from the TLR2 Sub-family 
TLR10 is grouped with the TLR2 sub-family and shares its closest homology with 
TLR1 (Figure 1.3). In fact, TLRs 1, 2 and 10 are all located in tandem arrangement on 
chromosome 4 suggesting they each arose from gene duplication. Despite this close 
similarity, phylogenetic evidence supports the hypothesis that TLR10 split off from TLR1 
thousands of years ago and evolved a separate function. This hypothesis is supported 
by the work done in this thesis as with several unpublished observations described 
below. The TLR2 sub-family is not known to form homodimers though biochemical 
analysis of the TLR10 extracellular LRR domain either by a native gel or size-exclusion 
chromatography shows that TLR10 naturally forms homodimers without the presence of 
any known ligand (Figure 1.4). Not only does TLR10 diverge from the TLR2 sub-family 
by forming homodimers but the presence of steady-state homodimers in the absence of 
a known ligand is reminiscent of the intracellular TLRs and may suggest that an 
unknown ligand causes a conformation shift instead of dimerization (Guan et al, 2010; 
Roach et al, 2005).  
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While no crystal structure exists for the extracellular domain of TLR10, the 
intracellular TIR domain of TLR10 was crystallized in 2008. The TLR10 TIR domain 
crystallized as a homodimer though this is not unusual in the case of TIR domains as 
they have a natural affinity for dimerization highlighted by the TIR domain of TLR6 
crystallizing as a homodimer. The importance of the TLR10 TIR domain crystal structure 
is that the TIR domain fold is intact and mimics the TIR domains of the other TLRs. The 
difference between the TLR10 TIR domain and other TLR2 family members lies at the 
sequence level. Examining the BB loop of TLR10 highlights some important differences. 
First, the proline residue critical for correct folding and TLR signaling is conserved in 
TLR10. Much like TLR1/6, TLR10 also does not contain the necessary aspartic acid 
residue in the BB loop known to be sufficient to recruit MyD88 suggesting it recruits a 
different TIR-adaptor protein. Human TLR10 contains four separate amino acid changes 
within the BB loop; H>Y, R>S, N>Y and V>D (Figure 1.5). Of these four mutations, only 
the V>D is conserved across all mammalian TLR10 proteins. The mutation disrupts a 
sequence of four hydrophobic amino acids conserved within the TLR2 sub-family and 
may represent the key mutation in altering TLR10’s historical function (Figure 1.6) (Jang 
& Park, 2014; Nyman et al, 2008). 
 
1.8 TLR10’s Possible Functions 
The function of TLR10 is the main topic of this thesis but I will highlight some 
important work done by others in the field that both support and disagree with my thesis 
work. Due to a lack of reagents, most the early work on TLR10 was done at the mRNA 
level. The mRNA expression pattern of TLR10 has been studied within different 
leukocyte populations that show strong expression generally within lymphoid tissues. 
More specifically, TLR10 message has been detected within B cells, monocytes and 
neutrophils though no study has examined the protein level expression of TLR10. This 
gap in knowledge is explored in varying detail throughout my thesis (Hornung et al, 
2002).  
Most of the studies on TLR10 have used cell lines to either artificially 
overexpress different TLR10 constructs or to knockdown TLR10 expression via siRNA. 
The first paper to provide a possible function for TLR10 by Hasan et al published in 2005 
showed TLR10 to be a proinflammatory receptor. This was done by using CD4-TLR10 
chimeric receptors, where the extracellular CD4 domain form constitutive dimers, 
allowing the TLR10 TIR domain to dimerize. This experiment was repeated by our lab 
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(shown in Chapter 2) with opposite experimental conclusions. In 2013 and 2014, two 
papers by Regan et al and Lee et al each presented data supporting the idea that TLR10 
is also a proinflammatory TLR. In Regan et al, infection by live Listeria monocytogenes 
in TLR10 knocked down THP-1 cells exhibited a blunted cytokine response. In Lee et al, 
a similar blunting of immune responses was shown with infection of live flu virus (H1N1 
or H5N1) in THP-1 cells. These manuscripts suggest that TLR10 is either involved in the 
recognition of L. monocytogenes and flu virus or in amplifying the immune response. It is 
important to note that in both of these studies, the effect of TLR10 was only seen in live 
replicating bacteria/virus and in either study they do not present a mechanism of how 
TLR10 is functioning nor are they directly engaging the receptor (Hasan et al, 2005; Lee 
et al, 2014; Mourao-Sa et al, 2013; Regan et al, 2013). 
Also in 2014, the first paper showing an anti-inflammatory role for TLR10 was 
published by Oosting et al. This work was done on primary human mononuclear cells 
using an αTLR10 monoclonal antibody, clone 3C10C5 (developed in our lab and 
licensed). Although they show that TLR10 is anti-inflammatory, they only report that 
TLR10 suppresses TLR2 mediated responses. They conclude that the 3C10C5 αTLR10 
antibody is a blocking antibody that prevents TLR10 from competing for ligand and 
dimerization partners via the non-functional TLR2/10 heterodimer. There work is also 
supported by a transgenic mouse expressing TLR10 that showed reduced cytokine 
responses when challenged with TLR2 agonists (Guan et al. 2010; Oosting et al. 2014). 
 
1.9 Thesis Outline 
In my thesis, I present evidence that TLR10 is an anti-inflammatory receptor that 
can suppress MyD88-dependent, MyD88-independent and TNF receptor signaling. 
Supporting this finding, our lab created several αTLR10 monoclonal antibodies including 
the 3C10C5 clone that was used by Oosting et al. In my studies, I utilize both the 
3C10C5 and 5C2C5 αTLR10 clones in different cell types to activate TLR10 signaling. 
In additional to the monoclonal antibodies, our lab has also generated two 
different transgenic mouse models expressing human TLR10. The first mouse model 
utilized in Chapter 2 expresses human TLR10 under a constitutive CMV promoter to 
drive strong expression of the transgene. The second mouse model used in Chapter 4 
expresses human TLR10 under its native human promoter in an attempt to recapitulate 
the human expression pattern with corresponding levels of expression. 
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In Chapter 2 of my thesis, we present the first evidence that when overexpressed 
in cell culture or in a mouse model, TLR10 has the function of suppressing the activation 
of other TLRs. We also show that the suppressive function mediated by TLR10 is 
through a homodimer complex and not via association with other TLRs (Jiang et al, 
2016). In this manuscript, I contributed the data comprising Figure 7 as well as extensive 
editing and data analysis of the entire manuscript. I was also the main contact during the 
submission and review process for this manuscript.  
In Chapter 3, I build off our findings from Chapter 2 by analyzing the endogenous 
function of TLR10 on primary human monocytes. In this Chapter, I primarily utilize 
antibody-mediated engagement of TLR10 by utilizing the in-house created TLR10 
antibody clone 5C2C5. We show that not only does TLR10 suppress monocyte 
activation, there are additional downstream effects on dendritic cell maturation and 
functional capacity to activate T cells ex vivo. Additionally, we present evidence that 
TLR10 can suppress non-TLR stimulatory signals such as CD40 stimulation which is 
further supported by work in Chapter 4. 
Chapter 4 utilizes the in-house generated 3C10C5 TLR10 antibody clone in 
connection with primary human B cells and a human TLR10 promoter driven mouse 
model to assess TLR10’s function on B cells. With these tools, we show that the anti-
inflammatory function of TLR10 present within monocytes is similarly conserved in 
primary human B cells. Furthermore, using our transgenic mouse model, we are able to 
show that TLR10 can suppress the production of antigen-specific antibodies via either a 
T cell independent or a T cell dependent antigen in a B cell intrinsic manner.  
In Chapter 5, I utilize the 3C10C5 antibody clone to track the changes in TLR10 
expression throughout the B cell lineage, from the bone marrow to the tonsillar tissue on 
primary human cells. By doing this work, we have learned that TLR10 expression is 
regulated and which may impact its function within B cells. 
Lastly, Chapter 6 broadly summarizes the work done in this Thesis while also 
highlighting some unpublished data I have collected on TLR10. Then, using what we 
currently know about TLR10, I speculate on what the real physiological function of 
TLR10 may be and what possible ligands it may be able to recognize. In my final 
concluding remarks, I offer some potential therapeutic opportunities for the use of TLR10 
in the future to both treat and prevent chronic inflammatory and autoimmune diseases.  
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1.10 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The Human Toll-like Receptor Family 
Humans possess 11 TLR genes though the TLR11 gene is a disrupted 
pseudogene and non-functional. The plasma membrane localized TLRs detect 
bacterial and fungal components while the endosomal TLRs detect viral nucleic 
acid components. This figure represents the current knowledge of TLRs prior to 
this thesis. 
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Figure 1.2 The Association of TLRs and UNC93B1 via the Acidic Residues 
Proximal to the TLR Transmembrane Sequence 
The presence of aspartic and glutamic acid residues on the N-terminal region of 
the transmembrane region determines their association with the chaperone 
protein UNC93B1. Other than TLR5, all TLRs associated with UNC93B1 are 
intracellular TLRs.  
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Figure 1.3 The Human TLR Phylogenetic Tree 
The TLR family is broadly grouped into the TLR2 (TLR1/2/6/10) and TLR7 
(TLR7/8/9) sub-families that each share similar ligands and localization. TLRs 
3/4/5/ do not map into a specific sub-family and are thus slightly distinct from 
the other TLRs is some aspect of their biology. 
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Figure 1.4 TLR10 Forms Constitutive Homodimers 
(A) Gel filtration chromatography on purified extracellular domains of TLR1 and 
TLR10 shows that TLR1 elutes as a monomer while TLR10 elutes as a 
homodimer. Data from Dr. Diana Ranoa. (B) Purified extracellular domains of 
TLR1 and TLR10 were run on a native gel. While TLR1 existed only as a 
monomer, the TLR10 extracellular domain shows some partial dimerization in 
the current conditions of this assay. 
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Figure 1.5 Alignment of the BB Loop of the Human TLRs and TIR Adaptor 
Proteins 
The RDXXP motif is conserved in all TLRs except for TLR10. The unrelated 
TLRs 3/8/10 all have acidic residues within the relatively conserved four residue 
hydrophobic region. 
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Figure 1.6 Alignment of the BB Loop of the Mammalian TLR10 Proteins 
The aspartic acid residue of TLR10 that lies within the relatively conserved 
hydrophobic patch of the TLR BB loop is the only residue that is completely 
conserved in other mammalian species. 
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CHAPTER II: TLR10 IS A NEGATIVE REGULATOR OF BOTH MYD88-DEPENDENT 
AND –INDEPENDENT SIGNALING 
 
Jiang, S., Li, X., Hess, N.J., Guan, Y., Tapping, R.I. TLR10 Is a Negative Regulator of 
Both MyD88-Dependent and -Independent TLR Signaling. J. Immunol. 196, 3834–3841. 
(2016). 
2.1 Abstract 
Toll-like receptors are central components of the innate immune system which, 
upon recognition of bacterial, fungal or viral components, activate intracellular signals 
that lead to protective inflammatory responses. Among the ten-member human TLR 
family, TLR10 is the only remaining orphan receptor without a known ligand or signaling 
function. Murine TLR10 is a disrupted pseudogene, which precludes investigation using 
classic gene knock-out approaches. We report here that TLR10 suppressed the 
production of an array of cytokines in stably transfected human myelomonocytic U937 
cells in response to other TLR agonists. This broad TLR suppressive activity affects both 
MyD88 and TRIF-mediated signaling pathways upstream of IκB and MAPK activation. 
Compared to non-transgenic littermate controls, monocytes of TLR10 transgenic mice 
exhibited blunted IL-6 production following ex vivo blood stimulation with other TLR 
agonists. After intraperitoneal injection of LPS, lower levels of TNFα, IL-6 and Type 1 
IFN was measured in the serum of TLR10 transgenic mice, compared to non-transgenic 
mice, but did not affect mouse survival in an LPS-induced septic shock model. Finally, 
treatment of human mononuclear cells with a monoclonal anti-TLR10 antibody 
suppressed pro-inflammatory cytokines released by LPS stimulation. These results 
demonstrate that TLR10 functions as a broad negative regulator of TLR signaling and 
suggests TLR10 may have a role in controlling immune responses in vivo.  
 
2.2 Introduction 
Toll-like receptors are type 1 transmembrane receptors that are part of a broad 
class of innate immune receptors known as pattern-recognition receptors. TLRs serve as 
the first line of defense against infectious pathogens by initiating protective inflammatory 
responses following the direct sensing of bacterial, fungal or viral components. 
Recognition of a cognate microbial ligand by the extracellular leucine-rich repeat domain 
of each TLR leads to receptor dimerization (Kawai & Akira, 2010). This event dimerizes 
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two C-terminal TIR-domains which provide a scaffold for the recruitment of other 
cytosolic TIR-domain containing adaptor molecules that propagate intracellular signaling 
(Kawasaki & Kawai, 2014; Gay et al, 2014).  
Humans possess 10 TLR family members, numbered 1 through 10, subsets of 
which are expressed in leukocytes and various tissue cells (Chuang & Ulevitch, 2001; 
Hornung et al, 2002). TLRs 1, 2, 4, 5 and 6 traffic to the plasma membrane, sense 
microbial and fungal cell wall components and stimulate the production of classic 
proinflammatory molecules. TLRs 3, 7, 8 and 9 are located in endosomal compartments, 
sense viral and bacterial nucleic acids and are best known for their ability to stimulate 
the production of Type 1 IFNs (Gay et al, 2014). Almost all TLRs utilize the TIR-domain 
containing adaptor MyD88 which upon recruitment to dimerized TLRs at the plasma 
membrane induce the activation of NF-κB and other transcription factors that promote 
expression of classic pro-inflammatory cytokines (Lin et al, 2010). TRIF is utilized by 
both TLR3 and endosomal TLR4 and, in a MyD88-independent manner, drives the 
expression of Type 1 IFN production through activation of the transcription factor 
interferon response factor 3 (IRF3) (Gay et al, 2014).  
To date, we have a fairly clear understanding of the ligand recognition, signaling 
and biological functions of human TLRs 1 through 9. In contrast, TLR10 is the only 
remaining orphan human TLR without a confirmed ligand, signaling pathway or 
biological function. The TLR10 gene was first cloned in 2001 and various studies has 
revealed strong transcriptional expression in the lymphoid tissues including the spleen, 
lymph node, thymus and tonsils. TLR10 is expressed among a number of leukocyte 
subtypes and perhaps most prominently by B cells (Chuang & Ulevitch, 2001; Hornung 
et al, 2002). A major obstacle toward defining a function for TLR10 is that several 
retroviral insertion elements have rendered TLR10 a pseudogene in mice thus 
precluding a classic knockout mouse model (Hasan et al, 2005). Although TLR10 is 
disrupted in mice, every other mammal sequenced to date contains an undisrupted 
TLR10 gene including numerous primate species, domestic animals and a variety of 
rodents (Mikami et al, 2012; Roach et al, 2005). 
TLR10 is most homologous to TLR1 and TLR6 which both cooperate with TLR2 
to mediate inflammatory responses to a variety of microbial lipids including bacterial 
lipoproteins (Mikami et al, 2012; Roach et al, 2005). Previously, we have shown that 
TLR10 is capable of binding the TLR2/1 ligand PAM3CSK4 in cooperation with TLR2. 
The resulting dimer is able to recruit MyD88 although no TLR-associated events 
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including the transcriptional activation of NF-κB, IL-8 and IFN-β promoters has been 
detected (Guan et al, 2010). Sequence analysis has revealed that the TIR domain of 
TLR10 is less conserved and has a calculated rate of evolutionary change that is higher 
than that of any other TLR (Mikami et al, 2012). This suggests that TLR10 may have a 
unique function among the TLR family. 
To assess the function of human TLR10 we have generated stably transfected 
monocytic cells lines, a transgenic mouse model as well as biologically active 
monoclonal antibodies to the TLR10 receptor. Collectively, our findings support the idea 
that TLR10 is an anti-inflammatory receptor. Importantly, we also show that the TLR10-
mediated suppression broadly effects both MyD88 and TRIF-dependent signaling 
pathways making TLR10 a potential global suppressor of TLR signaling. 
 
2.3 Materials and Methods 
Reagents 
Antibodies specific for phospho p38 (clone D3F9), phospho-JNK (clone 81E11), 
phospho-ERK (clone D13.14.4E), IκBα (clone 44D4) and β-actin (clone 13E5) were from 
Cell Signaling Technologies (Beverly, MA). Anti-FLAG antibody (clone M2) are from 
Sigma-Aldrich (St. Louis, MO).  FITC conjugated CD11b (clone 3A33) were from Abcam 
(Cambridge, MA). Directly conjugated antibodies to Ly6G (clone 1A8) and IL-6 (clone 
MP5-20F3) were from BioLegend (San Diego, CA). The synthetic triacylated lipopeptide 
Pam3CSK4 was purchased from Alexis Biochemicals (San Diego, CA), LPS from E. coli 
strain K235 and pI:C were from Sigma-Aldrich. Monoclonal antibodies against the 
extracellular domain of recombinant human TLR10 were produced in-house. One clone, 
3C10C5, is commercially available. The antibody clone used in this study is 5C2C5. The 
isotype control used was MOPC-21, a murine IgG1 with no known specificity. 
 
Plasmid Constructs 
Expression constructs for TLR10, TLR1, TLR1-10, TLR10-1, CD4-TLR10, CD4-
TLR1, MyD88, TRIF, IL-8 promoter driven luciferase, IFN-β promoter driven luciferase, 
and Renilla-luciferase transfection control are previously described (Guan et al., 2010). 
The pMX-IRES-Puro expression vector, used for the production of retrovirus, was 
purchased from Cell Biolabs (San Diego, CA).  This vector was then modified to include 
a preprotrypsin leader sequence and a FLAG linker region into which the coding region 
of TLR10 was sub-cloned to generate pMX-FLAG-TLR10. The CMV-FLAG-TLR10 
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plasmid, used in the generation of TLR10 transgenic mice, was constructed by inserting 
the TLR10 coding sequence lacking the endogenous signal peptide into pFLAG-CMV 
vector (Sigma-Aldrich).  
 
Development of Stable Cell Lines 
The NIH3T3 amphoteric packaging line was plated in 10cm dishes and 
transfected with either pMX-FLAG-TLR10 or the empty pMX-FLAG vector using FuGene 
6 according to manufacturer’s instructions (Roche, Indianapolis, IN).  Forty-eight hours 
after transfection, viral supernatants were cleared of cell debris and applied to parental 
U937 cells during log phase growth.  Twenty-four hours after viral transduction, virus 
was removed and stably transduced cells were selected in media containing 2 µg/ml 
Puromycin (Sigma-Aldrich).  Batch derived cells were expanded and surface expression 
of the FLAG epitope was verified. 
 
Cell Culture and TLR Stimulation 
Human cell lines were cultured in RPMI medium supplemented with 10% FBS, 
2mM L-Glutamine, 100 IU/ml Penicillin, and 100 µg/ml Streptomycin.  Stably transduced 
U937 cells were kept under selection in the presence of 2 µg/ml Puromycin (Sigma-
Aldrich).  To investigate cytokine production, cells were plated at 5x104 cells per well in 
96-well plates and differentiated with PMA at 100 ng/ml for 48 hours.  Cells were then 
washed and allowed to rest in fresh media for 24 hours.  Media was replaced before 
cells were stimulated with either 50ng/ml PAM3CSK4, 50 µg/ml pI:C, or 50 ng/ml LPS. 
Cells were stimulated overnight with the indicated agonist and cell-free supernatants 
were collected for cytokine analysis. 
 
Transient Transfection Assays 
HEK293T cells were transfected in 12-well plates using FuGene 6 with vectors 
encoding either MyD88 or TRIF constructs (20 ng/ml), TLR vectors (100 ng/ml), either 
IL-8 or IFN-β luciferase reporter (150 ng/ml) and Renilla luciferase as a transfection 
control (50 ng/ml).  Luciferase readings were obtained using the Dual-Luciferase Assay 
Kit (Promega, Madison, WI) according to the manufacturer’s instructions. 
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Real-time PCR Analysis 
U937 cell lines were plated at 2x106 cells/mL and differentiated for 48 hours in 
100 ng/ml PMA.  Media was changed and cells were allowed to rest for 24 hours before 
stimulation with 100 ng/ml PAM3CSK4 for 4 hours.  After stimulation, cells were 
harvested and RNA was isolated using the RNeasy kit (Qiagen, Hilden, Germany).  RNA 
quality was assessed by spectrophotometry and agarose gel electrophoresis. Specific 
mRNA transcripts were quantified using the SABiosciences TLR pathway qPCR Array 
(Qiagen), according to manufacturer’s instructions. The array includes analysis of 84 
genes involved in TLR signaling plus five housekeeping genes for normalization as well 
as controls for genomic DNA contamination, RNA quality, and general PCR 
performance.  
 
Analysis of MAPK Signaling and NFκB Activation 
Vector control and TLR10-expressing U937 cells were stimulated with either 50 
ng/ml PAM3CSK4, 50 µg/ml pI:C or 50 ng/ml LPS for the indicated time periods.  Cell 
lysates were prepared from 1x107 cells in RIPA lysis buffer (150mM NaCl, 50mM Tris-
HCl PH8.0, 1% NP-40, 1mM EDTA) supplemented with the Halt protease and 
phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL).  Equal amounts of 
protein lysate were loaded on SDS-PAGE gels, transferred to PVDF membranes and 
blotted using specific antibodies (Cell Signaling Technologies, Beverly, MA). 
 
Development of TLR10 Transgenic Mice 
CMV-FLAG-TLR10 plasmid (Guan et al., 2010) was digested with Spe1 and Stu1 
and 2μg of the purified linearized CMV-FLAG-TLR10 double stranded DNA was injected 
into C57BL/6 (Harlan Laboratories) fertilized oocytes. Early embryos were then 
transferred into Swiss Webster pseudo pregnant fosters to generate transgenic 
founders. Pups were weaned and genotyped using a primer set specific to the 5’ end of 
the transgene: Forward 5’-ACA AAG ACG ATG ACG ACA AGC-3’ and Reverse 5’-AAT 
AGA ACC GAT GTC TTA GC-3’. A second primer set was specific to the 3’ end of the 
transgene: Forward 5’-ACT TTG TCC AGA ATG AGT GG-3’ and Reverse 5’-TAT TAG 
GAC AAG GCT GGT GG-3’. All transgenic mice were generated by the Transgenic 
Mouse Core Facility at University of Illinois Urbana-Champaign under an approved 
IACUC protocol. 
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Southern Blot Analysis 
Mouse tail genomic DNA was isolated through proteinase K treatment and 
phenol:chloroform:isoamylalcohol (25:24:1) purification. A total of 5 μg of genomic DNA 
was digested with Sac1 and separated on a 1% agarose gel. DNA was blotted onto 
Immobilon-Ny+ membrane (Millipore Inc.), washed with 6 x SSC buffer and then cross-
linked using a UV Stratalinker (Agilent technologies). Hybridization was carried out at 
65C with a biotin-labeled 3’-transgene fragment containing the hGH polyA sequence of 
the CMV-FLAG-TLR10 vector as described by the manufacturer (South2North, Thermo 
Scientific). Transgene copy number was estimated from copy number standards 
containing varying amounts of unlabeled probe DNA. 
 
Tissue RNA Extraction and RT-PCR 
Approximately 100 mg of mouse tissue was homogenized in 1 ml Trizol (Ambion 
Inc.) reagent using a Dounce homogenizer (Wilmad lab glass). RNA was then purified 
with PureLinkTM RNA purification kit (Ambion Inc.) and used to generate 1st strand 
cDNA with SuperScript III reverse transcriptase (Invitrogen Inc.). PCR was carried out 
using the forward primer 5’-ACA AAG ACG ATG ACG ACA AGC-3’ and the reverse 
primer 5’-AAT AGA ACC GAT GTC TTA GC-3’.  
 
Western Blotting of TLR10 
Mouse tissue was ground with a Dounce homogenizer in 1 ml RIPA lysis buffer 
containing protease and phosphatase inhibitors. Cell homogenate was then incubated 
on ice for 2 hours followed by centrifugation at top speed for 15 minutes at 4C. Total 
protein was separated on a 7% SDS-PAGE gel, blotted onto PVDF membrane (GE 
Healthcare) and probed with HRP conjugated anti-FLAG antibody (clone M2).   
 
Mouse Whole Blood Stimulation and Intracellular IL-6 Staining 
Mouse whole blood was collected from the lateral tail vein of age and gender 
matched non-transgenic and transgenic mice. 50 μL of whole blood was mixed with an 
equal volume of RPMI medium containing either 500 ng/ml PAM3CSK4, 100 µg/ml pI:C 
or 200 ng/ml LPS and incubated at 37C with gentle agitation overnight. Centrifuged 
supernatants were assessed for cytokines by standard ELISA. For intracellular IL-6 
staining, 100 µl mouse whole blood was stimulated with 500 ng/ml LPS in the presence 
of Brefeldin A for 6 hours. Red blood cells were lysed with ACK buffer and peripheral 
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blood leukocytes were stained with anti-mouse CD11b and Ly6G antibodies. 
Permeabilized cells were stained with directly conjugated anti-mouse IL-6 antibody or 
isotype control antibody. 
 
Intraperitoneal Injection and Shock Assay 
Age and gender matched non-transgenic and transgenic mice (8-10 week old) 
were injected intraperitoneally with a high dose of LPS, 0111:B4 (20-25mg/kg). Tail 
blood was collected at 1 and 4 hours post injection and serum was prepared and 
assayed for cytokines as above. In the shock assay, injected mice were monitored for 
survival for up to 7 days. 
 
Cytokine Assays 
Human IL-6 and IL-8 as well as mouse IL-6 and TNFα were analyzed by paired-
antibody ELISA according to manufacturer’s instructions (Invitrogen, Grand Island, NY).  
Type 1 IFN was detected using an ISRE-L929 reporter cell line bioassay (a kind gift from 
Dr. Bruce Beutler, UT Southwestern).  Briefly, ISRE-L929 cells were plated at 2x104 cells 
per well in a 96-well format.  Cell culture media was replaced 24 hours later with cell-free 
supernatant from either stimulated U937 cells or mouse serum. ISRE-L929 cells were 
incubated for another 6 hours and luciferase activity was detected in cell lysates using a 
luciferase reporter assay system (Promega). 
 
Human Mononuclear Cell Stimulation 
Primary human mononuclear cells were obtained from venous blood of 
consenting healthy adult volunteers under an approved IRB protocol. Blood was mixed 
1:1 in Leukocyte Isolation Buffer (1X PBS, 2 mM EDTA, 2% FBS) before centrifuging 
over a Ficoll gradient (1.077g/L) at 1100xg for 15 min with no brake. The resulting buffy 
coat was washed twice in cell culture media before plating 100 μL of ~2-5x104 cells in a 
96 well plate. Cells were allowed to pre-incubate in the presence of either an isotype 
control (clone MOPC-21) or anti-TLR10 antibody (clone 5C2C5) before stimulation with 
either LPS (10 ng/mL), pI:C (5 μg/mL) or IFNβ (100 ng/mL). After 24h, cell-free 
supernatants were collected and assayed by ELISA.  
 
Statistical Analysis 
All data were analyzed with two-tailed Student’s t test unless otherwise indicated. 
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2.4 Results 
TLR10 is a Suppressor of TLR2/1-Induced Responses 
To examine the biologic function of TLR10, we stably expressed the receptor in 
U937 cells, a human myelomonocytic line which we found lacks detectable endogenous 
TLR10 expression (Fig. 2.1A). Using MMLV retrovirus, a N-terminally tagged FLAG-
TLR10 construct was stably transduced into U937 cells and TLR10 expression was 
confirmed by both RT-PCR and flow cytometry using an anti-FLAG antibody (Fig. 2.1, A 
and B). The stably transduced cell line exhibited no differences in cell growth or viability 
compared to either the parental or empty vector (MMLV) control lines (unpublished 
observation). To explore potential signaling outputs of TLR10, we compared the CMV 
and TLR10 cell lines for the expression of 84 genes known to be targets of TLR 
signaling following stimulation with the TLR2/1 lipopeptide agonist PAM3CSK4. 
Compared to CMV-U937 cells, the RNA message for 11 genes had lower PAM3CSK4 
induction levels in TLR10-U937 cells. These genes included those encoding the pro-
inflammatory cytokines TNFα, IL-1α, IL-6 and IFN-β. These genes also included the anti-
inflammatory cytokine IL-10 which was also suppressed in TLR10-U937 cells compared 
to control CMV-U937 cells (Table 2.1). Supernatants from cells stimulated with varying 
concentrations of PAM3CSK4 confirmed that TLR10-U937 cells secreted significantly 
lower levels of both IL-6 and TNFα (Fig 2.2). These data suggest that TLR10 mediates 
an anti-inflammatory function in U937 cells stimulated with TLR2/1 lipopeptide agonist. 
 
TLR10 Inhibits TLR-Induced Inflammatory Responses 
To examine the specificity of TLR10 suppression, we stimulated the U937 cell 
lines with TLR agonists in addition to those for TLR2/1 (PAM3CSK4), including TLR2/6 
(MALP-2), TLR3 (pI:C) and TLR4 (LPS). Compared to CMV-U937 cells, TLR10-U937 
cells secreted significantly less IL-6 in response to all the TLR agonists tested (Fig. 
2.1C). The secretion of Type 1 IFNs following stimulation with the TLR3 agonist pI:C 
(Fig. 2.1D) was also marked decreased in TLR10-U937 cells. The cell lines had 
indiscernible differences in IL-6 production in response to IFN-β as well as indiscernible 
differences in Type 1 IFN production in response to TNFα.  Taken together these results 
support the idea that TLR10 broadly inhibits production of both IL-6 and IFN-β induced 
by a variety of TLRs but not the production of these cytokines induced through other 
signaling pathways. 
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TLR10 Suppresses IκBα Degradation and the Phosphorylation of MAPKs 
To gain insight into the mechanism of TLR10-mediated suppression we analyzed 
the effect of TLR10 on various canonical TLR signaling pathways including the activation 
of NF-κB and various MAP kinases. As shown in Fig. 2.3, PAM3CSK4, pI:C and LPS 
each triggered IκBα degradation within 30 minutes of TLR stimulation in vector control 
cells. However, degradation of IκBα was consistently inhibited in TLR10-expressing 
cells, suggesting that TLR10 suppresses NF- κB signaling upstream of IκBα 
degradation. TLR10-U937 cells also exhibited reduced ERK, JNK, and p38 
phosphorylation levels compared to vector control cells following stimulation with TLR 
agonists PAM3CSK4, pI:C or LPS. Taken together, these results indicate that TLR10 acts 
as a broad suppressor of TLR-induced pro-inflammatory signaling including NF-κB and 
MAP kinase signaling pathways. 
 
TLR10 Suppresses MyD88 and TRIF Signaling 
The ability of TLR10 to broadly suppress responses from a variety of TLRs 
suggests that this receptor inhibits MyD88-dependent signaling. To assess this we 
examined the effect of TLR10 on HEK293T cells expressing MyD88. As expected, the 
overexpression of MyD88 in HEK293T cells resulted in strong constitutive induction of 
an IL-8 promoter-driven luciferase reporter (Fig. 2.4A). Consistent with its suppressive 
role, co-expression of TLR10 resulted in an 8-fold reduction of MyD88-induced IL-8 
luciferase activity. In contrast, co-expression of TLR1, the closest homologue of TLR10, 
had no measureable effect. 
The inhibitory effect on TLR3-induced IFN-β production strongly suggests that 
TLR10 also suppresses MyD88-independent signaling mediated by the TLR adaptor 
TRIF. To assess this we examined the effect of TLR10 on HEK293T cells expressing 
TRIF which induces constitutive activation of IRF3 thereby driving Type 1 IFN 
production. The overexpression of TLR10 resulted in a marked reduction of Type 1 IFN 
production, as measured by a bioassay, while co-expression of TLR1 had no 
measureable effect (Fig. 2.4B). Importantly, TLR10 suppression of both MyD88 and 
TRIF-mediated pathways is dose-dependent (Fig. 2.5). The data together suggest that 
TLR10 acts as a negative regulator of pro-inflammatory TLR signaling, targeting both 
MyD88 and TRIF-dependent TLR signaling. 
To assess the roles of the extracellular LRR domain and the intracellular TIR 
domain of TLR10 in suppression we generated chimeric receptors between TLR1 and 
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TLR10. Interestingly, neither the construct containing the extracellular domain of TLR1 
and the intracellular domain of TLR10 (TLR1-10) or the reverse chimeric receptor 
(TLR10-1) were able to suppress MyD88-dependent or TRIF-dependent activation 
demonstrating that both domains of TLR10 are required for its suppressive function (Fig. 
2.4, A and B).  To assess the role of receptor dimerization, we replaced the extracellular 
domain of TLR10 with that of CD4; an approach that has been shown to cause 
constitutive TIR domain-mediated signaling since CD4 naturally forms dimers. Similar to 
full length TLR10, CD4-TLR10 inhibited both MyD88 and TRIF-dependent signaling. In 
contrast, CD4-TLR1 had no effect on either MyD88 or TRIF signaling (Fig. 2.4, C and D). 
Cellular expression of all the chimeric receptors was confirmed by flow cytometry (Fig. 
2.6). Taken together, these data suggest that TLR10 functions as a homodimer to 
suppress both MyD88 and TRIF-dependent TLR signaling. 
 
Development of TLR10 Transgenic Mice 
To explore the potential function of TLR10 in vivo, we developed a transgenic 
mouse in which an N-terminally FLAG-tagged human TLR10 is constitutively expressed 
behind a strong viral promoter. Thirty-two pups were derived from oocyte injection of the 
vector and then screened for the transgene with 14 PCR positive founders further 
analyzed by southern blot (Fig. 2.7A). A founder with an intermediate copy number of 
the transgene and broad tissue expression was selected from among the 14 candidates 
for further analysis (Fig. 2.7B). TLR10 expression levels were highest in the spleen with 
confirmed expression in blood leukocytes (Fig. 2.7C). 
Founder mice showed no overt developmental abnormalities and reproduced at 
expected mendelian ratios. However, two founders which exhibited the highest level of 
TLR10 expression across a variety of tissues developed lethal urethral tract infections in 
the first two months of life. Necroscopy revealed a high concentration of Gram-positive 
bacteria including Staphylococcus aureus as well as species of Enterococcus in the 
urine (unpublished observation). These observations suggest that high levels of TLR10 
expression in mice may suppress the immune system allowing for the opportunistic 
overgrowth of commensal bacteria. 
 
TLR10 Transgenic Mice Exhibit Reduced TLR-Induced Responses 
To determine the effect of TLR10 expression on murine blood leukocytes we 
examined IL-6 production following ex vivo stimulation of whole blood with different TLR 
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agonists. Production of IL-6 in whole blood of TLR10 transgenic mice was significantly 
lower than that of non-transgenic control mice in response to PAM3CSK4, pI:C and LPS 
(Fig. 2.8A). The reduced cytokine production is not due to any significant differences in 
the numbers of peripheral blood monocytes or neutrophils (Fig. 2.9). To identify the cell 
type(s) that are targeted by TLR10-mediated suppression, we stimulated mouse 
peripheral blood ex vivo with LPS and measured intracellular IL-6 by flow cytometry. 
Monocytes (CD11b+, Ly6G-), but not neutrophils (CD11b+, Ly6G+), were shown to have 
suppressed IL-6 production in response to LPS stimulation compared to equivalent cells 
from non-transgenic control mice (Fig. 2.8 B and C). These data confirm our previous 
findings in human myelomonocytic cell lines and suggest that even in a murine 
background human TLR10 maintains its function as an inhibitor of pro-inflammatory 
cytokine production. 
 
TLR10 Suppresses in vivo Response to LPS 
To assess the role of TLR10 in vivo, we measured blood cytokine levels in mice 
following intraperitoneal injection with a sub-lethal dose of LPS. The induction of IL-6, 
TNFα and Type 1 IFNs were all reduced in the TLR10 transgenic mice compared to the 
non-transgenic littermate control mice (Fig. 2.10A). To determine if TLR10 can protect 
mice from LPS-induced septic shock, we monitored survival following intraperitoneal 
injection of mice with a high, almost uniformly fatal, dose of LPS. However, no significant 
difference in either mortality or time-to-death was observed between TLR10 transgenic 
and non-transgenic mice (Fig. 2.10B). These data show that TLR10 is able to suppress 
a broad array of TLR responses in both MyD88 and TRIF-dependent manners but is not 
capable of protecting mice from LPS-induced septic shock in vivo.  
 
Endogenous TLR10 Suppresses Human Mononuclear Cell Activation 
To assess the effect of TLR10 engagement on pro-inflammatory responses, we 
incubated human mononuclear cells isolated from the peripheral blood of healthy donors 
with either an anti-TLR10 antibody or a non-specific isotype matched control antibody. 
These cells were then stimulated overnight with either the TLR4 agonist LPS or the 
TLR3 agonist pI:C. Compared to an isotype control antibody, the anti-TLR10 antibody 
suppressed the secretion of both IL-6 and TNFα from the mononuclear cells of two 
independent donors (Fig. 2.11). This data shows that antibody engagement of 
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endogenous human TLR10 in primary human cells suppresses inflammatory responses 
mediated by MyD88. 
 
2.5 Discussion 
Previously we have shown that the TLR10, either alone or with TLR2, fails to 
activate pro-inflammatory responses typically associated with this family of receptors 
(Guan et al, 2010). In this paper, results stemming from a variety of experimental 
approaches support the idea that TLR10 functions as a broad suppressor of other TLRs 
with inhibitory activity toward both MyD88 and TRIF-dependent signaling.  We believe 
that, as a suppressor, TLR10 functions as a homodimer as evidenced by the fact that 
replacement of the extracellular domain of TLR10 with CD4, but not the extracellular 
domain of TLR1, results in a receptor that retains full suppressive function. Consistent 
with this notion is the observation that the crystal structure of the TLR10 TIR domain was 
solved as a symmetric homodimer (Nyman et al, 2008). Additionally, using gel filtration 
chromatography, we have found that the TLR10 extracellular domain purifies as a 
homodimer (data not shown). Together, these observations suggest that the 
extracellular and TIR domains of TLR10 contribute to homodimerization and that this 
event can be driven by either overexpression, in cell lines or mice, or through 
engagement of the endogenous receptor with a divalent monoclonal antibody. 
Among members of the TLR family, TLR10 is most homologous to TLRs 1 and 6 
with highest homology observed within the signaling TIR domain (Roach et al, 2005).  In 
the crystal structure of the TLR10 TIR domain a portion of the BB loop forms part of the 
dimer interface but much of the loop is exposed and available to interact with TIR 
domain adaptor molecules such as MyD88 and TRIF (Nyman et al, 2008).  In this 
context, there are notable differences in key residues of the BB loop that mediate 
intracellular signaling which include a two amino acid insertion just before the BB loop as 
well as amino acid changes within residues of the BB loop itself. Whether these 
difference are responsible for the suppressive activity of TLR10 remains to be 
investigated. 
In support of our studies, another report published last year revealed TLR10 as 
an anti-inflammatory receptor that suppresses TLR2-mediated inflammatory responses 
in both human mononuclear cells and in a transgenic mouse model (Oosting et al, 
2014). In that study TLR10 was shown to suppress the release of a number of pro-
inflammatory cytokines in response to the TLR2 agonists PAM3CSK4 as well as whole 
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Borrelia burgdorferi. In support of this, genetic polymorphisms in TLR10 have been 
shown to associate with variability of responses to bacterial lipopeptide (Mikacenic et al, 
2013). A number of possible mechanisms for suppression are proposed including 
possible competition for ligand and/or co-receptors as well as the induction of anti-
inflammatory cytokine expression. This study extends the suppressive function of TLR10 
to that of other TLR family members as well as to both MyD88 and TRIF-dependent 
signaling pathways. Our analysis of signaling pathways indicate that TLR10 acts 
proximally in the signaling cascade through a currently undefined mechanism. 
Two other studies have proposed an opposite, pro-inflammatory, function for 
TLR10. One study showed that siRNA-mediated knock down of endogenous TLR10 in 
HT-29 colonic epithelial cells blunted inflammatory responses to Listeria monocytogenes 
(Regan et al, 2013). Another study, showed that knock down of TLR10 in the THP-1 
myelomonocytic cell line inhibited cellular responses to the H1N1 and H5N1 flu virus 
strains (Lee et al, 2014). Interestingly, both studies revealed fairly broad effects on pro-
inflammatory cytokine and Type 1 IFN production that were dependent on infection of 
cells with live pathogens but not with heat-killed pathogens. Since both these organisms 
replicate in the cytoplasm, this suggests that intracellular forms of TLR10 may have a 
pro-inflammatory function following recognition of a PAMP associated with virulence 
(Mourao-Sa et al, 2013). In the study of flu virus, transfection studies suggested that 
TLR10 responds to viral ribonuclear protein complexes (Lee et al, 2014).  Although 
these findings contrast our own and others (Oosting et al, 2014), it is noteworthy that we 
have engaged endogenous TLR10 at the cell surface where it may possess an opposing 
signaling function. 
The finding that TLR10 is a negative regulator among members of the TLR family 
is perhaps not surprising (Kondo et al, 2012). Even within the closely related IL-1 
receptor family, whose members have TIR domains and utilize MyD88 to propagate 
signaling, are two inhibitory receptors known as ST2 (Brint et al, 2004) and SIGIRR 
(Wald et al, 2003). The transmembrane receptor ST2 has been shown to suppress NF-
κB activation mediated by TLR2, TLR4 and TLR9 but not TLR3 by sequestering the 
adaptor proteins MyD88 and MAL. SIGIRR has been shown to inhibit MyD88-dependent 
signaling through its interactions with TRAF6 (TNF receptor-associated factor 6) and 
IRAK (Interleukin-1 receptor-associated kinase 1) (Wald et al, 2003). Thus, there is 
precedence for regulatory or inhibitory function among members of the TLR/IL-1 
receptor superfamily. 
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The biologic function of TLR10 may not be truly understood until a natural ligand 
has been discovered. Nevertheless, since sustained TLR signaling is an underlying 
feature of a wide variety of chronic inflammatory conditions including many autoimmune 
diseases and cancers (Mikacenic et al, 2013), the characterization of TLR10 as a 
broadly acting suppressor of TLR activation has far reaching therapeutic implications. 
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2.7 Figures and Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Stable TLR10 expression in U937 cells suppresses TLR-induced 
cytokine production 
Parental U937 cells were transduced either with MMLV encoding FLAG-tagged 
TLR10 or an empty control MMLV.  Stably transduced cells were isolated after 
two weeks of selection under 2 µg/ml Puromycin. (A) RT-PCR analysis of TLR10 
expression in MMLV-U937 versus TLR10-U937 cell lines (B) Surface staining of 
TLR10 transfected and control cells using an anti-FLAG antibody. Cells were 
gated on forward and side scatter characteristics. (C) TLR10-U937 and MMLV-
U937 control cells were differentiated for 48 hours in PMA. Cells were stimulated 
with the indicated agonist overnight, after which IL-6 was measured in cell-free 
supernatants using a paired-antibody ELISA and (D) Type 1 IFN was measured 
using an ISRE-L929 luciferase reporter assay. Luciferase activity was normalized 
to that of unstimulated MMLV control cells. Error bars represent the standard 
deviation of three independent samples and statistical analysis was performed 
using two-tailed paired Student’s t test. * p<0.01 
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Table 2.1 Down-regulated genes in stably transfected TLR10-U937 cells  
TLR10-U937 and MMLV-U937 control cells were differentiated for 48hrs in PMA and 
stimulated with 50 ng/ml PAM3CSK4 for 4 hrs. RNA was isolated and analyzed by real-
time PCR for message levels of selected of inflammatory genes. Data represent a 
subset of the 84 genes tested in the array that, after normalization to house-keeping 
genes (last 5 rows), showed greater than 2-fold difference between TLR10 and MMLV 
control cells. 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 TLR10 Suppresses PAM3CSK4-induced Cytokine Production in Stably 
Transfected U937 cells  
TLR10-U937 and MMLV-U937 control cells where differentiated for 48hrs with PMA 
and stimulated overnight with varying concentrations of PAM3CSK4 as indicated. (A) 
IL- measured in cell-free supernatants using a paired-antibody 
ELISA. Error bars represent the standard deviation of three independent samples and 
statistical analysis was performed using two-tailed paired Student’s t test. * p<0.01 
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Figure 2.3 TLR10 suppresses phosphorylation of MAPKs and degradation of IκB 
TLR10-U937 and MMLV-U937 control cells were stimulated with either (A) 50 ng/mL 
PAM3CSK4, (B) 50 µg/mL polyI:C or (C) 50 ng/mL LPS.  Cell lysates were analyzed by 
immunoblotting for the indicated signaling targets.  Data are representative of at least 
three independent experiments. 
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Figure 2.4 TLR10 suppresses both MyD88 and TRIF signaling 
HEK293T cells were co-transfected with the indicated TLR construct and either (A and 
C) MyD88 and an IL-8 promoter-driven luciferase construct or (B and D) TRIF and an 
IFN-β-driven luciferase reporter construct. Results indicate fold induction of luciferase 
over empty vector after normalizing each sample for transfection efficiency using 
Renilla luciferase. Error bars represent the standard deviation of three independent 
samples and statistical analysis was performed using two-tailed paired Student’s t test. 
* p < 0.05, ** p<0.005 
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Figure 2.5 Dose-Dependent Suppression of MyD88 and TRIF Signaling by TLR10 
HEK293T cells were co-transfected with varying concentrations of TLR10 and either 
(A) MyD88 and an IL-8 promoter-driven luciferase construct or (B) TRIF and an IFN-β-
driven luciferase reporter construct. Results indicate fold induction of luciferase over 
empty vector after normalizing each sample for transfection efficiency using Renilla 
luciferase. Error bars represent the standard deviation of three independent samples 
and statistical analysis was performed using two-tailed paired Student’s t test. * p<0.05 
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Figure 2.6 Cell Surface Expression of TLR Constructs 
HEK293T cells were transfected with the indicated FLAG-TLR or CD4-TLR construct 
and stained with either an anti-FLAG or anti-CD4 antibody. FLAG-TLR and CD4-TLR 
constructs (black line) show surface expression of each construct compared to MMLV 
control cells (gray histogram). Cells were gated based upon forward and side scatter 
characteristics. 
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Figure 2.7 Generation of a TLR10 transgenic mouse under a constitutive CMV 
promoter 
(A) Southern blot analysis of genomic DNA from 14 TLR10 positive founder mice with 
varying copy number insertions. (B) Reverse transcriptase dependent detection of 
FLAG-TLR10 in various tissues of a transgenic mouse. Western blots of (C) various 
tissues or (D) peripheral blood leukocytes from transgenic (Tg) and non-transgenic 
(Nc) mice using the anti-FLAG antibody to detect TLR10. FLAG-TLR10 migrates as a 
~150 kDa band while a non-specific band appears at ~100 kDa.  
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Figure 2.8 Blood monocytes of TLR10 transgenic mice exhibit suppressed 
cytokine production in response to TLR agonists 
(A) Whole blood from either TLR10-transgenic (tg) or non-transgenic (nc) littermate 
controls was stimulated with the indicated agonists and IL-6 release was measured in 
cell-free supernatants by ELISA.  (B) Whole blood was stimulated with LPS and IL-6 
production was measured by intracellular staining in monocyte (CD11b+, Ly6G-) and 
neutrophil (CD11b+, Ly6G+) populations. Dot plot represents ungated cell populations. 
(C) Median fluorescent intensity (MFI) of IL-6 is shown relative to unstimulated cells. 
Error bars represent the standard deviation of three independent samples and 
statistical analyses were performed using two-tailed paired Student’s t test. * p < 0.05, 
** p < 0.01 
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Figure 2.9 Whole Blood Monocyte and Neutrophil Populations of TLR10 and 
Non-Transgenic Mice are Indistinguishable 
Monocyte (CD11b+ and Ly6G-) and neutrophil (CD11b+, Ly6G+) populations from 
TLR10 transgenic (tg) and non-transgenic control mice (nc) were assayed by flow 
cytometry. A representative dot blot from each mouse is shown with averages and 
standard deviations derived from 6 transgenic mice and 6 non-transgenic mice. Dot 
plot represents ungated cell populations.  
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Figure 2.10 TLR10 transgenic mice exhibit suppressed responses to injected 
LPS but are not protected in a model of septic shock 
Four TLR10-transgenic (tg) or four non-transgenic littermate controls (nc) were 
injected IP with 25 mg/kg of LPS. Blood was collected at 1 hr and 4 h post injection 
and serum TNFα and IL-6 levels were measured using a paired antibody ELISA. 
Serum Type 1 IFN levels were measured using the ISRE-L929 reporter line. Error bars 
represent the standard deviation of at least three independent mice and statistical 
analysis was performed using one-tailed student’s t-test. * p < 0.05.  (B) Six TLR10-
transgenic (tg) and seven non-transgenic (nc) mice were injected IP with 25 mg/kg 
LPS and monitored for survival with results plotted in Kaplan-Meier format. 
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Figure 2.11 Anti-TLR10 antibody inhibits TLR-induced activation of peripheral 
blood mononuclear cells 
Human peripheral blood mononuclear cells from two separate donors were pre-
incubated with either an anti-TLR10 antibody or isotype matched control antibody prior 
to stimulation with the indicated agonist for 24 h. Cell-free supernatants were collected 
and IL-6 and TNFα production was assayed using an antibody-paired ELISA. Error 
bars represent standard error of the mean of three intra-donor replicates and statistical 
analysis was performed using the Holm-Sidak T-test assuming equal population 
scatter. * p < 0.05; ** p < 0.01  
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CHAPTER III: TLR10 SUPPRESSES THE ACTIVATION AND DIFFERENTIATION OF 
MONOCYTES WITH EFFECTS ON DC-MEDIATED ADAPTIVE IMMUNE 
RESPONSES 
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3.1 Abstract 
Toll-like receptors (TLRs) are important pattern recognition receptors involved in 
the activation of innate immune responses against foreign pathogens. Humans possess 
ten TLRs, of which TLR10 is the only remaining TLR without a known ligand, signaling 
pathway or clear cellular function. Previous work has shown that TLR10 is able to 
suppress pro-inflammatory cytokine production in response to TLR agonists in a mixed 
human mononuclear cell population. We report here that TLR10 is preferentially 
expressed on monocytes and is able to suppress proinflammatory cytokine production 
resulting from either TLR or CD40 stimulation. TLR10 engagement affects both the 
MAPK and Akt signaling pathways leading to changes in the transcriptome of isolated 
human monocytes. Differentiation of monocytes into dendritic cells in the presence of an 
αTLR10 monoclonal antibody reduced the expression of maturation markers and the 
induction of proinflammatory cytokines again in response to either TLR or CD40 
stimulation. Finally, in co-culture experiments, TLR10 differentiated dendritic cells 
exhibited a decreased capacity to activate T-cells as measured by IL-2 and IFN-γ 
production. These data demonstrate that TLR10 is a novel regulator of innate immune 
responses, as well as differentiation of primary human monocytes to effective dendritic 
cells.  
 
3.2 Introduction 
Toll-like receptors are one class of pattern-recognition receptors that sense 
conserved pathogen associated molecular patterns (PAMPs) on a variety of different 
bacterial, fungal and viral organisms (Kawai & Akira, 2010). TLRs play a significant role 
in the activation of myeloid cells comprised of monocytes, macrophages and dendritic 
cells (Hornung et al, 2002). These cells represent a group of leukocytes tasked with 
orchestrating protective immune responses following detection of invading pathogens 
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(Geissmann et al, 2003; Waschbisch et al, 2016). Upon activation by pattern-recognition 
receptors, monocytes residing in the blood will secrete pro-inflammatory cytokines such 
as IL-6, TNF-α and IL-1β to combat the invading microorganism. Furthermore, 
monocytes have the ability to migrate to the site of infection and infiltrate tissues where 
they receive signals to differentiate into either macrophages or dendritic cells (Lauvau et 
al, 2015; Xiong & Pamer, 2015).  
Dendritic cells are critically important in the activation of the adaptive immune 
system. As professional antigen-presenting cells, DCs take up antigen and present it on 
the MHC complex, a process that is stimulated by TLR activation (Arnold-Schrauf et al, 
2015; Krawczyk et al, 2010). Naïve T-cells interact with the antigen-primed dendritic 
cells MHC complex via the TCR. The interaction between CD80/86 on dendritic cells and 
CD28 on T-cells provides the co-stimulation necessary for T-cell activation. Cytokines 
secreted by dendritic cells, such as IL-12, serve to polarize T-cells into type 1 effector T-
cells (Den Haan et al, 2014).  
Recognition of the TLRs cognate ligand initiates dimerization of the receptor and 
recruitment of MyD88 to the C-terminal toll/interleukin-1 homology (TIR) domains of the 
receptor dimers (Jenkins & Mansell, 2010; Gay et al, 2014; Kawasaki & Kawai, 2014). 
This Myddosome complex further activates downstream signaling proteins that results in 
gene expression changes through activation of NF-κB and/or IRF transcription factors 
(Lin et al, 2010).   
Of the ten human TLRs, TLRs 1-9 have been extensively studied and have been 
shown to have critical functions in the activation of myeloid cells. Conversely, TLR10 
remains the last human TLR without a known ligand, signaling function or clear function 
(Guan et al, 2010). TLR10 was first cloned in 2001 and has been shown to be 
transcriptionally expressed in a variety of different cell types of both the lymphoid and 
myeloid lineage (Xiong & Pamer, 2015; Chuang & Ulevitch, 2001). Previously, we have 
shown that when overexpressed in a myeloid cell line, pro-inflammatory cytokine 
production is suppressed in response to MyD88-dependent and MyD88-independent 
TLR signaling pathways. Furthermore, we generated a transgenic mouse which 
expressed human TLR10 which also showed suppressed cytokine responses to LPS 
stimulation (Jiang et al, 2016).  
In this study, we have expanded upon those initial findings by exploring the 
effects of an in-house generated monoclonal antibody against TLR10 on isolated human 
monocytes ex vivo. We show that antibody-mediated engagement of TLR10 decreases 
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pro-inflammatory cytokine production and the phosphorylation status of several signaling 
pathways activated through either TLR or CD40 stimulation. Additionally, we show that 
engagement of TLR10 affects the differentiation of monocytes into dendritic cells as 
evidenced by decreased co-stimulatory markers and suppressed cytokine production in 
response to a stimuli. Importantly, we show that these TLR10-differentiated dendritic 
cells have a reduced capacity to activate T-cells. These data show that antibody-
mediated engagement of TLR10 suppresses both proximal and long-term functions of 
monocytes that may both advance our understanding of innate immune regulation and 
have potential medical benefits for treating chronic inflammatory diseases.  
 
3.3 Materials and Methods 
Reagents 
Antibodies for CD33, CD3, CD19, CD83, CD86, CD80, CD40, HLA-II as well as 
all corresponding isotype control antibodies were purchased from BD Biosciences. The 
αTLR10 mAb (5C2C5) hybridoma was developed in-house using the extracellular 
domain of TLR10 (AA 20-474) as an antigen. Characterization of our in-house antibody 
can be found here (Hess et al, 2017). The 5C2C5 antibody as well as the MOPC-21 
isotype control antibody (BioLegend) were directly conjugated to Alexa-647 using a 
fluorophore conjugation kit (Life Technologies). Flow buffer was comprised of 10% rabbit 
serum in PBS.  
 
Cell Culture 
Peripheral blood was obtained from consenting healthy donors under an 
approved IRB protocol.  Ficoll-density centrifugation was used to isolate mononuclear 
cells. For isolated monocytes and T-cells, whole blood was mixed with a monocyte or T-
cell isolation cocktail from STEMCELL Technologies prior to Ficoll-density centrifugation.  
Monocyte-derived dendritic cells were differentiated from isolated monocytes by the 
addition of 50μg/mL of GM-CSF and 10μg/mL of IL-4 (PeproTech) for 4 days changing 
half of the media after day 2. The TLR10 (5C2C5) or isotype control (MOPC-21) 
antibodies were added at the same time at a concentration of 10μg/mL. Cells were 
plated in a 6-well dish at ~2E6 cells/well. The media used for all experiments was RPMI 
1640 with glutamine supplemented with a 1X concentration of non-essential amino acids 
(Corning).  
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Flow Cytometry 
Approximately 1E6 cells were blocked on ice in flow buffer for 30 min prior to the 
addition of the different cellular markers. After washing, the cells were fixed in 4% 
paraformaldehyde for 15 min, washed and re-suspended in flow buffer. All flow data was 
collected on a BD FACSCanto running FACSDiva software. Delta MFI was calculated by 
subtracting the geometric median fluorescence intensity of the isotype control treated 
cells from that of the αTLR10 antibody treated cells. GraphPad Prism was used to 
generate the graphs and perform the unpaired t-tests to determine statistical 
significance. 
 
Cellular Stimulations 
Mononuclear cells, monocytes or dendritic cells were plated at 2E4 cells/well in a 
96 well plate. Either the TLR10 mAb (5C2C5) or the isotype control antibody (MOPC-21) 
was added 10 min prior to stimulation at 10μg/mL. LPS 0111:B4 (InvivoGen) was added 
at 10ng/mL, TL8-506 (InvivoGen) at 50ng/mL and αCD40 (R&D Systems) at 100ng/mL. 
After 24 hrs, cell-free supernatants were collected and stored at -20°C. 
For T-cell:dendritic cell co-cultures, dendritic cells were plated at 4E4 DC/well in a 24 well 
plate. T-cells were added at ~8E5 T-cells/well with a final volume of 300μL. LPS was 
added as stated earlier and the superantigen TSST-1 (IBT BioServices) was added at 
500 pg/mL. After 72 hrs, cell-free supernatants were collected and stored at -20°C. 
Supernatants were analyzed for IL-6, TNFα, IL-1β, IL-12, IL-2 and IFN-γ (Invitrogen) 
according to the manufactures instructions. Intra-donor triplicates were completed for 
each different donor. When appropriate, “Relative Activation” was calculated by taking 
the average triplicate value from TLR10 treated cells divided by the average triplicate 
value of isotype control treated cells. GraphPad Prism was used to generate the graphs 
and perform the unpaired t-tests to determine statistical significance.  
 
Western Blots 
Isolated monocytes were stimulated as stated earlier and lysates were generated 
from PBS-washed cells using the Blue Loading Buffer Pack (Cell Signaling 
Technologies) with 1X HALT Protease and Phosphatase Inhibitor Cocktail (Thermo 
Scientific). Gels were run on pre-cast gels (BioRad) and transferred to a nitrocellulose 
membrane. Blots were blocked in a 10% milk-TBST solution for 30 minutes prior to 
overnight incubation with the primary antibody in a 10% BSA-TBST solution. Blots were 
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then washed and blotted with a secondary antibody for 30 min. SuperSignal West Femto 
(Thermo Scientific) was used for visualization. ImageLab software (BioRad) was used to 
generate images and for densitometry measurements. GraphPad Prism was used to 
generate the bar graphs and perform the unpaired t-tests to determine statistical 
significance. 
 
RNA-Sequencing 
Isolated monocytes were stimulated as stated earlier and RNA was collected 
after two hours using an RNeasy Mini Kit (Qiagen). DNA digestion was performed on-
column and checked by PCR. RNA integrity was assessed by an Agilent 2100 
Bioanalyzer to be greater than or equal to an RIN of 8.8. RNA-seq libraries were 
prepared using Illumina’s TruSeq Stranded mRNAseq Sample Prep Kit (Illumina). The 
libraries were quantified by qPCR and sequenced on two lanes for 101 cycles from one 
end of the fragments on a HiSeq2500 using a HiSeq Rapid SBS sequencing kit version 
2. Each sample had an average of 25 million reads from 4 different donors. Fastq files 
were generated and demultiplexed with the bcl2fastq v2.17.1.14 conversion software 
(Illumina). Analysis was performed by High Performance Biological Computing Center at 
the University of Illinois Urbana-Champaign. 
 
Statistics 
All data were analyzed using the students t-test unless otherwise indicated. Data 
shown as relative activation was calculated by averaging intra-donor triplicates for 
TLR10-treated and isotype-treated cells and then dividing the average value from 
TLR10-treated cells with the average value of isotype-treated cells.  
 
3.4 Results 
Antibody-Mediated Engagement of TLR10 Suppresses Monocyte Cytokine 
Production 
To determine the effect of antibody-mediated engagement of TLR10, we first 
stimulated a population of mononuclear cells with LPS in the presence of either an 
αTLR10 antibody or an isotype control antibody. We observed decreased production of 
IL-6 in αTLR10-treated cells compared to isotype control cells after 24 hours of 
stimulation (Fig 3.1A). The suppression was consistent across a panel of seven different 
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donors with αTLR10-treated cells producing on average approximately 80% of the IL-6 
and TNFα compared to isotype treated cells (Fig 3.1B, C).  
Mononuclear cells consist of a mixed leukocyte population that could each be 
effected by TLR10 engagement. To determine which cell types express TLR10, we 
analyzed five different donors by flow cytometry for TLR10 expression. Of the three 
major constituents of the mixed mononuclear populations, only B cells and monocytes 
expressed detectable levels of TLR10 (Fig 3.1D, E). This confirms our previous finding 
with a different TLR10 antibody clone (3C10C5) in which we detected TLR10 expression 
on B cells but not T cells (17).  
To exclude the possibility that TLR10 engagement on B cells is the mediator of 
the observed cytokine suppression, we tested isolated monocytes for TLR10-mediated 
cytokine suppression. Similar to our previous data, isolated monocytes also showed 
suppressed production of the expanded repertoire of pro-inflammatory cytokines IL-6, 
TNFα, IL-1β and MIP-1β. Interestingly, the anti-inflammatory cytokine IL-10 was also 
suppressed by TLR10 engagement (Fig 3.2). These data suggests that TLR10 
engagement is directly affecting monocyte activation that is not dependent on other 
leukocytes.   
 
The TLR10 Receptor Actively Suppresses Both the TLR and TNF Signaling 
Pathways 
 To determine if antibody-engagement prior to stimulation is essential for 
suppression, we performed a time-course assay where the αTLR10 antibody was added 
at different time intervals post-stimulation. The αTLR10 antibody was able to suppress 
LPS-induced IL-6 production in isolated monocytes up to eight hours post-stimulation but 
not when added 30 minutes prior to stimulation (Fig 3.2A). This suggests that the 5C2C5 
TLR10 antibody clone is not a blocking antibody but is capable of activating the TLR10 
receptor.  
Previous research has shown that TLR10 can suppress TLR-related signaling 
but also TLR-independent stimuli in the context of B cell activation (16, 17). We wanted 
to determine if TLR10-engagment could suppress non-TLR signaling in the context of 
monocyte activation. We stimulated isolated monocytes with either LPS, TL8-506 or an 
αCD40 antibody which respectively represents an extracellular TLR (TLR4) ligand, 
intracellular TLR (TLR8) ligand and a stimulator of the TNF pathway (CD40). We chose 
CD40 because of its importance in the myeloid lineage with respect to co-stimulation of 
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T cells and because of our previous work in B cells. Irrespective of the stimulant, TLR10-
engagment was equally sufficient to suppress both the pro-inflammatory and anti-
inflammatory cytokines that we tested (Fig 3.2B, C).  
 While there are many differences between the TLR and TNF signaling pathways 
proximally, there is also considerable cross-talk that may allow TLR10-engagment to 
suppress both pathways. To examine which signaling proteins are effected by TLR10-
engamgent, we analyzed the phosphorylation status of the NF-κB regulator IκB, several 
MAPK families and the main kinase in the PI3K signaling pathway, Akt (protein kinase 
B). As shown in Fig 3.3 and Fig 3.4, TLR10-engagement is able to suppress the 
degradation of IκB as well as the phosphorylation of both the MAPK and PI3K/Akt 
signaling pathways 20 min after stimulation. This effect was detected when the cells 
were stimulated with either a TLR agonist or αCD40 stimulant. Alternatively, these 
pathways can also be activated without any additional stimulant by integrins on the 
surface of monocytes. Interestingly, TLR10-engagment was also able suppress the 
residual integrin-mediated activation (mediated by receptor tyrosine kinases) of these 
pathways from the initial plating of the cells (seen in the unstimulated condition). Taken 
together, these data suggest that TLR10 acts as a broad proximal suppressor of 
inflammatory signaling.    
 
TLR10 Alters the Transcriptome of Primary Monocytes  
 To understand the broad effect of TLR10-engagment on primary monocytes, we 
evaluated the transcriptome of monocytes in the presence and absence of the αTLR10 
antibody with and without LPS stimulation. RNA from four different donors was collected 
and sequenced. After setting an arbitrary cutoff for significance at a p-value less than 
0.05 and a fold change greater than 50%, relatively few genes were significantly 
differentially expressed, either negatively or positively (Fig 3.5, Table 3.1). Of these 
genes, KEGG analysis showed that genes involved in cytokine-cytokine receptor 
interactions were the largest family of genes negatively regulated in both the 
unstimulated and LPS-stimulated conditions which included the genes CSF1 (M-CSF), 
CSF2 (GM-CSF), IL-4, IL-13, CCL3 and several members of the TNF superfamily. Of the 
genes that were positively regulated, no functional pathway was identified due to the 
high number of uncharacterized genes present. To confirm the differential expression, 
the genes TNFα, CSF1, COX7C, ALOX12, EGF, IL-4 and MGLL, some of which did not 
necessarily make our RNA-seq significance cutoff but were significant at a level close to 
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0.05 and were functionally interesting, were validated by qPCR and showed matching 
expression patterns to the RNA-seq data (Fig 3.6). 
 
Long-term Engagement of TLR10 Suppresses Monocyte Differentiation  
The suppression of the colony stimulating factor genes in the RNA sequencing 
data suggested to us that TLR10 may have an effect on monocyte differentiation. To test 
this hypothesis, monocytes were differentiated for four days using CSF2 (GM-CSF) and 
IL-4 in the presence of either αTLR10 or isotype control antibodies and tested for the 
expression of several dendritic cell maturation markers. While CD83 expression was not 
affected, the expression of the B7 complex consisting of CD80/86 was significantly lower 
in αTLR10-treated cells. The other markers examined, CD40 and HLA-II had increased 
variability but trended toward lower expression levels as well (Fig 3.7).  
The αTLR10-cultured monocyte-derived immature dendritic cells were next 
tested for their ability to produce cytokines after TLR or αCD40 stimulation. The 
cytokines IL-6, TNFα and IL-12 either trended downward or were significantly 
suppressed in the presence of the αTLR10 antibody (Fig 3.8). Additionally, the 
expression of TLR10 itself decreased upon differentiation into DCs though the degree of 
cytokine suppression seen in monocytes compared to dendritic cells did not change (Fig 
3.9). Overall, the data shows that monocytes differentiated in the presence of the 
αTLR10 antibody produced dendritic cells with reduced expression of costimulatory 
markers and the production of inflammatory cytokines.  
 
αTLR10-Differentiated Dendritic Cells Have a Reduced Capacity to Activate T-cells  
 Lastly, we examined whether the αTLR10-differentiated dendritic cells have 
reduced functional capacity to stimulate T-cells. To this end, we co-cultured DCs with 
autologous T-cells in the presence of superantigen and measured the induction of the T-
cell cytokines IL-2 and IFN-γ. Neither the T-cells nor DCs, alone or in co-culture 
produced a significant amount of IL-2 and IFN-γ without superantigen present. When 
treated with the superantigen, both IL-2 and IFN-γ were strongly induced with neither IL-
4 nor IL-17 being produced under these conditions (data not shown). T-cell activation in 
the presence of the superantigen was significantly suppressed when co-cultured with the 
αTLR10-differentiated DCs (Fig 3.10). These data show that TLR10-engagment on 
differentiating monocytes yields dendritic cells with a reduced functional capacity to 
activate T-cells ex vivo.  
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3.5 Discussion 
 Our group has previously shown that when overexpressed, TLR10 is able to 
suppress cytokine production in human monocytic cell lines and in a transgenic mouse 
expressing human TLR10 (16). This study expands upon our previous results that 
TLR10 functions as a suppressor of MyD88-dependent and –independent responses by 
utilizing an in-house generated αTLR10 antibody. One limitation of this study is that we 
do not possess direct evidence that the 5C2C5 αTLR10 antibody is a blocking or 
activating antibody though we have several indirect lines of evidence that suggest the 
latter. The two hypotheses that explain why we see decreased cytokine production upon 
addition of the αTLR10 antibody is that we are either blocking the pro-inflammatory 
function or activating the anti-inflammatory function of TLR10. To be blocking, we would 
have to assume TLR10 induces a pro-inflammatory response which no group has been 
able to detect. Much of the support for the activation of an anti-inflammatory function 
comes from our previous manuscript where we detect suppression when TLR10 is 
overexpressed as a homodimer (16). Additionally, our time-course experiment that 
detects TLR10-mediated suppression up to eight hours post-stimulation suggests an 
active signal propagating from the TLR10 complex after ligation by our antibody. For 
those reason we believe that antibody-mediated engagement of the TLR10 receptor 
induces homodimerization and activation of a suppressive response.  
 TLR10 is most homologous to TLRs1 and 6 which are all tandemly arranged on 
the chromosome and are thought to have arisen from several gene duplication events 
(19). Despite this close homology, TLR10 contains several key mutations within its TIR 
domain and more specifically within the BB loop of the TIR domain that has previously 
been shown to be critical in TLR signaling (20, 21). The crystal structure of TLR10 
reveals a TIR domain similar to the other TLR family members with the BB loop exposed 
and available to interact with potential TIR domain containing adaptors (18). The amino 
acids within the BB loop of human TLR10 though are unique among the human TLR 
family and more importantly, are conserved across different mammalian species 
suggesting that those mutations are critical for TLR10’s function (unpublished 
observations). 
 With TLR10 containing several key amino acid differences in its BB loop and the 
novel suppressive function of the receptor, it is unlikely that TLR10 is able to mediate 
this function through one of the classical TLR adaptor proteins including MyD88, MAL 
(TIRAP), TRIF and TRAM. Despite this, there are several other TIR domain containing 
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proteins that have more recently been discovered and whose functions within the cell 
are not yet clearly defined (22). These proteins include SARM (23), BCAP (24) and 
BANK1 (25). Both SARM and BCAP have been suggested to have regulatory roles 
within the cell. BCAP in particular has been shown to connect TLR signaling to the 
PI3K/Akt signaling pathway that can lead to suppression of inflammatory cytokine 
release (24).   
 An alternate hypothesis is that TLR10-mediated activation is able to induce other 
anti-inflammatory cytokines such as IL-10. Our data suggests that this is not what is 
occurring in isolated monocytes where we measured suppressed levels of IL-10 after 
stimulation. Additionally, the TLR10-mediated suppression was detected in the MAPK 
and Akt signaling proteins after only 15 minutes of stimulation suggesting suppression 
occurs prior to the transcription of pro-inflammatory or anti-inflammatory cytokines. 
Lastly, from our analysis of the transcriptome of isolated monocytes after TLR10-
engagment, we show a lack of anti-inflammatory cytokines up-regulated in the conditions 
we tested. Currently, we do not believe anti-inflammatory cytokine production to be the 
primary mechanism of TLR10-mediated suppression.  
In support of our studies, another publication reported that antibody-mediated 
engagement of TLR10 with a different TLR10 monoclonal antibody is capable of 
suppressing TLR2-mediated inflammatory responses in mononuclear cells. In that study, 
TLR10-engagment blocked the inflammatory responses of both primary human cells and 
a TLR10 transgenic mouse treated with the TLR2 agonist PAM3CSK4 or whole Borrelia 
burgdorferi (26). Our study expands upon their data to show a much broader 
suppression profile for TLR10 including other TLRs and CD40 stimulations. 
Two other studies have found proinflammatory roles for TLR10 in the context of 
live H1N1 flu virus or Listeria monocytogenes infections. In these studies, they used 
either THP-1 or HT-29 cell lines to knockdown TLR10 expression using siRNA and 
measured an increase in the proinflammatory cytokines produced. It is interesting to 
note that in both of these studies, TLR10 knockdown cells only exhibited a 
proinflammatory role when infected with live and not UV-inactivated or heat-killed 
pathogens (27, 28). Although in our study we challenge cells with an intracellular TLR8 
agonist resulting in suppression, there is perhaps a role for intracellular TLR10 in the 
recognition of an in vivo-PAMP that results in alternative signaling outputs (29).   
 Overall, this work advances our knowledge of the last orphan human TLR and its 
potential function in vivo. Our data shows that antibody-mediated engagement of TLR10 
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is capable of suppressing classical pro-inflammatory signaling pathways induced by 
several different agonists that results in decreased levels of pro-inflammatory cytokines. 
Additionally, long-term engagement of TLR10 is sufficient to effect the differentiation of 
monocytes into dendritic cells by lowering their capacity to active T-cells. While the true 
biological function of TLR10 might not fully be understood until the discovery of a natural 
ligand, the suppressive function of TLR10 described in this manuscript has far-reaching 
therapeutic implications for a variety of diseases characterized by dysregulated immune 
activation. 
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3.7 Figures and Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Antibody-mediated engagement of TLR10 suppresses mononuclear 
cell cytokine production 
(A) Human peripheral blood mononuclear cells were pre-incubated with either an 
αTLR10 antibody (5C2C5) or an isotype matched control antibody for 10min prior to 
stimulation with LPS for 24hrs or left unstimulated. Cell-free supernatants were 
collected and antibody-paired ELISA was used to measure the indicated cytokine. 
Mononuclear cell stimulations were repeated on seven different donors (B) and plotted 
as relative activation by dividing TLR10-treated cells by isotype-treated cells for each 
donor and indicated analyte (C). (D) Representative histograms of human peripheral 
blood mononuclear cells stained with either an αTLR10 antibody (5C2C5) or an isotype 
control antibody conjugated to Alexa647 in addition to a cell marker (see materials and 
methods). (E) Data from at least 4 donors was combined by averaging the fold median 
fluorescent intensity (MFI) normalized to isotype-treated cells. All error bars represent 
the standard error of the mean. * p < 0.05; ** p < 0.01, *** p < 0.001 
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Figure 3.2 TLR10 suppresses cytokine production from TLR-dependent and 
TLR-independent stimuli 
Isolated human monocytes from peripheral blood were pre-incubated with either 
an αTLR10 (5C2C5) or an isotype control antibody for 10min prior to stimulation 
with the indicated agonist for 24hrs. Supernatants were collected and analyzed as 
described in Fig 1. (A) Time-course assay where the TLR10 ab was added at 
different time intervals before and after LPS stimulation at time 0. (B) 
Representative stimulation data from 4-6 different donors. (C) Summary data 
where each dot represents a single donors’ TLR10-treated cells after normalizing 
the values to isotype-treated cells for the indicated analyte and stimulant. * p < 
0.05; ** p < 0.01, *** p < 0.001 
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Figure 3.3 TLR10 suppresses the phosphorylation of the Akt and MAPK 
signaling pathways 
Isolated human monocytes from peripheral blood were pre-incubated with either an 
αTLR10 (5C2C5) or an isotype control antibody for 10min prior to stimulation with 
the indicated agonist for 15min. Cell lysates were collected and analyzed by 
immunoblotting for each signaling target as indicated. Data are representative of at 
least three independent experiments. 
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Figure 3.4 TLR10 Suppresses the MAP kinase and Akt Signaling Pathways 
Isolated monocytes were stimulated as in Fig. 3. Densitometry readings were 
performed and normalized to total protein levels of the same signaling protein except 
for IκB which was normalized to β-Actin. The relative phosphorylation status of each 
signaling protein is shown. Error bars represent the SEM of 4 different donors. * p < 
0.05; ** p < 0.01, *** p < 0.001.    
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Figure 3.5 The monocyte transcriptome is differentially regulated by TLR10-
engagement 
Isolated human monocytes from peripheral blood were pre-incubated with either an 
αTLR10 (5C2C5) or an isotype control antibody for 10min prior to either no stimulation 
or LPS stimulation. RNA was collected after 2hrs of stimulation and sequenced as 
described in the materials and methods. Two pairwise calculations were performed, 
one that compared the isotype and TLR10-treated samples that were left unstimulated 
(A) and the two samples that were stimulated with LPS (B). The dotted line represents 
the cut-off values of at least a 50% fold change and a p-value of at least 0.5. “X’s” 
denote genes of interest while stars denote uncharacterized proteins within the 
prescribed cutoff values.  
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Symbol Gene Name 
Counts/ 
Million 
Reads 
TLR10/Isotype 
FC 
p-
value 
AZIN1-AS1 AZIN1 antisense RNA 1 0.3 -3.39 0.00 
SNORD3A small nucleolar RNA, C/D box 3A 0.5 -3.01 0.00 
UBE2E2-AS1 
UBE2E2 antisense RNA 1 (head 
to head) 
0.2 -2.72 0.01 
MIR212 microRNA 212 0.7 -2.66 0.02 
LOC105378946 uncharacterized LOC105378946 0.3 -2.66 0.05 
IGKV3D-20 
immunoglobulin kappa variable 
3D-20 
0.4 -2.63 0.00 
GPX1P1 
glutathione peroxidase 
pseudogene 1 
2.1 -2.52 0.00 
CCL3L3 
chemokine (C-C motif) ligand 3-
like 3 
220.3 -2.43 0.00 
BHLHE22 
basic helix-loop-helix family, 
member e22 
0.3 -2.38 0.03 
LOC101929285 uncharacterized LOC101929285 0.6 -2.23 0.03 
MIR6732 microRNA 6732 0.4 -2.22 0.02 
IGLV4-60 
immunoglobulin lambda variable 
4-60 
0.3 -2.19 0.02 
IGKV1-12 
immunoglobulin kappa variable 
1-12 
0.3 -2.18 0.01 
KCCAT211 
renal clear cell carcinoma-
associated transcript 211 
0.3 -2.11 0.02 
SHROOM3 shroom family member 3 0.4 -2.07 0.05 
SCT secretin 1.0 -2.07 0.01 
TNFSF9 
tumor necrosis factor (ligand) 
superfamily, member 9 
1.1 -2.00 0.00 
LOC105374738 uncharacterized LOC105374738 0.8 -1.99 0.03 
IL13 interleukin 13 3.0 -1.93 0.02 
CCL3 chemokine (C-C motif) ligand 3 655.2 -1.89 0.01 
PLEKHA4 
pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 4 
1.4 -1.89 0.01 
IL17RB interleukin 17 receptor B 0.5 -1.85 0.04 
NR4A2 
nuclear receptor subfamily 4, 
group A, member 2 
106.0 -1.83 0.01 
FFAR2 free fatty acid receptor 2 3.0 -1.82 0.04 
Table 3.1 List of Genes Differentially Regulated by TLR10 
List of all genes that made the arbitrary significance cutoff of a greater than 50% fold 
change and a p-value of a least 0.05 in the (A) unstimulated and (B) LPS stimulated 
conditions. 
A 
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LOC105371783 uncharacterized LOC105371783 0.4 -1.82 0.05 
IGFN1 
immunoglobulin-like and 
fibronectin type III domain 
containing 1 
0.7 -1.80 0.04 
BUB1 
BUB1 mitotic checkpoint 
serine/threonine kinase 
1.0 -1.78 0.01 
SLCO5A1 
solute carrier organic anion 
transporter family, member 5A1 
0.4 -1.78 0.03 
CRHBP 
corticotropin releasing hormone 
binding protein 
0.8 -1.78 0.01 
LOC105378382 uncharacterized LOC105378382 1.0 -1.76 0.03 
LOC105370579 uncharacterized LOC105370579 1.4 -1.69 0.01 
NSUN7 
NOP2/Sun domain family, 
member 7 
0.7 -1.68 0.02 
KRT72 keratin 72, type II 1.3 -1.66 0.00 
RPLP0P6 
ribosomal protein, large, P0 
pseudogene 6 
1.5 -1.65 0.01 
IGLON5 IgLON family member 5 2.3 -1.65 0.02 
SLC1A2 
solute carrier family 1 (glial high 
affinity glutamate transporter), 
member 2 
2.1 -1.65 0.02 
SLC35F3 
solute carrier family 35, member 
F3 
0.9 -1.64 0.03 
LOC105377303 uncharacterized LOC105377303 3.4 -1.63 0.04 
POLR3K 
polymerase (RNA) III (DNA 
directed) polypeptide K, 12.3 
kDa 
0.9 -1.63 0.00 
LOC101928403 uncharacterized LOC101928403 0.6 -1.63 0.03 
CARNS1 carnosine synthase 1 1.1 -1.62 0.02 
LOC105377782 uncharacterized LOC105377782 0.6 -1.61 0.03 
BACH1-IT2 BACH1 intronic transcript 2 0.8 -1.60 0.04 
LDHAP4 
lactate dehydrogenase A 
pseudogene 4 
1.7 -1.58 0.00 
NEB nebulin 1.4 -1.58 0.04 
RPL39 ribosomal protein L39 12.6 -1.57 0.01 
LOC105377774 uncharacterized LOC105377774 3.2 -1.57 0.03 
RMDN2 
regulator of microtubule 
dynamics 2 
3.7 -1.56 0.02 
LOC102724428 
serine/threonine-protein kinase 
SIK1 
4.5 -1.56 0.00 
TRABD2A TraB domain containing 2A 0.7 -1.56 0.03 
IGLV6-57 
immunoglobulin lambda variable 
6-57 
1.7 -1.55 0.01 
CLSPN claspin 0.9 -1.55 0.02 
TYMS thymidylate synthetase 1.9 -1.55 0.00 
Table 3.1 (Continued) 
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GADD45B 
growth arrest and DNA-damage-
inducible, beta 
80.4 -1.54 0.01 
IGLV4-69 
immunoglobulin lambda variable 
4-69 
1.9 -1.54 0.00 
HSD17B8 
hydroxysteroid (17-beta) 
dehydrogenase 8 
1.3 -1.53 0.01 
HID1 HID1 domain containing 0.8 -1.53 0.02 
RPL29P4 
ribosomal protein L29 
pseudogene 4 
3.4 -1.53 0.01 
CCNB1 cyclin B1 2.4 -1.53 0.04 
TONSL tonsoku-like, DNA repair protein 1.1 -1.52 0.02 
LOC105371418 uncharacterized LOC105371418 0.7 -1.52 0.03 
NR4A1 
nuclear receptor subfamily 4, 
group A, member 1 
195.8 -1.52 0.04 
LOC101928123 uncharacterized LOC101928123 1.1 -1.51 0.02 
IGHJ3P 
immunoglobulin heavy joining 
3P (pseudogene) 
0.6 -1.51 0.03 
PTMAP4 
prothymosin, alpha pseudogene 
4 
1.1 -1.51 0.04 
IGLV3-1 
immunoglobulin lambda variable 
3-1 
6.8 -1.50 0.01 
TRH thyrotropin-releasing hormone 1.8 -1.50 0.03 
CEMIP 
cell migration inducing protein, 
hyaluronan binding 
2.5 -1.50 0.05 
C4orf48 
chromosome 4 open reading 
frame 48 
2.4 -1.50 0.03 
RAD51AP1 RAD51 associated protein 1 1.0 -1.50 0.03 
LOC728613 
programmed cell death 6 
pseudogene 
0.9 -1.50 0.04 
TBC1D3E TBC1 domain family, member 3E 1.0 1.50 0.03 
FERMT2 fermitin family member 2 1.5 1.51 0.03 
LOC105377359 uncharacterized LOC105377359 0.9 1.52 0.04 
AVPR1A arginine vasopressin receptor 1A 0.8 1.53 0.04 
LOC102724360 uncharacterized LOC102724360 2.0 1.53 0.00 
TANC1 
tetratricopeptide repeat, ankyrin 
repeat and coiled-coil containing 
1 
0.8 1.54 0.04 
LOC105376896 uncharacterized LOC105376896 0.8 1.54 0.03 
CALD1 caldesmon 1 2.2 1.60 0.05 
LOC100287036 uncharacterized LOC100287036 1.8 1.61 0.02 
LOC105378936 uncharacterized LOC105378936 4.6 1.62 0.01 
LINC01260 
long intergenic non-protein 
coding RNA 1260 
1.4 1.62 0.05 
SSSCA1-AS1 
SSSCA1 antisense RNA 1 (head to 
head) 
1.6 1.68 0.00 
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LOC105374807 uncharacterized LOC105374807 0.8 1.73 0.01 
AP1M2 
adaptor-related protein complex 
1, mu 2 subunit 
0.6 1.76 0.03 
HS3ST1 
heparan sulfate (glucosamine) 3-
O-sulfotransferase 1 
1.1 1.77 0.00 
LOC653503 
guanine nucleotide binding 
protein (G protein), gamma 10 
pseudogene 
1.4 1.79 0.02 
TDGP1 
thymine-DNA glycosylase 
pseudogene 1 
1.0 1.98 0.02 
MRPS24 
mitochondrial ribosomal protein 
S24 
0.9 2.03 0.02 
LOC105376742 uncharacterized LOC105376742 0.4 2.06 0.02 
LOC105372752 uncharacterized LOC105372752 0.3 2.30 0.02 
LOC100128413 
X-linked inhibitor of apoptosis, 
E3 ubiquitin protein ligase 
pseudogene 
0.3 2.32 0.05 
LOC105370375 uncharacterized LOC105370375 0.7 2.35 0.01 
LOC105377384 uncharacterized LOC105377384 0.7 2.80 0.01 
LOC105373046 uncharacterized LOC105373046 0.4 2.85 0.00 
 
 
Symbol Gene Name 
Counts/ 
Million 
Reads 
TLR10/Isotype 
FC 
p-
value 
RCAN1 regulator of calcineurin 1 7.3 -2.16 0.00 
MMP1 matrix metallopeptidase 1 0.6 -2.02 0.01 
WASF4P 
WAS protein family, member 4, 
pseudogene 
0.6 -1.89 0.02 
SNORD3A small nucleolar RNA, C/D box 3A 0.5 -1.88 0.01 
LOC100652758 uncharacterized LOC100652758 0.7 -1.87 0.01 
COPZ2 
coatomer protein complex, 
subunit zeta 2 
1.0 -1.81 0.01 
LOC100507195 uncharacterized LOC100507195 0.7 -1.80 0.01 
MIRLET7D microRNA let-7d 0.7 -1.79 0.01 
LOC105372709 uncharacterized LOC105372709 0.6 -1.75 0.02 
SNUPN snurportin 1 8.8 -1.69 0.00 
SULT1A2 
sulfotransferase family, 
cytosolic, 1A, phenol-preferring, 
member 2 
0.5 -1.68 0.04 
LOC728730 uncharacterized LOC728730 0.7 -1.67 0.02 
TNFSF15 
tumor necrosis factor (ligand) 
superfamily, member 15 
29.2 -1.67 0.02 
GPR161 G protein-coupled receptor 161 0.8 -1.66 0.02 
LIF leukemia inhibitory factor 13.9 -1.65 0.02 
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EGR2 early growth response 2 83.9 -1.64 0.03 
RASD1 RAS, dexamethasone-induced 1 1.8 -1.63 0.01 
ATP5E 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, 
epsilon subunit 
1.4 -1.62 0.02 
LOC101927451 uncharacterized LOC101927451 0.8 -1.62 0.01 
HELLS helicase, lymphoid-specific 1.1 -1.62 0.00 
FAM53A 
family with sequence similarity 
53, member A 
1.2 -1.61 0.02 
ENKD1 enkurin domain containing 1 1.0 -1.60 0.03 
PPAP2B 
phosphatidic acid phosphatase 
type 2B 
5.1 -1.58 0.03 
LOC105374947 uncharacterized LOC105374947 2.9 -1.58 0.01 
TMEM102 transmembrane protein 102 1.6 -1.57 0.01 
ZNF48 zinc finger protein 48 1.1 -1.56 0.05 
CSF1 
colony stimulating factor 1 
(macrophage) 
15.6 -1.56 0.03 
CES1P1 carboxylesterase 1 pseudogene 1 0.4 -1.55 0.02 
MRPL45P2 
mitochondrial ribosomal protein 
L45 pseudogene 2 
0.8 -1.54 0.04 
SPRY2 
sprouty RTK signaling antagonist 
2 
1.4 -1.54 0.02 
FDX1L ferredoxin 1-like 0.9 -1.54 0.04 
IL4 interleukin 4 3.8 -1.53 0.01 
SAMSN1-AS1 SAMSN1 antisense RNA 1 0.7 -1.53 0.02 
LOC105374107 uncharacterized LOC105374107 0.4 -1.52 0.03 
IGKV1D-43 
immunoglobulin kappa variable 
1D-43 
0.1 1.50 0.01 
SEC14L5 SEC14-like lipid binding 5 1.8 1.50 0.02 
MAP3K14-AS1 MAP3K14 antisense RNA 1 1.0 1.51 0.05 
CENPF 
centromere protein F, 
350/400kDa 
0.8 1.52 0.04 
MYL9 myosin, light chain 9, regulatory 9.0 1.52 0.01 
CDC42BPG 
CDC42 binding protein kinase 
gamma (DMPK-like) 
2.2 1.53 0.01 
ITGB3 
integrin, beta 3 (platelet 
glycoprotein IIIa, antigen CD61) 
41.9 1.53 0.01 
ZFP64 ZFP64 zinc finger protein 1.0 1.53 0.02 
GNAZ 
guanine nucleotide binding 
protein (G protein), alpha z 
polypeptide 
7.9 1.54 0.01 
PCSK6 
proprotein convertase 
subtilisin/kexin type 6 
5.1 1.54 0.01 
LOC102723521 uncharacterized LOC102723521 1.5 1.55 0.03 
MKS1 Meckel syndrome, type 1 1.2 1.56 0.01 
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LOC105369378 uncharacterized LOC105369378 0.9 1.57 0.02 
GP1BA 
glycoprotein Ib (platelet), alpha 
polypeptide 
5.0 1.58 0.01 
EVA1C eva-1 homolog C (C. elegans) 0.9 1.58 0.01 
NPHS1 
nephrosis 1, congenital, Finnish 
type (nephrin) 
0.6 1.58 0.00 
BHLHE22 
basic helix-loop-helix family, 
member e22 
0.3 1.58 0.03 
EPB41L5 
erythrocyte membrane protein 
band 4.1 like 5 
1.1 1.58 0.01 
IGHV4-4 
immunoglobulin heavy variable 
4-4 
0.5 1.59 0.04 
PKHD1L1 
polycystic kidney and hepatic 
disease 1 (autosomal recessive)-
like 1 
2.2 1.61 0.02 
HLA-K 
major histocompatibility 
complex, class I, K (pseudogene) 
1.4 1.62 0.00 
LOC102724748 uncharacterized LOC102724748 1.3 1.62 0.00 
DET1 
de-etiolated homolog 1 
(Arabidopsis) 
1.3 1.63 0.03 
VWCE 
von Willebrand factor C and EGF 
domains 
0.7 1.65 0.01 
LOC105376220 uncharacterized LOC105376220 1.3 1.67 0.01 
CDKL1 
cyclin-dependent kinase-like 1 
(CDC2-related kinase) 
1.3 1.67 0.02 
LOC105378124 uncharacterized LOC105378124 0.2 1.72 0.03 
CYP21A2 
cytochrome P450, family 21, 
subfamily A, polypeptide 2 
0.4 1.77 0.04 
PLTP phospholipid transfer protein 1.3 1.78 0.00 
KLHDC8B kelch domain containing 8B 1.0 1.78 0.04 
LOC105370375 uncharacterized LOC105370375 0.7 1.80 0.03 
SIGLEC17P 
sialic acid binding Ig-like lectin 
17, pseudogene 
1.1 1.85 0.03 
CDPF1 
cysteine-rich, DPF motif domain 
containing 1 
0.6 1.93 0.01 
OR2W3 
olfactory receptor, family 2, 
subfamily W, member 3 
0.7 1.97 0.01 
MFSD2B 
major facilitator superfamily 
domain containing 2B 
0.6 2.03 0.00 
BTBD6P1 
BTB (POZ) domain containing 6 
pseudogene 1 
0.5 2.20 0.04 
ZGLP1 zinc finger, GATA-like protein 1 0.9 2.40 0.00 
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Figure 3.6 Verification of Significant RNA-Seq Genes by qPCR  
Seven genes were selected for verification by qPCR. Each gene was tested in 
triplicate and repeated on the same three donors used for the RNA-seq experiment. 
Each gene was normalized to levels of B2M to account for any loading discrepancy in 
the cDNA preparation. Differential expression was calculated by ΔΔct equation for 
relative quantification and then normalized to isotype treated unstimulated cells. Error 
bars represent the SEM. * p < 0.05; ** p < 0.01. 
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Figure 3.7 TLR10-engagement suppresses dendritic cell maturation marker 
expression of differentiating monocytes 
Monocytes were differentiated into dendritic cells with GM-CSF/IL-4 for four days in 
the presence of either the TLR10 antibody (5C2C5) or an isotype control antibody. 
Cells were then collected and stained for the indicated maturation markers. (A) 
Representative histograms from 5 donors. (B) Summary data where each dot 
represents a single donors TLR10-treated cells after normalizing the values to 
isotype-treated cells for the indicated marker. * p < 0.05 
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Figure 3.8 Dendritic cells differentiated with αTLR10 have a decreased capacity 
to produce pro-inflammatory cytokines 
Monocytes were differentiated into dendritic cells with GM-CSF/IL-4 for four days in 
the presence of either the TLR10 antibody (5C2C5) or an isotype control antibody 
and then stimulated for 24hrs with the indicated agonist. Supernatants were 
collected and analyzed as described in Fig 1. (A) Representative data from 4 
different donors. (B) Summary data where each dot represents a single donors 
TLR10-treated cells after normalizing the values to isotype-treated cells for the 
indicated analyte and stimulant * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Figure 3.9 Expression of TLR10 on Monocyte-Derived Dendritic Cells 
Monocytes differentiated for four days (iDC) or iDCs incubated with LPS for 24 hrs 
(mDC) were stained for TLR10 expression as described in Fig 1E. Error bars represent 
the SEM of at least 4 donors. * p < 0.05; ** p < 0.01, *** p < 0.001.    
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Figure 3.10 TLR10 cultured dendritic cells have a decreased capacity to 
activate T-cells 
Monocytes were differentiated into dendritic cells with GM-CSF/IL-4 for four days in 
the presence of either the TLR10 antibody (5C2C5) or an isotype control antibody. 
DCs were co-cultured at a 1:20 ratio with autologous T-cells and incubated with or 
without superantigen (SA) for 3 days as indicated. Supernatants were collected and 
analyzed as described in Fig 1. (A) Representative data from 4 different donors. (B) 
Summary data where each dot represents a single donors TLR10-treated cells after 
normalizing the values to isotype-treated cells for the indicated analyte. * p < 0.05; 
** p < 0.01. 
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CHAPTER IV: TLR10 IS A B CELL INTRINSIC SUPPRESSOR OF ADAPTIVE 
IMMUNE RESPONSES 
 
Hess, N.J.; Jiang, S.; Li, X.; Guan, Y.; and Tapping, R.I. TLR10 Is a B Cell Intrinsic 
Suppressor of Adaptive Immune Responses. J. Immunol. 198, 699–707 (2017). 
 
4.1 Abstract 
Toll-like receptors (TLRs) play a central role in the initiation of adaptive immune 
responses with several TLR agonists acting as known B-cell mitogens. Despite 
thousands of publications on TLRs, the function of TLR10 remains unknown. We have 
found that antibody mediated engagement of TLR10 on primary human B-cells 
suppresses B-cell proliferation, cytokine production and signal transduction. When 
challenged with either a T-independent or T-dependent antigen, TLR10 transgenic mice 
exhibit diminished antibody responses. Adoptive transfer of splenic B-cells into B-cell 
deficient mice revealed that the suppressive effects on antigen-specific humoral immune 
responses are entirely B-cell intrinsic.  Our results demonstrate that TLR10 has a 
functional role within the B-cell lineage that is distinct from that of other TLR family 
members and may provide a potential therapeutic target for diseases characterized by 
dysregulated B-cell activity. 
 
4.2 Introduction 
As central elements of the innate immune system TLRs provide a first line of 
immune defense against infectious agents. Through direct sensing of bacterial, fungal or 
viral components TLRs activate intracellular signaling events that drive the cellular 
expression and release of immune mediators. These activation events not only drive 
inflammatory processes, but also initiate and orchestrate the longer term protective 
responses of the adaptive immune system (Kawai & Akira, 2010).  
Humans possess 10 TLR family members, numbered 1 through 10, which are 
differentially expressed in leukocytes and the epithelial cells of mucosal surfaces 
(Hornung et al, 2002; Bourke et al, 2003; Dorner et al, 2009). Subsets of TLRs that are 
expressed on the plasma membrane stimulate the production of classic proinflammatory 
molecules while other TLRs expressed in endosomal compartments are best known for 
their ability to stimulate the production of type I IFNs (O’Neill, 2008; Kawasaki & Kawai, 
2014). All TLRs are type 1 transmembrane receptors comprised of extracellular leucine 
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rich repeat domains and an intracellular TIR (Toll-Interleukin-1 Receptor homology) 
signaling domain. TLRs signal via ligand-induced receptor dimerization in which two 
juxtaposed TIR domains act as a scaffold for the recruitment of proximal adaptor 
molecules. With the exception of TLR3, which solely utilizes TRIF (TIR-domain-
containing adaptor-inducing interferon-β), TLRs utilize the proximal adaptor MyD88 
which is required for transducing signals that ultimately culminate in proinflammatory 
gene expression (Lin et al, 2010; Gay et al, 2014). 
TLR activation not only induces classic inflammatory mediators but also provides 
a critical link between the innate and adaptive arms of the immune response (Janeway, 
1989; Medzhitov, 2009). The ability of TLRs to induce adaptive responses is best 
understood through their actions on dendritic cells; however TLR subsets are also 
expressed on B-cells where they have direct stimulatory activity. For example, certain 
TLR agonists are well known T-independent (TI) antigens for B-cells. In addition, B-cell 
intrinsic TLR activation has been shown to promote antibody production and class-
switching responses to both TI and T-dependent (TD) antigens (Pasare & Medzhitov, 
2005; Browne, 2012; Rawling et al, 2012). Importantly, TLR-mediated B-cell activation 
has been shown to be a major driver of disease progression in various mouse models of 
autoimmune disease. In addition to studies in mice, genome wide association studies, as 
well as in vitro studies with patient cells, have identified a significant role for TLRs in 
promoting both the progression and severity of autoimmune diseases, particularly 
systemic lupus erythematosus (SLE) (Shlomchik, 2009; Koh et al, 2013; Pelka et al, 
2016). 
TLRs have been the subject of intense research over the last decade providing a 
fairly clear picture of the ligand recognition, signaling and biologic functions of TLRs 1 
through 9, but not TLR10. To date, TLR10 remains an orphan receptor with no agreed 
upon function in part due to the murine TLR10 gene being disrupted by several retroviral 
insertions making classical knockout studies impossible. Human TLR10, which was 
initially cloned and sequenced in 2001 (Chuang & Ulevitch, 2001), is most homologous 
to TLRs 1 and 6, and intact orthologues of the TLR10 gene have been found in every 
other sequenced mammal to date including several rodent species (Roach et al, 2005; 
Mikami et al, 2012).  
We have previously shown that similar to TLR1, TLR10 cooperates with TLR2 in 
the sensing of triacylated lipopeptide agonists. However, TLR10, either alone or in 
cooperation with TLR2, fails to induce typical TLR-associated signaling events including 
90 
 
activation of NF-κB, IL-8 or IFN-β driven reporters (Guan et al, 2010). More recently, we 
and others have reported that TLR10 is able to suppress both MyD88-dependent and –
independent signaling in mononuclear cell preparations ultimately inhibiting the 
production of inflammatory mediators including IL-6 and IFN-β (Oosting et al, 2014; 
Jiang et al, 2016). We report here that TLR10 is functionally expressed on the surface of 
primary human B-cells and is able to suppress responses mediated by a variety of B-cell 
co-stimulatory signals. Furthermore, we show that in a TLR10 knock-in mouse model, 
TLR10 is able to suppress both TI and TD antibody production showing that human 
TLR10 is a functional receptor with a novel anti-inflammatory function in B-cells. 
 
4.3 Materials and Methods 
Reagents 
All cells were grown in RPMI 1640 supplemented with 10% FBS, 2mM glutamine 
and 1X non-essential amino acids. Anti-IgM and anti-mouse IgG antibodies were 
purchased from Jackson Laboratories. Anti-CD40 was purchased from R&D Systems. 
R848 and Class C CpG were purchased from InvivoGen. Phospho-specific antibodies 
p38 (clone D3F9), JNK (clone 81E11), Syk Y525/526 (C87C1), Akt S473 (D9E), β-actin 
(clone 13E5) were purchased from Cell Signaling Technologies. The isotype control 
antibody (clone MOPC-21) was purchased from BioLegend.  
Two αTLR10 antibodies, 3C10C5 and 5C2C5, were generated with the 
assistance of the University of Illinois Immunological Resource Center. A soluble TLR10 
fragment consisting of the extracellular domain of TLR10 (AA’s 20-474) was purified 
following the protocol we previously used for other TLRs (Ranoa et al, 2013). Female 
Balb/c mice were injected every three weeks with the TLR10 antigen and checked for 
serum antibody activity after the third immunization. Splenic cells were fused with SP2/0 
tumor cells using polyethylene glycol and selected under HAT media. All hybridoma 
clones were counter screened against plate-bound soluble TLR1 to remove cross-
reactive clones. Lastly, a subset of clones were chosen to determine their ability to stain 
HEK cell transfected with TLR10 or a CMV empty vector. From this screen, two clones, 
3C10C5 and 5C2C5, were selected for future studies (Figure 4.1). The αTLR10 clone 
3C10C5 was chosen for licensing and is currently commercially available from several 
different biotechnology companies.  
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Flow Cytometry 
Approximately 2-4 x 106 cells/test were blocked in flow buffer (1X PBS, 10% 
Rabbit Serum) for 30 min. Cells were centrifuged and re-suspended in 100 μL of flow 
buffer containing primary antibody at 10 μg/mL and incubated for 30 min. After washing, 
the cells were suspended in 100 μL of flow buffer containing αMouse IgG1-Biotin 
Conjugate (Jackson Laboratories) for 30 minutes. Cells were washed again and 
suspended in 100 μL of flow buffer containing a Streptavidin-APC conjugate (Jackson 
Laboratories). After washing, cells were fixed in 300 μL of 4% paraformaldehyde for 15 
min after which they were washed and re-suspended in 100 μL of flow buffer. All labeling 
steps were performed on ice. Cells were analyzed on a BD FACS Canto II Flow 
Cytometer operated by the Roy J. Carver Biotechnology Center at the University of 
Illinois.  
 
Reverse Transcriptase PCR 
RNA was isolated using a RNeasy Mini Kit (Qiagen) following the manufacturer’s 
instructions. The cDNA was prepared with a 1:1 mixture of oligo-dT and random primers 
(Invitrogen), 1 μg of RNA and the Superscript III enzyme (Invitrogen). Reverse 
transcriptase negative samples were generated by withholding Superscript III from the 
reaction mixture. PCR was performed using AmpliTaq Gold 360 Master Mix (Applied 
Biosystems). Primers used for TLR10 (F -CAGTGGAACACTTTCAGATCC, R - 
CCAAGGGTGTGTTGTTAGC); HPRT1 (F - TGGGCTTACCTCACTGCTTT, R - 
CTAATCACGACGCTGGGACT). 
 
Human B-cell Isolation 
Peripheral blood B-cells were isolated by centrifuging whole blood over a Ficoll-
Paque solution (GE Healthcare) at 1100xg for 10 min with 0 brake to obtain 
mononuclear cells (MNCs). B-cells were isolated from the MNCs using a MACS B-cell 
Isolation Kit II (Milteny Biotech) according to the manufacturer’s instructions. Tonsillar 
tissue, obtained from surgical discards at Carle Foundation hospital, was homogenized 
and passed through a 40μM filter. MNCs were obtained by centrifuging the filtered 
homogenate over a Ficoll-Paque solution as described above. MNCs were mixed at a 
1:50 ratio with previously isolated human RBC’s and a Human B-cell Enrichment 
RossetteSep (STEMCELL Technologies) antibody cocktail prior to centrifuging over a 
Ficoll-Paque solution with the resulting buffy coat consisting of >95% B-cells. 
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Human B-cell Stimulation Assays 
Isolated human B-cells were pre-incubated with either an isotype control 
(20μg/mL) or αTLR10 (3C10C5 at 20μg/mL) antibody with the addition of a secondary 
αMouse IgG1 F(ab)’2 fragment (20μg/mL) for 30 min. The secondary antibody is used to 
further cross-link the primary antibody and to prevent IgG FcR-mediated inhibition. After 
pre-incubation, cells are stimulated with a subset of the following: αIgM (20μg/mL), 
αCD40 (0.1μg/mL), the TLR7/8 agonist R848 (100ng/mL) or the TLR9 agonist CpG 
(2μg/mL). For the PCR Superarray, total RNA was isolated after 24 hours of stimulation 
and sampled using a T-cell and B-cell Activation PCR Array (SA Biosciences). Also after 
24 hours, cell-free supernatants were assayed using a MIP-1β antibody pair (Life 
Technologies) using a 1:20 dilution. Proliferation was assayed using an ELISA based 
BrdU detection kit (Roche). In short, a 1X solution of BrdU was added to the cells. After 
24 hours, the supernatant was removed and the cells fixed to the plate. Cells were then 
incubated with a HRP-conjugated-anti-BrdU antibody for 2 hours prior to washing and 
the addition of TMB for color detection at 450nm.  
 
Human B-cell Signaling 
Tonsillar B-cells were pre-incubated with an isotype control (20μg/mL) or αTLR10 
antibody (20μg/mL) for 30 min prior to stimulation. After 15 min, cell lysates were 
generated in RIPA lysis buffer (150mM NaCl, 50mM Tris-HCl pH 8.0, 1% NP-40 and 
1mM EDTA) supplemented with Halt protease and phosphatase inhibitor (Thermo 
Scientific). Equivalent amounts of protein lysate were separated by SDS-PAGE, 
transferred to PVDF membranes and blotted against specific phospho-antibodies (Cell 
Signaling Technologies).  
 
Generation of TLR10 Transgenic Mice 
A constitutive human TLR10 knock-in mouse expressing the full-length human 
TLR10 gene was generated by the UIUC Transgenic Facility. The BAC clone #1148D18 
containing the full coding region of TLR10 with its native promoter was purchased from 
Empire Genomics. BAC DNA was isolated with Qiagen’s Large Construct Kit with 
genomic DNA removed by endonuclease digestion. Approximately 80μg of plasmid DNA 
was digested with 100 units of BsrB1 and HF-Not1 to release a 16,584bp fragment 
containing the full TLR10 transcript along with ~4kb of the upstream and ~3kb of the 
downstream sequence. Excised DNA was recovered with Qiagen’s Large Fragment 
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Extraction Kit before continuing with the transgenic process. Fifty four transgenic pups 
from the C57BL/6 genetic background were received and screened for TLR10 insertion 
by PCR. Southern blot analysis revealed that seven of the transgenic pups carried the 
transgene and that 6 founders possessed at least 10 copies of the transgene. Three 
lines were selected for further characterization of TLR10 expression in various tissues by 
RT-PCR and immunoprecipitation. Line 5-1 was chosen for further experimental 
characterization. Genotyping of the mice was performed using For- 
CAGTGGAACACTTTCAGATCC and Rev-CCAAGGGTGTGTTGTTAGC primers for 
TLR10. All mice used for experiments were between the ages of 4 – 12 weeks. For 
consistency, only males were used in our experiments. 
 
Splenic B-cell Isolation 
Murine splenocytes were isolated by manual disruption of the spleen in sterile 
PBS followed by passage through a 40μM filter. MNCs were furthered purified by 
centrifuging through a Ficoll-Paque gradient. B-cells were isolated using STEMCELL 
Technologies EasySep Mouse B-cell Isolation Kit (Cat #19854A). 
 
Murine B-cell Stimulations 
Murine splenic B-cells are isolated as described above and prepared at a 
concentration of 2-3x106 B-cells/100μL of media in BD Falcon tubes. Prior to stimulation, 
cells were incubated in 10nM CFSE (Life Technologies) in PBS for 20 min at RT in the 
dark. Cells were then washed and re-suspended in media followed by stimulation with 
αIgM (20μg/mL), αCD40 (1μg/mL) or CpG (4μg/mL). After 72 hrs cell pellets were 
prepared for flow and run on a BD FACS Canto II flow cytometer to measure CFSE 
fluorescence in the FITC channel. Additionally, cell-free supernatants were collected and 
IL-6 was measured by paired antibody ELISA (Life Technologies).  
 
Immunization & NP-Specific Antibody ELISA 
Age and sex matched mice were immunized with either NP(27)-CGG or NP(7)-
LPS (BioSearch Technologies) mixed in a 1:1 ratio with Imject Alum (ThermoScientific). 
Each mouse received a 200 μL intra-peritoneal injection of NP(27)-CGG or NP(7)-LPS 
equal to 100 ug and 20 ug of antigen respectively. Prior to immunization along with 7 
and 14 days after immunization, blood was collected from the submandibular vein and 
the resulting serum stored. NP-specific ELISA plates were prepared by coating NP(5)-
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BSA (BioSearch Technologies) onto ThermoScientific Nunc plates at concentration of 
10ug/mL in Coating Buffer B (4.3g NaHCO3, 5.3g Na2CO3, 1L H2O) and incubated at 
4°C overnight. Plates were then blocked in Assay Buffer (1X PBS, 2% BSA, 0.05% 
Tween 20) for 1 hr. Samples used a 1:10,000 dilution for IgM and IgG1 and a 1:100 
dilution for IgG2b, IgG2c, IgG3 and IgA. An 8-point standard curve was created by taking 
pooled undiluted serum from previous NP injections and creating serial dilutions starting 
at 1:50 or 1:5000 for each respective isotype. Samples and standards were allowed to 
incubate for 1 hr. Biotin conjugated goat anti-mouse detection antibodies (Southern 
Biotech) specific to each isotype were added at 50 ng/mL and allowed to incubate for 1 
hr. Streptavidin-HRP (Jackson ImmunoResearch) was added at 0.1 ug/mL and 
incubated for 30 min before developing in an OPD solution. Wells were washed in ELISA 
Wash Buffer (1X PBS, 0.05% Tween 20) between each step and measured at 490 nm.  
 
B-cell Transfer 
Splenic B-cells were isolated as described previously from between 5-9 male 
mice per group. Splenocytes were pooled for subsequent B-cell isolation and then re-
suspended in sterile PBS at a concentration of 1E8 B-cells/mL. A total of 200μL, equaling 
2E7 B-cells was injected via intra-venous injection into the caudal tail vein of male μMT 
mice and allowed to colonize for 24 hrs before immunization. To further boost the 
immune reaction, LPS was added to the NP(27)-CGG immunizations equivalent to 5 ug 
of LPS per mouse. 
 
Statistics 
All statistics were performed using the GraphPad Prism software. Significance 
was determined by a t-test using the Holm-Sidak method.  
 
4.4 Results 
TLR10 Expression in Primary Lymphocytes 
To assess human TLR10 expression, lymphocytes from whole blood of healthy 
individuals were labelled with an anti-TLR10 antibody developed in our lab. In order to 
detect weakly expressed TLR10, a biotin-streptavidin labeling procedure was employed 
prior to flow cytometric analysis (see Materials and Methods).  Compared to an isotype 
control antibody, a shift in TLR10 fluorescence was detected in a subpopulation of the 
gated lymphocytes (Fig. 4.2A). Co-staining revealed that lymphocytes expressing TLR10 
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also expressed the B-cell marker CD19, but not the T-cell marker CD3 (Fig. 4.2B). The 
presence of cell surface TLR10 on B-cells is consistent with high levels of TLR10 RNA 
message observed in lymphoid tissues believed to originate from B-cells. Our findings 
prompted us to investigate the function of this highly uncharacterized TLR in this 
immune cell. 
 
TLR10 Antibody-Mediated Suppression of Primary Human B-cells 
Upon appropriate co-stimulation, clonal B-cells undergo proliferation and 
differentiation to antibody producing plasma cells. To determine if TLR10 can suppress 
human B-cell proliferation, we assessed the effect of an αTLR10 monoclonal antibody on 
B-cell proliferation induced by co-stimulation through pairwise engagement of the BCR, 
TLR7 and the CD40 receptor. Compared to an isotype control antibody, the αTLR10 
antibody suppressed the proliferation of B-cells, isolated from six different donors, 
irrespective of the stimulus (Fig. 4.3A). TLR10 engagement also suppressed B-cell 
proliferation induced by Staphylococcus aureus Cowan strain (SAC), a well-established 
B-cell mitogen. Together, these results suggest that TLR10 serves to dampen B-cell 
activation mediated by either T cell-independent or T cell-dependent mechanisms. 
B-cell stimulation results in changes in expression of a wide range of genes 
which function to drive functional B-cell responses. To more broadly examine the effect 
of TLR10 engagement on B-cell activation, we co-stimulated B-cells through the BCR 
and TLR9 for 24 hours in the presence of either αTLR10 or an isotype control antibody. 
After stimulation, RNA was collected and the expression of an array of lymphocyte 
specific activation genes was measured by real-time PCR. Of the 84 genes tested, 39 
exhibited statistically significant changes as either an increase or decrease in expression 
following B-cell stimulation.  Compared to an isotype control antibody, αTLR10 affected 
33 of the 39 genes by consistently dampening the increase or decrease in individual 
gene expression normally induced by B-cell stimulation (Fig. 4.3B, Table 4.1). The three 
genes that exhibited the greatest degree of suppression were Chemokine Ligand 3 
(CCL3), Chemokine Ligand 4 (CCL4) and Activation Induced Cytosine Deaminase 
(AICDA). The chemokine CCL3 and CCL4, also known as MIP-1α and MIP-1β 
respectively, are each potent chemoattractants secreted by lymphocytes that function to 
drive lymphocyte migration in the germinal center. AICDA is necessary for both somatic 
hypermutation and class switch recombination during clonal expansion in the germinal 
center. 
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To confirm that the suppression observed in the RNA array translates to 
functional effects, secretion of MIP-1 β (CCL4) was measured from B-cells stimulated in 
the presence of either isotype control or the αTLR10 antibody. TLR10 antibody 
engagement suppressed the production of MIP-1 β induced by pairwise co-stimulation of 
either the BCR and TLR7 or the BCR and CD40 which serve to mimic T-independent 
and T-dependent activation, respectively (Fig. 4.3C). TLR10 engagement also 
suppressed MIP-1 β production induced by Staphylococcus aureus Cowan strain. These 
results suggest that the TLR10 not only suppresses TLR-mediated activation events but 
also broadly regulates B-cell activation induced by a variety of stimuli. 
 
Suppression of BCR Signaling through TLR10 
Given the broad suppressive activity of TLR10, we next assessed the effect of 
the αTLR10 antibody on a number of early signaling events which drive B-cell activation. 
To this end, primary human B-cells were stimulated through the BCR either alone or with 
TLR7 or CD40 as a co-stimulus.  Compared to isotype control, we observed that the 
αTLR10 antibody was able to suppress the phosphorylation of the MAP kinase JNK but 
not P38 or ERK. Additionally, the αTLR10 antibody was able to suppress Akt signaling 
when stimulated with αBCR and R848, suggesting TLR10 may also be able to target the 
PI3 kinase pathway (Fig. 4.4).  
 
Generation of TLR10 Transgenic Mice 
To better study TLR10, we sought to develop a suitable animal model. Since 
TLR10 is a pseudogene in mice, and orthologues of the TLR10 gene are present in all 
other rodents and mammals examined thus far, it seemed reasonable to believe that 
humanTLR10 would function in mice. Therefore, the full-length human TLR10 gene, 
including several kilobases of the 5’ and 3’ UTR, was stably integrated in the mouse 
genome (see Materials and Methods). A total of three TLR10 transgenic founder lines 
were established that both expressed detectable levels of TLR10 and successfully 
passed the transgene to offspring. Of the three founder lines, line 5-1 was selected for 
further functional assessment based on intermediate levels of TLR10 expression and 
sizable litters. Line 5-1 exhibits RT-dependent expression of TLR10 in a variety of 
different tissues (Fig. 4.5A). TLR10 transgenic mice are viable, breed well and do not 
exhibit any overt physical abnormities. 
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Suppression of ex vivo Transgenic B-cell Activation 
Given that TLR10 is expressed by human B-cells we examined isolated splenic 
B-cells from TLR10 transgenic mice and found that the receptor was expressed at both 
the mRNA and protein level (Fig. 4.5B,C). To assess the effects of TLR10 expression, 
we compared the proliferative responses of splenic B-cells as a result of ex vivo 
stimulation. Compared to non-transgenic control mice, splenocytes from TLR10 
transgenic mice exhibited less proliferation when stimulated with αIgM/αCD40 according 
to the CFSE profile of viable cells as determined by their forward and side scatter 
characteristics. Although αIgM/CpG stimulation showed similar trends, the data did not 
reach statistical significance (p = 0.116). Since we did not measure absolute numbers of 
dividing cells, the data do not address potential differences in activation-induced cell 
death (Fig 4.6A, B). Transgenic B-cells, irrespective of either of the two stimulatory 
conditions we tested, exhibited significantly decreased CD69 expression and IL-6 
secretion compared to non-transgenic control mice (Fig. 4.6C, D). These data 
demonstrate that human TLR10 is capable of suppressing murine B-cell activation ex 
vivo and that TLR10-mediated suppression of B-cells is conserved across different 
mammalian species.  
The ex vivo experiments on splenic B-cells were conducted without the addition 
of an αTLR10 antibody suggesting that the observed suppression is the direct result of 
heterologous expression of human TLR10. This prompted us to assess whether TLR10 
transgenic mice had deficiencies in either B-cell development or antibody production. To 
assess the former, we examined the ratio and abundance of the major B-cell 
subpopulations in the bone marrow, blood, spleen and lymph nodes but no differences 
were observed between TLR10 transgenic and non-transgenic littermate control mice 
(Table 4.2). Additionally, there was no difference in the steady state serum 
concentrations between the TLR10 transgenic mice compared to the non-transgenic 
control mice for any of the immunoglobulin isotypes (Fig 4.7). Together, these results 
demonstrate that human TLR10 transgene expression in mice does not grossly effect B-
cell development and antibody production. 
 
Transgenic B-cells are Suppressed in vivo 
To assess the effect of TLR10 expression on B-cell responses in vivo, we 
immunized transgenic or non-transgenic control mice with the TI antigen, and B-cell 
mitogen, LPS which was conjugated to the hapten nitrophenol (NP). One and two weeks 
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after immunization, serum levels of NP-specific antibodies in TLR10 transgenic mice 
were significantly decreased in both the IgM and IgG3 subclasses compared to serum 
levels in immunized non-transgenic control mice (Fig. 4.8).  NP-specific antibody levels 
for other immunoglobulin subclasses also trended lower in TLR10 transgenic mice but 
did not reach significance in our studies. These results demonstrate that TLR10 
transgenic mice are deficient in TI antibody responses to LPS however, since TLR10 is 
expressed throughout various cells and tissues of the mice the in vivo effects observed 
may be extrinsic to B-cells. 
 
Transgenic TLR10 Suppression is B-cell Intrinsic 
To determine whether the in vivo effects of TLR10 on antibody responses are B-
cell intrinsic we performed adoptive transfer experiments in which μMT mice, naturally 
deficient in B-cells, received pooled splenic B-cells from either TLR10 transgenic or non-
transgenic control mice prior to immunization with NP-LPS. Initial adoptive transfer 
experiments showed no difference in the populations of transgenic or non-transgenic 
B220+ B-cells residing in the spleen of μMT mice 24 hrs after injection (unpublished 
data). 
Similar to the above immunization findings, mice reconstituted with B-cells from 
TLR10 transgenic mice had significantly lower NP-specific IgM antibody responses to 
NP-LPS that those reconstituted with B-cells from non-transgenic control mice. 
Additionally, NP-specific antibody levels for all the other immunoglobulin isotypes 
trended lower in mice receiving B-cells from TLR10 transgenic mice (Fig. 4.9).  
Together, these findings show that the suppression of antibody responses by TLR10 to 
the TI antigen LPS is B-cell intrinsic. Our in vitro studies showed that TLR10 suppresses 
B-cell responses and signaling in response to CD40 co-stimulation suggesting that 
TLR10 may also regulate immune responses to TD antigens. To assess this, we 
immunized μMT mice, reconstituted with splenic B-cells from either TLR10 transgenic or 
non-transgenic mice, with the TD protein antigen NP-CGG (chicken-gamma globulin) 
along with an immune adjuvant. In addition to IgM, NP-specific serum antibody levels of 
IgG1, IgG2b and IgA were all significantly reduced in mice receiving TLR10 transgenic 
B-cells with other antibody isotypes also trending lower (Fig. 4.10). This shows that, 
even when presented with co-stimulatory signals from T-cells, TLR10 is able to suppress 
B-cell antibody responses. Taken together, we conclude that TLR10 is a B-cell intrinsic 
suppressor of both TI and TD B-cell activation. 
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4.5 Discussion 
Since its reported discovery in 2001 (Chuang & Ulevitch, 2001), the biological 
function of TLR10 has remained unknown. Recently, several groups have ascribed 
different biological functions for TLR10 of whose function is now controversial. We have 
previously shown that when overexpressed in a monocytic cell line or in a transgenic 
mouse, TLR10 is able to suppress TLR signaling irrespective of either MyD88 or TRIF 
recruitment (Jiang et al, 2016). In this manuscript, we support the hypothesis that TLR10 
is a novel suppressor of inflammatory responses and can suppress the adaptive immune 
responses of B-cells in vivo.  
Since the discovery of TLRs, much of the focus has been on how TLRs positively 
regulate inflammation although more recently research has focused on the negative 
regulation of TLR signaling. Two proteins, SIGIRR and ST2, have been shown to 
negatively regulate TLR signaling by sequestering the proximal adaptor MyD88 (Wald et 
al, 2003; Brint et al, 2004; Kondo & Akira, 2012). This regulation is most likely not how 
TLR10 functions though as TLR10 has the ability to suppress both TLR-dependent and 
TLR-independent signaling in B-cells (Jiang et al, 2016). 
Additionally, the observation that TLR10 is not under convergent evolution, has 
numerous nonsynonymous mutations in its TIR domain and is able to form a stable 
homodimer may allow TLR10 to recruit novel TIR-domain containing proteins (Roach et 
al, 2005; Nyman et al, 2008; Mikami et al, 2012). TLR10 contains several mutations 
within the BB loop of its TIR domain which has been shown to be important in TLR 
signaling. Furthermore, those mutations are conserved across different mammalian 
TLR10 proteins suggesting it has important implications in TLR10 signaling (Roach et al, 
2005). Much of TLR biology focuses on the five well-studied TIR-domain containing 
proteins; MyD88, MAL (TIRAP), TRIF, TRAM and SARM while there exists the 
possibility that there are additional TIR-domain containing proteins either understudied 
or undiscovered (Kawasaki & Kawai; 2014). Two such examples are the proteins B-cell 
adaptor for PI3K (BCAP) (Troutman et al, 2012) and B-cell scaffold with ankyrin repeats 
1 (BANK1) (Wu et al, 2016) which are novel TIR-domain containing protein that has 
been linked to TLR signaling. More importantly, a BCAP knockout mouse was shown to 
have elevated levels of inflammation in response to a S. typhimurium infection 
(Troutman et al, 2012). This highlights the possibility that TLR10 could be recruiting a 
novel TIR-domain protein to mediate the suppression.    
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There is also a growing body of evidence that there is a large synergy between 
the BCR, TLRs and TNF receptors in B-cells. Several key mediators of each pathway 
have been shown to be important in the regulation of the complementary pathway such 
as the proteins Protein Kinase D (PKD) (Haxhinasto & Bishop, 2003), Bruton’s Tyrosine 
Kinase (BTK) (Kenny et al, 2013), TRAF5 (Buchta & Bishop, 2014) and Syk (Ying et al, 
2011). It is possible that by suppressing one of these pathways, TLR10 is able to alter B-
cell signaling that allows it to suppress several pathways simultaneously.   
In support of our study, another manuscript from our lab has shown that when 
TLR10 is overexpressed in cell lines or in a mouse model, it is able to suppress 
proinflammatory signaling and cytokine production. We also show that TLR10-
engagment with a monoclonal antibody is able to suppress IL-6 production in primary 
mononuclear cells (Jing et al, 2016). In a different study, another group showed that 
TLR2 responses to either PAM3CSK4 or whole Borrelia burgdorferi are suppressed after 
TLR10-engagment with a monoclonal antibody. They also use a transgenic mouse 
model to confirm that TLR10 is able to suppress TLR2-mediated inflammatory signaling 
(Oosting et al, 2014). Our study expands upon this work by showing that TLR10-
mediated suppression is not limited to mononuclear cells and can also suppress B-cell 
adaptive immune responses. 
Two other studies have presented an opposing hypothesis that TLR10 is a pro-
inflammatory receptor. They use either THP-1 or HT-29 cell lines to knockdown TLR10 
followed by challenge with either H1N1 flu virus or live Listeria monocytogenes. In each 
case, they reported increased expression of proinflammatory cytokines only upon 
infection with live pathogen (Regan et al, 2013; Lee et al, 2014). This suggests a 
possible alternative function for TLR10, perhaps in the context of live intracellular 
pathogens that will require further investigation.  
Nonetheless, our study has vast implications for many B-cell malignancies that 
are driven by dysregulated TLR activation. It is now well established that unwanted or 
over activation of TLR 7, 8 and 9 in B-cells are drivers of autoimmune diseases. Studies 
have shown that mice deficient in TLRs 7-9 have attenuated autoimmune diseases 
characterized by autoantibody production as in rheumatoid arthritis and lupus (Herlands 
et al, 2008; Shlomchik, 2009). Additionally, genetic polymorphisms in several TLR 
signaling components such as IRF5, IRAK1 and TNFAIP3 have been shown to 
predispose individuals to lupus (Delgado-Vega et al, 2010). This manuscript highlights 
the ability of TLR10-engagment to suppress B-cell responses after TLR activation, 
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potentially offering a therapeutic opportunity for individuals with B-cell autoimmune 
diseases.  
TLR10 remains a vastly understudied TLR that for many years was believed to 
have no biological function. In this manuscript, we have shown that TLR10 is expressed 
within human B-cells and through antibody-mediated crosslinking can suppress the 
activation of human B-cells. Furthermore, we have shown that the TLR10 machinery is 
conserved across mammals by creating a knock-in mouse model that expresses the full-
length human TLR10 gene under its native human promoter which has the ability to 
suppress murine B-cell activation. Lastly, we have shown that the TLR10-mediated 
suppression is a B-cell intrinsic property and is able to suppress both T-cell independent 
and T-cell dependent antibody responses. This initial evidence that TLR10 is a B-cell 
suppressor may assist in the future development of novel immunotherapies for B-cell 
autoimmune diseases.  
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4.7 Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Generation of αTLR10 Antibodies 
(A) SDS-PAGE analysis of the purified TLR10 extracellular domain. (B) Culture 
supernatants of the indicated hybridomas as assessed by ELISA on TLR10 and 
TLR1 coated plates. (C) Hybridoma supernatants assessed for cell surface 
staining on HEK cells transfected with FLAG-CMV or FLAG-TLR10 vectors.  
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Figure 4.2 TLR10 is expressed on the plasma membrane of primary human 
B-cells 
(A) Flow cytometry of lymphocytes gated from whole blood. Cells were triple 
labeled for TLR10 expression (see Materials & Methods) using either an isotype 
control or TLR10 antibody. (B) Lymphocytes were stained as in (A) for TLR10 with 
the addition of either the T-cell marker CD3 or the B-cell marker CD19 to 
differentiate the lymphocyte population into its constituent components. 
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Figure 4.3 Primary human B-cell activation is suppressed by an αTLR10 
antibody 
Human primary B-cells were isolated from peripheral blood of healthy donors by 
negative selection and pre-incubated with either an isotype control or TLR10 mAb 
for 30 minutes prior to stimulation. (A) B-cells were stimulated with the indicated 
agonists for 96 hours with BrdU added after 72 hours of stimulation. BrdU 
incorporation was assayed by ELISA on six different donors. (B) B-cells were 
stimulated with αIgM and CpG for 24 hours after which RNA was isolated and 
assayed for activation using a B-cell PCR superarray. Bars represent the fold 
expression of stimulated cells compared to control cells which were left 
unstimulated in the presence of the isotype control antibody for 30 min. (C) B-cells 
were stimulated with the indicated agonists. Cell-free supernatants were collected 
after 24 hours and assayed for MIP-1β by ELISA.* p < 0.1; ** p < 0.05; *** p < 0.01 
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Table 4.1 List of genes regulated by TLR10-engagement on B-cells 
List of all the genes tested in Figure 4.3B denoting the fold stimulation numerically 
from the largest positive regulation to the largest negative regulation. All fold 
changes are relative to an unstimulated control group. 
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Figure 4.4 BCR signaling is suppressed by a TLR10 mAb on primary human 
B-cells 
Primary human B-cells were isolated from tonsillar tissue by homogenization, 
density gradient centrifugation and a negative selection antibody cocktail. B-cells 
were pre-incubated with an isotype control or TLR10 mAb for 30 min prior to 
stimulation with the indicated agonist for 15 minutes after which the cells were 
lysed and frozen at -20°C. (A) Lysates were probed for phosphorylated targets of 
TLR signaling. Data is representative of three independent experiments (two for 
pP38). (B) Blots were normalized against β-Actin and densities shown relative to 
the unstimulated isotype control cells. Error bars represent the standard error of 
the mean. * p < 0.1; ** p < 0.05 
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Figure 4.5 Human TLR10 transgenic mice stably express TLR10 on B-cells 
(A) Mouse organs were harvested and homogenized in Trizol with a Dounce 
homogenizer prior to RNA isolation from each indicated tissue. RNA was reverse 
transcribed in the presence and absence of reverse transcriptase (RT-) and 
checked for TLR10 expression by PCR. (B) Isolated murine B-cell RNA was 
isolated from 3 non-transgenic and 3 transgenic mice before preparing cDNA and 
assaying for TLR10 as in (A). (C) Murine spleenocytes from 3 non-transgenic and 
3 transgenic mice were triple labeled for TLR10 and the B-cell markers B220 and 
IgM. Histogram shows the TLR10 fluorescence compared to an isotype control 
antibody from a representative non-transgenic and transgenic mouse. Bar graph 
shows the ΔMFI from the 3 transgenic and non-transgenic mice. 
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Figure 4.6 Primary TLR10 transgenic murine B-cell activation is suppressed 
compared to non-transgenic control mice 
Murine spleens from 3 transgenic and 3 non-transgenic mice were collected, 
pooled and a single-cell suspension was obtained. Murine B-cells were further 
purified by a negative selection antibody cocktail. (A, B, C) B-cells were pre-
incubated with CFSE prior to stimulation with the indicated agonists for 72 hours. 
After stimulation, live cells were gated by forward and side scatter characteristics. 
(A) Representative example of a fluorescent CFSE B-cell cycling profile. The 
percentage of divided B-cells (B) and CD69 expression (C) was analyzed from 
three different replicates based upon the marker present in (A). (D) Pooled B-cells 
were stimulated for 24 hours with the indicated agonists and cell-free supernatant 
collected to measure mIL-6 production. Data is representative of three 
independent experiments. * p < 0.1; ** p < 0.05; *** p < 0.01 
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Table 4.2 Human TLR10 transgenic mice show no developmental differences 
in B-cell populations 
Transgenic and non-transgenic mice were assayed for developmental deformities in 
their B-cell populations. Each B-cell sub-type was differentiated by flow cytometry 
using the markers indicated. Percent positive cells are an average of at least two 
mice per group.  
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Figure 4.7 Human TLR10 transgenic mice show no developmental difference in 
isotype specific antibody production 
Serum was collected from seven transgenic and seven non-transgenic mice and 
assayed via a murine isotype specific multiplex kit for gross abnormalities in isotype 
concentration. Concentrations were determined by a standard curve supplied by the 
manufacturer of the multiplex kit. 
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Figure 4.8 TLR10 transgenic mice exhibit suppressed type 1 T-independent 
antibody responses 
Six transgenic and non-transgenic age-matched male mice were immunized with 
10 μg of NP-LPS by i.p. injection. Serum was collected one day pre-immunization 
and seven and fourteen day’s post-immunization. Serum was assayed for the 
presence of NP-specific antibodies by ELISA. Arbitrary units were calculated by a 
7-point serially diluted standard curve of previously immunized mouse serum and 
then normalized to day 0. * p < 0.1; ** p < 0.05; *** p < 0.01 
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Figure 4.9 TLR10 transgenic mice type-1 T-independent antibody response 
suppression is B-cell intrinsic 
B-cells from five male transgenic and five male non-transgenic mice were isolated 
and pooled. Approximately 2E7 B-cells were i.v. injected into eight age-matched 
μMT mice. One day post-transfer, mice were immunized with 20 μg of NP-LPS by 
i.p. injection. Serum was collected and assayed as described in figure 6. * p < 0.1; ** 
p < 0.05; *** p < 0.01 
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Figure 4.10 TLR10 transgenic mice T-dependent antibody response 
suppression is B-cell intrinsic 
B-cells were collected and transferred as described in figure 7. One day post-
transfer mice were immunized with 100 μg of NP-CGG and 5 μg of LPS by i.p. 
injection. Serum was collected and assayed as described in figure 6. * p < 0.1; ** p 
< 0.05; *** p < 0.01 
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CHAPTER V: HUMAN B CELL MATURATION IS ACCOMPANIED BY DYNAMIC 
CHANGES IN TLR10 EXPRESSION 
 
5.1 Abstract 
 TLR10 is the only remaining orphan receptor of the Toll-Like Receptor (TLRs) 
family. Previous studies have shown that TLR10 is highly expressed at the 
transcriptional level in lymphoid tissues. In an effort to better characterize human TLR10 
expression and regulation at the protein level, we have screened different B cell 
populations from the bone marrow, peripheral blood and tonsillar tissue using an 
αTLR10 antibody. We show that TLR10 is expressed on the surface of peripheral blood 
B cells with expression decreasing in the germinal center reaction. Terminally 
differentiated plasma cells display the lowest level of TLR10 surface expression and 
instead express an intracellular form of the receptor not detected in other B cell 
populations. These results demonstrate that both the expression and subcellular location 
of TLR10 varies within the B cell lineage. Collectively, these findings contribute to a 
better understanding of the function of TLR10 within the B cell lineage.  
 
5.2 Introduction 
TLRs are germ-line encoded type I transmembrane receptors that sense 
conserved components of non-self microorganisms. Sensing of microbial components by 
TLRs lead to intracellular signaling events that result in the release of a variety of 
mediators that induce inflammation and orchestrate both innate and adaptive immune 
responses following infection (Kawai & Akira, 2010). TLRs are expressed on a wide 
variety of cell types and tissues throughout the body and can crudely be broken down 
into two groups (Hornung et al, 2002). The cell surface TLRs; whose ligands comprise 
bacterial and fungal outer surface components including lipopolysaccharide, lipoproteins 
and flagellin and the intracellular TLRs; whose ligands comprise bacterial and viral 
nucleic acids (Husebye et al, 2006; Blasius & Beutler, 2010). 
TLRs have classically been considered components of the innate immune 
system due to their wide expression on myeloid cells, yet they also have important roles 
in the direct stimulation of both T and B lymphocytes (Pasare & Medzhitov, 2005; 
Bekeredjian-Ding & Jego, 2009; DeFranco et al, 2012). Subsets of TLRs are expressed 
throughout B cell development from hematopoietic stem cells to terminally differentiated 
plasma cells (Dorner et al, 2009).  TLR activation of B cells has been shown to enhance 
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secretion of cytokines, antigen presentation, cellular proliferation and class-switch 
recombination leading to high-affinity antibody responses (Pasare & Medzhitov, 2005; 
Bekeredjian-Ding & Jego, 2009; DeFranco et al, 2012).  In addition to the initial 
generation of an antibody response, TLR activation promotes the clonal expansion of 
memory B cells (Bernasconi et al, 2003). 
While enhancing protective antibody production in response to pathogens, TLR 
activation in B cells also contributes to chronic diseases in which B cells are 
inappropriately activated. In systemic lupus erythematosus (SLE) and rheumatoid 
arthritis, activation of TLR 7 and 9 in B cells has been directly implicated in autoimmune 
reactions against self-RNA and DNA complexes, respectively (Christensen et al, 2005; 
Shlomchik, 2009).  In this context, B cell receptors specific for antigens of nucleic acid 
complexes mediate cellular uptake which then stimulates TLR7/TLR9 within endosomal 
compartments ultimately leading to B cell proliferation and anti-DNA autoantibody 
production (Barton & Kagan, 2009; Koh et al, 2013). TLR activation, driven by a 
constitutively active mutation within the proximal TLR adaptor MyD88, also defines 
several B cell malignancies including Waldenstrom’s macroglobulinemia and diffuse 
large B cell lymphoma (Avalos et al, 2010; Choi et al, 2013; Wang et al, 2014).  
Despite an understanding of the ligands, signaling properties and function of the 
human TLRs, TLR10 remains an orphan receptor without a clear function (Chuang & 
Ulevitch, 2001; Guan et al, 2010). Several studies have shown that TLR10 message is 
predominantly expressed in lymphoid tissues such as the spleen and tonsils (Chuang & 
Ulevitch, 2001; Hasan et al, 2005). This is consistent with high levels of TLR10 message 
observed in B cell lines as well as primary B cells isolated from peripheral blood 
(Hornung et al, 2002; Bourke et al, 2003; Hasan et al, 2005; Månsson et al, 2006; 
Dorner et al, 2009). In this study, we use a TLR10 monoclonal antibody that was 
previously generated and characterized by our lab, to assess the protein expression 
level of TLR10 at various stages of B cell development and maturation. We anticipate 
that a more thorough characterization of TLR10 expression will assist in determining the 
physiological function of TLR10 in primary human B cells.  
 
5.3 Materials and Methods 
Reagents 
Antibodies against the B cell markers CD19-PE, CD27-FITC and CD38-FITC 
were purchased from BD Biosciences. The secondary antibodies biotin-labeled donkey 
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anti-mouse IgG1 and streptavidin conjugated Alexa-647 was purchased from Jackson 
Laboratories. The anti-TLR10 mAb (3C10C5) was generated and characterized in our 
lab as previously described [22]. The 3C10C5 antibody as well as the MOPC-21 isotype 
control antibody (BioLegend) were directly conjugated to Alexa-647 using a fluorophore 
conjugation kit (Life Technologies). Flow buffer was comprised of 10% rabbit serum in 
PBS.  
 
Cells and Tissues 
Peripheral blood was obtained from consenting healthy donors under an 
approved IRB protocol.  Ficoll-density centrifugation was first used to isolate 
mononuclear cells after which B cells were isolated using the MACS B cell Isolation Kit II 
(Miltenyi Biotech). Tonsillar tissue was obtained from discarded tissue obtained from 
routine tonsillectomies performed at Carle Foundation Hospital (Urbana, IL).  Tonsils 
were minced and ground through a sieve yielding a single-cell suspension that was 
rinsed in cold PBS. The single-cell suspension was then run on a Ficoll gradient to 
isolate the mononuclear cell fraction. B cells were isolated using the MACS B cell 
Isolation Kit II. Frozen aliquots of bone marrow mononuclear cells were purchased from 
Lonza and used without any further isolation. 
 
Flow Cytometry 
We have observed that the anti-TLR10 3C10C5 antibody produces a weak but 
reliable signal by flow cytometry. To validate this signal and to increase the signal-to-
noise ratio we have adopted a tertiary conjugated staining protocol in which cells were 
stained step-wise with either the TLR10 antibody (3C10C5) or the isotype control 
antibody (MOPC-21), followed by staining with biotin-conjugated secondary antibody 
and finally, fluorophore-conjugated streptavidin. All staining steps were performed in 
100μL of flow buffer on ice for 30 min and cells were washed several times with flow 
buffer after each staining step. After washing the tertiary antibody, cells were stained 
with primary conjugated antibodies against other cellular markers of interest. After 
staining, cells were fixed for 15 min in 4% paraformaldehyde.  
For intracellular staining, cells were first stained for any extracellular markers 
followed by fixation. Cells were then incubated in permeabilization buffer (flow buffer 
containing 0.1% saponin) for 30 min at room temperature. Cells were then washed and 
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re-suspended in 100μL of permeabilization buffer containing labelled primary antibody 
followed by washing. 
All flow data was collected on a BD FACSCanto running FACSDiva software. 
Compensation was performed when applicable using BD CompBeads single stained 
controls.  Data was analyzed using FCS Express v4. Delta MFI was calculated by 
subtracting the geometric median fluorescence intensity of the isotype control treated 
cells from that of the anti-TLR10 antibody treated cells. GraphPad Prism was used to 
generate the graphs and perform the unpaired t-tests to determine statistical 
significance. 
 
5.4 Results 
TLR10 Lymphocyte Prolife 
To begin our studies, we analyzed TLR10 expression in peripheral blood 
lymphocytes by labelling cells with the 3C10C5 anti-TLR10 monoclonal antibody and 
detected TLR10 expression in a subset of the lymphocyte population (Fig 5.1A). To 
further differentiate this cellular subset we stained these cells for the T-cell and B cell 
marker CD3 and CD19 respectively. Only cells expressing CD19 were identified as 
TLR10 expressing cells (Fig 5.1B). Furthermore, we examined human bone marrow 
mononuclear cells for TLR10 expression and again detected TLR10 expression only on 
cells concordantly expressing CD19 (Fig 5.2). This data suggests that TLR10 expression 
may be linked to B cell development and maturation.  
 
Analysis of B cell Subsets 
To determine if TLR10 expression changes on different B cell subsets, we 
analyzed the naïve and memory B cells located in peripheral blood for any differences. 
We show that memory B cells (CD19+, CD27+) express higher levels of TLR10 than 
naïve B cells (CD19+, CD27-) (Fig 5.3). While previous studies have shown TLRs to be 
upregulated on memory B cells [9, 23], this indicated to us that TLR10 expression might 
be further regulated during the maturation process in the germinal center. 
 To determine the expression of TLR10 on rapidly dividing and differentiating B 
cells in the germinal center, we used human tonsillar tissue and the B cell activation 
marker CD38 to separate the different B cell populations [24, 25]. We observed that 
TLR10 expression is inversely correlated with the CD38 activation marker. Naïve 
germinal center B cells (CD19+, CD38low) had the highest expression of TLR10 with a 
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stepwise decrease in expression on proliferating centrocytes (CD19+, CD38mid) and 
differentiating plasmablasts (CD19+, CD38high) (Fig 5.4). This data reveals that the fate of 
B cell differentiation in the germinal center has opposing effects on TLR10 expression 
with an increase expression of TLR10 on memory cells and decreased expression on 
plasmablasts.  
 
Intracellular TLR10 Expression  
TLRs are expressed either at the plasma membrane or in endosomal 
compartments. Although TLR10 is grouped with the TLR2 subfamily which are 
expressed on the plasma membrane, we examined the different B cell subsets for any 
intracellular expression of TLR10 with a primary conjugated 3C10C5 anti-TLR10 
antibody. In tonsillar tissue, neither the naïve germinal center B cells nor centrocytes 
expressed appreciable levels of intracellular TLR10. Surprisingly however, we observed 
high levels of intracellular TLR10 expression in the plasmablast population (Fig 5.5). 
Notably, this shift obtained via a primary fluophore-conjugated antibody was of 
comparable magnitude to the previous shift seen via the tertiary conjugated system we 
used to analyze extracellular TLR10 expression.  
To confirm the intracellular TLR10 expression pattern did not represent a 
transitional event as cells advanced through the process of terminal B cell differentiation, 
we analyzed TLR10 expression in mature, long-lived plasma cells in the bone marrow. 
Plasma cells as defined by high CD38 expression showed a similarly strong intracellular 
expression of TLR10 that did not exist in either immature B cells (CD19+, CD38low) or 
non B cells (CD19-) (Fig 5.6). Taken together, this data shows a unique TLR expression 
and localization pattern that is differentially regulated during B cell activation and 
terminal differentiation.  
 
5.5 Discussion 
The goal of this study was to determine the expression and regulation of TLR10 
at the protein level within the B cell lineage. Previous studies have shown that TLR10 
message is detectable within different B cell populations but data at the protein level was 
absent. Importantly, several studies, some utilizing the 3C10C5 αTLR10 antibody, have 
shown that TLR10 is capable of suppressing the immune response on mononuclear 
cells and isolated B cells (Oosting et al, 2014; Jiang et al, 2016; Hess et al, 2017). Our 
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study aids in understanding the function of TLR10 in B cells by analyzing the expression 
pattern within the B cell lineage. 
 
TLR10 B cell Expression 
The apparent connection between TLR10 expression and CD19 suggests a 
potential link with the B cell specific transcription factor PAX5 which is responsible for 
CD19 expression (Cobaleda et al, 2007). Interestingly, the promoter of TLR10 contains 
several proximal and distal putative PAX5 binding sites (unpublished observations). 
Furthermore, during terminal differentiation of B cells to plasma cells, the transcription 
factor Blimp-1 becomes antagonistic to PAX5 causing a subsequent decrease in CD19 
expression on fully mature bone marrow plasma cells (Shapiro-Shelef & Calame, 2005; 
Martins & Calame, 2008). We detected a similar expression pattern with extracellular 
levels of TLR10 when we compared naïve germinal center and mature plasma cells in 
the bone marrow (Fig 2.) While extracellular TLR10 and CD19 expression is reduced 
concordantly upon plasma cell differentiation, the total levels of TLR10 in the cell is 
harder to interpret with the identification of an intracellular form of TLR10. This data 
suggests that TLR10 extracellular expression and possibly cellular localization may be 
partly linked to PAX5 and CD19 expression. 
 
Intracellular TLR10 
The shift in TLR10 subcellular localization that we detected as plasmablasts 
mature to plasma cells is thought to be unique among TLR family members whose 
subcellular localization has not been reported to change during cellular development. 
Currently, we do not know if intracellular TLR10 originates from the internalization of the 
existing receptor from the plasma membrane or if it is the result of differential trafficking 
of newly synthesized TLR10 to intracellular compartments. Interestingly, TLR10 contains 
a cryptic start codon 42bp downstream of the standard start codon whose utilization 
would result in a 14 amino acid deletion of the N-terminal signal sequence normally 
required for trafficking of the receptor to the plasma membrane. It is also possible that 
intracellular TLR10 results from a post-translational modification process that is activated 
in plasma cells. One study has detected low levels of TLR10 mRNA in bone marrow 
plasma cells suggesting that plasma cells continue to synthesize new TLR10 
(Bernasconi et al, 2003). Clearly, further studies are needed to determine the structure, 
subcellular location and origin of intracellular TLR10.  
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Functional Significance  
Several recent publications have reported a suppressive function for TLR10 in 
mononuclear cells (Oosting et al, 2014; Jiang et al, 2016). Using 3C10C5 antibody-
engagement on primary human B cells as well as a TLR10 transgenic mouse model, we 
discovered that TLR10 suppresses cytokine production, clonal expansion and antibody 
production of activated B cells (Hess et al, 2017). This finding supports the hypothesis 
that TLR10 is a negative regulator of B cell activation whose expression, as shown here, 
is down-regulated during B cell maturation and development. While we do not yet know 
the functional significance of intracellular TLR10 in terminal plasma cells, it is likely to  
have a different function from extracellular TLR10 either due to lack of access to a 
natural ligand and/or a differential signaling function.  
Two independent studies have shown that TLR10 has a proinflammatory function 
in monocytes following infection with either Listeria monocytogenes or H1N1 flu virus 
(Regan et al, 2013; Lee et al, 2014). Importantly, both of these pathogens are 
intracellular and TLR10-mediated suppression was only observed with live, but not heat 
killed microbes, suggesting a functionally unique intracellular sensing function for 
TLR10. 
Several studies have linked TLR10 genetic variations with autoimmune 
pathologies such as asthma, Crohn’s disease, cancer and childhood IgA nephropathy 
(Lazarus et al, 2004; Park et al, 2011; Guirado et al, 2012; Morgan et al, 2012). While it 
is uncertain how these genetic variants might be disrupting normal TLR10 biology, there 
is a growing correlation between TLR10 and loss of control of B cell responses (Savva & 
Roger, 2013). While these genetic variants might directly affect TLR10 function, others 
might impair the normal expression, regulation and/or localization of TLR10. 
 
Conclusion 
In this study, we have shown a unique expression pattern for TLR10 within the B 
cell lineage which changes during B cell development and maturation. Since innate 
immune receptors such as TLRs play significant roles in tailoring the adaptive immune 
response, it is important to fully understand how the expression of these pattern 
recognition receptors is regulated. This study is the first comprehensive look at the 
expression profile of TLR10 at the protein level within B cells. These findings will inform 
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future work directed toward elucidating the functional role of TLR10 within the adaptive 
immune system. 
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5.7 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 TLR10 is Expressed by B cells 
(A) Representative histogram of whole blood gated lymphocytes showing 
TLR10 expression (black line) compared to an isotype control antibody 
(shaded grey). (B) Representative dot plots of lymphocytes co-stained with the 
anti-TLR10 antibody and either a CD3 or CD19 antibody. A tertiary staining 
method was used for both TLR10 and isotype control antibodies.  
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Figure 5.2 TLR10 Expression Correlates with CD19 Expression in the 
Bone Marrow  
(A) Representative dot plot of bone marrow cells co-stained with CD19 and 
CD38. Cell populations are indicated as follows; immature B cells (right box), 
plasma cells (upper box) and non B cells (unboxed cells). (B) Representative 
histograms of each cell population showing TLR10 expression (black line) 
compared to an isotype control antibody (shaded gray). (C) Bar graph 
representing the difference in median fluorescent intensity (MFI) between 
TLR10 and isotype from 4 donors. A tertiary staining method was used for 
both TLR10 and isotype antibodies. Error bars represent SEM. 
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Figure 5.3 Peripheral Blood Memory B cells Have Increased TLR10 
Expression  
(A) Representative dot plot of peripheral blood B cells isolated by negative 
selection and stained with CD27. B cell populations were analyzed for CD27 
expression (shown in boxes) which represent memory B cells (upper box) and 
naïve B cells (unboxed). (B) Representative histograms of each B cell 
population shown as TLR10 staining (black line) compared to an isotype 
control antibody (shaded gray). (C) Bar graph representing the ΔMFI between 
TLR10 and isotype antibodies from 3 donors. A tertiary stain was used for both 
TLR10 and isotype antibodies. Error bars represent SEM. 
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Figure 5.4 Germinal Center Activation is Negatively Correlated with 
TLR10 Expression 
(A) Representative dot plot of B cells isolated by negative selection from 
tonsillar tissue co-stained with CD19 and CD38. B cell populations were 
divided by CD38 expression (shown in boxes) to represent naïve germinal 
center B cells (bottom), centrocytes (middle) and plasmablasts (top). (B) 
Representative histograms of each B cell population shown as TLR10 staining 
(black line) compared to an isotype control antibody (shaded gray). (C) Bar 
graph representing the ΔMFI between TLR10 and isotype antibodies from 3 
donors. A tertiary stain was used for both TLR10 and isotype antibodies. Error 
bars represent SEM. 
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Figure 5.5 Plasmablasts Express Intracellular TLR10 
(A) Representative histograms of permeabilized tonsillar tissue comparing 
intracellular TLR10 expression (black line) with an isotype control antibody 
(shaded gray) from cell populations differentiated as in Figure 4A. (B) Bar 
graph representing the ΔMFI between intracellular TLR10 and isotype 
antibodies from 3 donors. A primary stain was used for both TLR10 and 
isotype antibodies. Error bars represent SEM. 
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Figure 5.6 Plasma cells in Bone Marrow Express Intracellular TLR10 
(A) Representative histograms of permeabilized bone marrow cells comparing 
intracellular TLR10 expression (black line) with an isotype control antibody (shaded 
gray) from cell populations analyzed as described in Figure 2A. (B) Bar graph 
representing the ΔMFI between intracellular TLR10 and isotype antibodies from 3 
donors. A primary staining method was used for both TLR10 and isotype antibodies. 
Error bars represent SEM. 
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CHAPTER VI: CONCLUSION 
 
6.1 Summary 
In this thesis, I have presented evidence that Toll-like Receptor 10 (TLR10) is a 
functional human TLR with immunosuppressive capabilities. Using a TLR10-specific 
monoclonal antibody, I have shown that antibody-mediated engagement of TLR10 is 
sufficient to suppress the induction of both pro-inflammatory and anti-inflammatory 
cytokines on isolated monocytes. Additionally, TLR10-engagement has long-term effects 
on the differentiation of monocytes into dendritic cells as measured by their cytokine 
profile, costimulatory markers and their ability to activate T cells ex vivo (Chapter 2; 
Jiang et al, 2016).  
 Next, I examined B cells to determine if the suppressive function of TLR10 is 
monocyte-specific. I show in Chapter 3 that antibody-engagement of TLR10 on B cells is 
sufficient to suppress several different outputs of B cell activation including cytokine 
production and proliferation. Utilizing a knock-in TLR10 transgenic mouse model, I was 
also able to show that expression of TLR10 within the transgenic mouse is sufficient to 
suppress antibody production when immunized against a T cell independent or -
dependent antigen (Hess et al, 2016).  
 In Chapter 4, I utilized our TLR10 antibody to further assess the regulation of 
TLR10’s expression on the B cell lineage. Utilizing human B cells sampled from the bone 
marrow, primary blood and tonsillar tissue, I was able to isolate several different B cell 
populations based on their developmental differentiation and activation status. The data I 
presented suggests that TLR10 expression is highest early in development in the bone 
marrow and in differentiated memory B cells. From that starting point, TLR10 expression 
is shown to decrease based on the activation status of the cell with the lowest 
expression seen on differentiating plasmablasts and plasma cells. Interestingly, I also 
show that an intracellular form of TLR10 appears in plasmablasts and plasma cells, 
possibly suggesting a different function for TLR10 within these cells. 
 
6.2 Unpublished Observations 
 In my thesis, I have analyzed the extracellular expression of TLR10 on 
mononuclear cells. Within this subset of leukocytes, monocytes and B cells showed 
detectable levels of TLR10 expression while TLR10 expression on T cells was 
undetected. The expression of TLR10 within B cells and the absence within T cells 
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aligned with other studies that have analyzed TLR10 transcriptional expression. 
Interestingly, those studies detected no transcriptional expression within monocytes and 
omitted neutrophils entirely from their study. I then asked if I could detect TLR10 
expression within the neutrophil population. I detected moderate levels of extracellular 
TLR10 expression on neutrophils though the majority of TLR10’s expression was 
observed intracellularly. In fact, intracellular TLR10 was detected at a low level within 
monocytes, B cells and T cells. In comparison, neutrophils had approximately a 5-fold 
higher intracellular expression level than any other cell type tested (Figure 6.1). This 
observation is reminiscent of the intracellular TLR10 detected on differentiating 
plasmablasts and plasma cells (Chapter 5). Due to the higher abundance of neutrophils 
in peripheral blood, I started a project to characterize the intracellular form of TLR10 
within neutrophils.   
 Work by other groups have shown that the intracellular TLRs 3 and 7-9 are all 
proteolytically processed for proper signal recognition and function (Park et al, 2008; Qi 
et al, 2012). I wanted to determine if intracellular TLR10 was similarly processed. To test 
this, I took lysates of isolated neutrophils, B cells, T cells and monocytes and blotted for 
TLR10 using a C-terminal commercial antibody. Interestingly, a single band around 
70kDa was detected in the neutrophil lysates. This suggested to me that the normally 
110kDa TLR10 protein was being processed within neutrophils. Unfortunately, I detected 
multiple different bands at different molecular weights for the other cell types I tested 
making it difficult to make any firm conclusions (Figure 6.2). Next I attempted to pull-
down the TLR10 protein with either of our two antibodies (3C10C5 & 5C2C5) to confirm 
that the detected bands were TLR10 but I could not achieve a successful pull-down of 
TLR10. Due to the lack of other testable TLR10 antibodies, I was unable to move 
forward further on this project. Despite this setback, production of additional TLR10 
antibodies in the future or further optimization could solve this problem and allow others 
to answer the question of intracellular TLR10 processing.  
 In addition to the intriguing western blotting data, some computational work has 
identified a cryptic splice variant of TLR10 that removes the first 42bp/14aa from the N-
terminus of the TLR10 protein. Since TLR10 is a single-pass transmembrane protein, if 
the cryptic spice variant results in a functional protein, it must reveal an alternative 
amino-terminal signal sequence for ER translocation which I have not confirmed. One 
idea is that this splice variant (if functional) could alter the glycosylation of TLR10 leading 
to differential localization of the receptor from the plasma membrane to intracellular 
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vesicles/endosomes. While I have no direct evidence of this occurring, I do notice 
differential binding of our antibodies based on localization. The 5C2C5 antibody is able 
to detect extracellular TLR10 but not intracellular and with the exception of B cells, the 
3C10C5 antibody is able to detect intracellular TLR10 but not extracellular (Figure 6.1). It 
is important to note that there are many possible reasons for this such as our method of 
fixing the cell in 4% paraformaldehyde possibly ruining the 5C2C5 epitope but an 
alternative hypothesis is that the epitopes of these antibodies are disrupted by 
differential glycosylation events that may occur in the ER and Golgi body. As I have 
already highlighted in Chapter 1, there are several ER-resident TLR chaperone proteins 
that may assume some role in directing the proper folding and glycosylation of TLR10 
that may be altered due to the hypothetical truncated form of the TLR10 receptor (Hart & 
Tapping, 2012; Huh et al, 2014; Liu et al, 2010; Randow & Seed, 2001).  
 The relatively high abundance of the TLR10 receptor within neutrophils 
suggested to us that expression maybe correlated with the equally abundance neutrophil 
granules present in there cytosol (Kolaczkowska & Kubes, 2013). Preliminary confocal 
microscopy revealed TLR10 expression localized to distinct punctate within neutrophils 
that may represent neutrophil granules (Figure 6.3). Unfortunately this work was not 
followed up on and I currently do not have co-localization data with a granule marker or 
a DIC overlay to confirm this interesting hypothesis.  
 Lastly, with the discovery of TLR10 expression within human monocytes and 
neutrophils, I thought that I could use our transgenic mouse model previously used in 
Chapter 4 to assay for innate immunity differences attributable to TLR10 expression. 
Unfortunately, no differences were detected by either endotoxin shock or Yersinia pestis 
infection. The endotoxin shock assay revealed no differences in the induction of TNFα or 
IL-6 at lethal and sub-lethal doses with also no difference in survival (Figure 6.4). 
Similarly, no differences were detected in bacterial burden in the spleen or survival after 
I.P. infection of Y. pestis (Figure 6.5). This result is most likely due to the lack of TLR10 
expression on murine monocytes and neutrophils despite the TLR10 transgene 
expressed under its endogenous human promoter. There are many possible reasons 
why the transgenic mouse model does not recapitulate the human system perfectly, 
some of which are biological (highlighted in Mestas & Hughes, 2004) and other which 
are technical such as transgenic knock-in mouse models having a tendency lose copies 
of the transgene over many generations (this work was done after Chapter 4 was 
completed). Despite this setback, our previous mouse model that expressed TLR10 
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ubiquitously under a CMV promoter did show suppressed cytokine production in 
monocytes (Chapter 2; Jiang et al, 2016). Future studies will have to utilize either 
conditional constitutive TLR10 expression via a CRE-LOX system or generate a knock-
out rat model to undertake additional in vivo studies.  
 The discovery of TLR10 expression on neutrophils confirms that TLR10 is a 
widely expressed receptor on leukocytes. While our hypothesis that engagement of 
TLR10 on neutrophils would be suppressive, engaging an intracellular receptor via an 
antibody presents another layer of technical challenge. Importantly, research has shown 
that localization of TLRs can alter their signaling responses (ex.TLR4 switching from 
MyD88 to TRIF signaling after internalization) such that intracellular TLR10 may be 
recruiting different adaptors to mediate an alternative function (Barton & Kagan, 2009). 
This is highlighted by two papers showing a pro-inflammatory role for TLR10 in the 
context of infection with two different intracellular pathogens, Listeria monocytogenes 
and the H1N1 flu virus (Lee et al, 2014; Regan et al, 2013). Perhaps processing of 
TLR10 alters both its signaling output and its ligand recognition such that it acts as more 
of a classical TLR (Mourao-Sa et al, 2013). These questions will perhaps remain 
unanswered until the true ligand for TLR10 is discovered.  
 
6.3 Potential Physiological Role for TLR10 
 The unique anti-inflammatory function of TLR10 discovered during my Thesis 
work presents an interesting conundrum of why a pattern-recognition receptor would 
evolve an opposing function to its other family members. As mothers often say to their 
children about eating too much candy, “Too much of a good thing can be a bad thing”, 
the same principle holds true for many aspects of biology. The immune system is about 
balance and with any evolutionary advancement in the immune response, the host must 
also evolve a mechanism to regulate that response. For example, many negative 
regulators of a given signaling pathway are induced by the activation of that pathway. In 
this way, the cell prevents over-activation of the signaling pathway and the common 
maladies that are normally associated with it such as pyroptosis or cancer. A few 
examples of negative regulators are the dominant negative protein IRAK-M, the anti-
inflammatory cytokine IL-10, the internalization and degradation of receptors (such as 
TLR4 covered in Chapter 1) and the IL-1 family of ligand mimics and dummy receptors 
including IL-1RA, ST2 and SIGRR. In each case, negative regulation is achieved by 
either preventing binding of ligand to a functional receptor, elimination of the activation 
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complex or blocking signal transduction with a non-catalytic signaling protein. These 
anti-inflammatory mechanisms act as a dial, slowly modulating the immune response so 
that excessive damage does not occur to the host (Avalos et al, 2010; Pasare & 
Medzhitov, 2003). 
 Despite highlighting these common negative regulatory pathways, I believe 
TLR10’s true function may be slightly more complex and expansive than simple negative 
regulation of a target signaling pathway. One observation that supports this theory is the 
regulation of TLR10 expression within the host. I have not detected the induction of 
TLR10 expression upon stimulation in any of the leukocytes I tested. Specifically 
assayed in the RNA-Seq data of Chapter 2, if TLR10 was acting as the negative 
regulator of TLR signaling, I should see an increase in its expression. Additionally, data 
presented in Chapter 4 shows that TLR10 expression is seen to decrease during B cell 
activation, not increase, suggesting TLR10 expression is under its own unique regulation 
and not specifically induced by other signaling pathways.  
 Another mechanism of suppression that has been commonly proposed for 
TLR10 involves its ability to heterodimerize with TLR2. While the TLR2:10 heterodimer 
cannot be ignored and does represent a viable mechanism of TLR2 suppression, the 
anti-inflammatory activity that I have seen throughout my thesis points to TLR10 being 
able to suppress a broader range of signals than just TLR2 signaling (Guan et al, 2010; 
Jiang et al, 2016; Oosting et al, 2014). The TLR2:10 heterodimer may represent an 
evolutionary artifact and not its true functional complex. Unpublished data from Dr. Diana 
Ranoa in our lab shows that TLR2 has a lower affinity for TLR10 compared to its 
functional counterpart, TLR1. Since TLR10 evolved from a gene duplication event with 
TLR1, it can be assumed TLR10’s ability to heterodimerize with TLR2 is an evolutionary 
artifact. In fact, TLR10’s LRR and TIR domains both show the highest evolutionary rate 
among the 13 mammalian TLRs suggesting that unlike the other TLRs, TLR10 is not 
under stabilizing selection and is still evolving its own unique unknown physiological role 
within the host (Mikami et al, 2012).   
 Taken together, I believe these observations point to TLR10 having a unique 
physiological role within the host, a few of which I will now subsequently explore. While I 
am confident TLR10 is acting as a homodimer (see Chapter 2), I am less confident in 
whether the physiological steady state of the receptor exists as a monomer or 
constitutive homodimer. One early hypothesis of mine was that TLR10 did not possess a 
ligand and was a constitutive homodimer that was basally active at very low levels 
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(Figure 1.4). By constantly being active, it acted as a barrier toward cellular activation, 
only allowing the cell to become activated once a prolonged robust signal was acquired. 
In short, TLR10 acted as an arbitrary threshold value that had to be exceeded for cellular 
activation. This would prevent the cell from becoming activated in response to 
weak/moderate activation signals which would be analogous to host self components. I 
believed this explained why antibody-mediated engagement of the TLR10 receptor 
resulted on average only a 10-30% reduction in cytokine levels. In our experimental 
system, our antibodies were only capable of stabilizing the already constitutively active 
complex resulting in only a moderate increase in suppression. 
 While I believe the previous hypothesis may still be valid, many still believe that 
TLR10 possesses a natural ligand that regulates its function. If true, the natural ligand of 
TLR10 can be implied to be a host derived molecule instead of a PAMP with one major 
exception. Helminths or parasitic worms are a class of pathogens that are well-known to 
systemically suppress host immune responses. Helminths are highly successful parasitic 
organisms that have chronically infected Homo sapiens until the 19th century and the 
widespread adoption of clean drinking water in developed countries. One striking off-
target epidemiological effect is the rise of autoimmune diseases in these developed 
countries, a trend that is not seen in countries that still report high prevalence of helminth 
infections. While several studies are now looking into using helminths or helminth 
derived components as therapies for autoimmune diseases, the questions remains if 
helminths are controlling the hosts immune system or if the host becomes 
immunologically tolerant to the infection (Luis et al, 2016; Maizels, 2016). 
 The hypothesis that TLR10’s natural ligand is a component of helminths may 
gain traction as a mechanism for the host to induce immunological tolerance. Helminths 
possess an outer protective coating called a tegument that is responsible for both the 
inhibition of host digestive enzymes and immune evasion. The tegument is a complex 
structure that consists of a variety of highly glycosylated glycolipids and glycoproteins 
that could serve as potential TLR10 ligands. In general, helminths have the ability to 
down-regulate TH1 IFN-γ responses while also modulating the TH2 response away from 
elevated IgE levels (many believe that the IgE isotype evolved to specifically combat 
helminth infections). This results in a subdued immune response that can be protective 
against chronic inflammatory diseases. While the observed effects by helminths and 
TLR10 appear correlated, a perplexing thought is what evolutionary advantage is gained 
by the host. While it seems helminths may protect against autoimmune diseases, the 
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onset of those diseases normally occur after child-bearing years and does not represent 
a strong evolutionary pressure. Perhaps with further research we may better understand 
the relationship between helminths, the host and the true ligand for TLR10 (Luis et al, 
2016; Maizels, 2016).  
 An opposing hypothesis is that TLR10 has evolved to recognize a conserved 
host derived component that is only selectively synthesized or presented to immune 
cells. Since the TLR2 sub-family recognizes several different lipid components on the 
surface of bacteria, a reasonable hypothesis would be that TLR10’s true ligand may be 
lipid-based. An observation made many years ago was that macrophages have a 
reduced inflammatory profile after phagocytosing apoptotic cells. While the field does not 
know what mediates apoptotic cells immunosuppression, a common feature of apoptotic 
cells is the externalization of the plasma membrane phospholipid phosphatidylserine 
(PS). This leads to the hypothesis that TLR10 could be recognizing PS or other 
phospholipids to aid in either recognition of apoptotic cells or the immunosuppression 
exerted on apoptotic-phagocytizing cells (Birge & Ucker, 2008).   
This would solve an important gap in knowledge in the field of immunology. To 
fully appreciate the enormity of this response, up to 1011 apoptotic neutrophils are 
cleared each day in a healthy adult human. Interestingly, apoptotic-mediated 
immunosuppression is distinct from the phagocytosis process as blocking the 
engulfment of apoptotic cells does not hinder the immunosuppression on phagocytotic 
cells. It is also important to note that apoptotic cells seem to gain this 
immunosuppressive function which is not detected on either necrotic or pyroptotic cells 
(Birge & Ucker, 2008). It is not then inconceivable to extrapolate that defects in clearing 
apoptotic cells can lead to the accumulation of auto-antigens that can raise the risk of 
developing an autoimmune disorder.  
 Another hypothesis stems from our RNA-Seq data from Chapter 2. In that data, I 
detected several genes involved in arachidonic acid metabolism that were selectively 
downregulated and upregulated in response to our αTLR10 antibody. Arachidonic acid 
(AA), a 20 carbon polyunsaturated omega-6 fatty acid (20:4ω6) that normally present in 
the plasma membrane of cells. When cleaved by phospholipases (triggered by cellular 
signaling) AA serves as the precursor to several different flavors of lipid-based pro-
inflammatory mediators including prostaglandins and leukotrienes (Zhang et al, 2016). 
The two enzymes critical to producing prostaglandins and leukotrienes respectively are 
cyclooxygenase-1/2 (COX-1/2 or PTGS1/2) and cyclooxygenase-5 (COX-5) 
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respectively. Importantly, both of these enzymes were downregulated by our TLR10 
antibody while a third enzyme, 12-lipoxygenase (ALOX12) was conversely upregulated. 
While docosahexaenoic acid (DHA) 22:6ω3, normally is associated with anti-
inflammatory functions, ALOX12 can convert AA into a class of anti-inflammatory 
mediators known as resolvins. Resolvins, as their name implies, are a class of 
specialized pro-resolving mediators (SPMs) that normally act in the latter stages of the 
immune response known as the resolution phase. Research into resolvins is relatively 
new but already several resolvins such as RvD1 and RvD3 are associated with 
enhancing IL-10-mediated suppression and shown to be reduced in rheumatoid arthritis 
(RA) patients compared to healthy controls respectively (Choi & Hwang, 2016; Titos et 
al, 2016). While we have correlative evidence that TLR10 may induce the synthesis of 
resolvins, it is also not impossible that TLR10 could recognize resolvins as its natural 
ligand to help perpetuate the resolution of the inflammatory process. 
 
6.4 Concluding Remarks 
 In my thesis, I have presented evidence that human TLR10 is a functional 
receptor expressed on a variety of different leukocytes that has a functional role of 
suppressing inflammatory responses. While other groups have published data 
contradicting this anti-inflammatory role for TLR10, I believe our model system using 
antibody-mediated engagement on primary human cells represents the most accurate 
depiction of TLR10’s function to date.  
 While I am only at the beginning of our research into TLR10’s biology, TLR10’s 
unique function may allow for the development of unique treatments to combat both 
common and uncommon medical maladies. For example, NSAIDs (non-steroidal anti-
inflammatory drug) such as ibuprofen and aspirin are common drugs that inhibit the 
activity of the COX enzymes to produce pro-inflammatory prostaglandins as mentioned 
in Chapter 1. Ibuprofen and aspirin are non-selective COX inhibitors that target both the 
constitutively expressed COX-1 and the inducibly expressed COX-2. Despite their 
positives, they can also have detrimental side effects such as both stomach and 
gastrointestinal bleeding due to the loss of protective prostaglandins at these sites. 
Ibuprofen has been reported to have reduced side effects because it is a competitive 
inhibitor of COX activity while aspirin is an irreversible inhibitor because it acetylates the 
COX active site (Rao & Knaus, 2008; Toth et al, 2013). As a side note, acetaminophen, 
also known as paracetamol and commonly sold as Tylenol is not considered an NSAID 
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because it has very little anti-inflammatory activity. The actual mechanism of 
acetaminophen is not yet fully understood but early evidence suggest that it inhibits 
COX-2 activity only in the nervous system. This has the effect of reducing both fever and 
pain while not having any direct event on inflammatory events occurring in other tissues 
(Andersson et al, 2011; Hinz et al, 2007). Importantly, I have shown that TLR10 
engagement may have a role in modulating COX expression and while not yet directly 
tested, may have a role in limiting COX activity (Chapter 3).  
Additionally, derivatives of the host-derived stress hormone cortisol (known as 
glucocorticoids) are traditionally used to treat patients with chronic inflammatory 
diseases. Common examples of this class of drugs include cortisone, prednisone and 
dexamethasone. Glucocorticoids naturally diffuse through the plasma membrane and 
interact with the glucocorticoid receptor to transactivate several pro-inflammatory genes 
while simultaneously transrepressing pro-inflammatory genes. One example is the 
upregulation of Lipocortin-1 (Annexin A1). Lipocortin-1 suppresses the phospholipase 
activity of PLC and PLA to decrease prostaglandin production. Because the 
glucocorticoid receptor is a nuclear receptor, glucocorticoids are capable of effecting a 
large swath of inflammatory genes. But because their main mechanism of action is 
effecting the expression levels of inflammatory genes, they are best used over longer 
time periods and have no immediate effect on inflammatory events (Coutinho & 
Chapman, 2011). Similarly, TLR10 engagement has been shown to have long-term 
effects on the expression of pro-inflammatory genes in both monocytes and B cells 
(Chapters 2, 3 and 4).    
Both of these drugs classes, NSAIDs and glucocorticoids, are used regularly in 
the medical field to treat chronic inflammatory diseases by suppressing specific 
components of the immune system to great effect. Their mechanisms of actions 
complement each other giving medical professionals a variety of tools to treat patients. 
Our work has shown that TLR10 engagement can mediate an immediate suppressive 
response not unlike NSAIDs but also have long-term effects on both the expression of 
pro-inflammatory genes and physiology of the cell. I believe that in the future, TLR10 
engagement may give the medical field a third therapeutic option to treat chronic 
inflammatory diseases.    
 Chronic inflammatory diseases are described as the inability of the host to 
resolve an inflammatory state while autoimmune diseases are characterized by the 
host’s immune system becoming activated against self components. While the two are 
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arguably intertwined, chronic inflammation has been proposed as a precursor to many 
autoimmune diseases, one of which I will highlight here (Marshak-Rothstein & Rifkin, 
2007). System lupus erythematosus (SLE) is a disease characterized by over-activation 
of TLR9 via the recognition of self-DNA that can cause the production of antibodies 
against the self-nuclear protein complexes. These self-nuclear protein complexes have 
been hypothesized to be released either by impaired apoptosis or via pyroptosis trigged 
by an infection. In support of this hypothesis, SLE patients often report flare-ups (times 
of increased inflammation and sickness) that are commonly preceded by even mild 
infections. Lupus is treated with NSAIDs and glucocorticoid steroids to reduce 
inflammation though no cure is available. As a B cell centric disease, TLR10 may be 
able to assist in the treatment and/or the eventually prevention of SLE because of the 
work I have done showing that TLR10 engagement is sufficient to suppress both 
monocyte (chronic inflammatory mediator) and B cell (autoimmune mediator) activation.  
 In summary, there is more we don’t know about TLR10 then we do know but 
what our early experiments suggest is that TLR10 is a unique member of the TLR family. 
Our hope is that future research can learn from our experiments and slowly piece 
together the interesting story that is toll-like receptor 10.  
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6.5 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Extracellular versus Intracellular TLR10 Expression within Blood 
Leukocytes 
There is differential expression of TLR10 by the 3C10C5 and 5C2C5 mAbs. The 
5C2C5 ab detects extracellular TLR10 on most blood leukocytes excluding T cells 
with the highest expression on monocytes. In contract, the 3C10C5 ab only detects 
extracellular TLR10 on B cells but can detect intracellular TLR10 on all other 
leukocytes tested with the highest expression on neutrophils. Conversely, the 
5C2C5 ab cannot detect intracellular TLR10. 
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Figure 6.2 αTLR10 Western Blot of Blood Leukocyte Lysates 
Primary leukocyte lysates were blotted for TLR10 using a ThermoFisher 
polyclonal TLR10 antibody (catalog #PA5-29364) that was raised against 
the C-terminal residues 547-772 of TLR10. The band at ~95kDa is 
predicted to be TLR10 while the single band in neutrophils may also be a 
processed form of TLR10.  
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Intracellular TLR10 Localizes to Distinct Puncta within 
Primary Human Neutrophils 
Primary human neutrophils were stained with the 3C10C5 TLR10 ab and a 
secondary Alexa647 ab. TLR10 staining can be seen in red while the 
nucleus was stained in DAPI, seen in blue.  
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Figure 6.4 Line 5-1 Transgenic Male Mice Exhibit No Differences in 
Cytokine or Survival After Endotoxin Shock  
Six to eight week old male mice were injected I.P. with the indicated dose 
of LPS. Serum was collected at the indicated time points and measured for 
IL-6 or TNFα by ELISA. Mice were then monitored for several days for 
survival in which the transgenic mice were not protected from lethal 
endotoxin shock. 
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Figure 6.5 TLR10 Does Not Impair or Protect Line 5-1 Female Mice From 
Y. pestis Infection 
Six to eight week old female mice were I.P. injected with 12,500 CFU of 
exponentially growing Y. pestis and monitored for survival over several days. 
The transgenic mice showed no differences in survival compared to the non-
transgenic littermate controls.  
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